SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

  Quarterly Report Pursuant to Section 13 or 15(d) of the Security Exchange Act of 1934 for the quarterly period ended May 31, 2017

 

OR

 

  Transmission Report Pursuant to Section 13 or 15(d) of the Security Exchange Act of 1937 for the transition period from ______ to ______

 

Commission file number: 001-32046

 

Simulations Plus, Inc.

(Name of registrant as specified in its charter)

 

California 95-4595609
(State or other jurisdiction of Incorporation or Organization) (I.R.S. Employer identification No.)

 

42505 10 th Street West

Lancaster, CA 93534-7059

(Address of principal executive offices including zip code)

 

(661) 723-7723

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filings requirements for the past 90 days. Yes      No

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes      No

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.

 

See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):

 

   Large accelerated filer    Accelerated filer
   Non-accelerated filer (Do not check if a smaller reporting company)      Smaller reporting company
   Emerging Growth Company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes    No

 

The number of shares outstanding of the registrant’s common stock, par value $0.001 per share, as of July 10, 2017 was 17,245,346; no shares of preferred stock were outstanding.

 

 

 

     
 

 

Simulations Plus, Inc.

FORM 10-Q

For the Quarterly Period Ended May 31, 2017

 

Table of Contents

 

PART I. FINANCIAL INFORMATION
    Page
     
Item 1. Condensed Consolidated Financial Statements 3
     
  Condensed Consolidated Balance Sheets at May 31, 2017 (unaudited) and August 31, 2016 (audited) 3
     
  Condensed Consolidated Statements of Operations for the three months and nine months ended May 31, 2017 and 2016 (unaudited) 4
     
  Condensed Consolidated Statements of Cash Flows for the nine months ended May 31, 2017 and 2016 (unaudited) 5
     
  Notes to Condensed Consolidated Financial Statements (unaudited) 6
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Result of Operations 16
     
  General 16
     
  Results of Operations 23
     
  Liquidity and Capital Resources 25
     
Item 3. Quantitative and Qualitative Disclosures about Market Risk 26
     
Item 4. Controls and Procedures 26
     
PART II. OTHER INFORMATION
     
Item 1. Legal Proceedings 26
     
Item 1A. Risk Factors 27
     
Item 2. Changes in Securities 36
     
Item 3. Defaults upon Senior Securities 36
     
Item 4. Mine Safety Disclosures 36
     
Item 5. Other Information 36
     
Item 6. Exhibits 36
     
Signature 38

 

 

 

  2  
 

 

Part I. Financial Information

 

Item 1. Condensed Consolidated Financial Statements

 

SIMULATIONS PLUS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS


 

    (Unaudited)     (Audited)  
    May 31,     August 31,  
ASSETS            
    2017     2016  
Current assets                
Cash and cash equivalents   $ 8,248,197     $ 8,030,284  
Accounts receivable, net of allowance for doubtful accounts of $0     5,010,589       3,009,517  
Revenues in excess of billings     1,130,154       694,131  
Prepaid income taxes     241,540       555,486  
Prepaid expenses and other current assets     304,408       410,811  
Total current assets     14,934,888       12,700,229  
Long-term assets                
Capitalized computer software development costs, net of accumulated amortization of $9,477,930 and $8,613,487     4,077,144       4,013,127  
Property and equipment, net (note 3)     257,552       256,381  
Intellectual property, net of accumulated amortization of $1,864,375 and $1,408,750     4,210,625       4,666,250  
Other intangible assets net of accumulated amortization of $405,625 and $295,000     1,244,375       1,355,000  
Goodwill     4,789,248       4,789,248  
Other assets     34,082       34,082  
Total assets   $ 29,547,914     $ 27,814,317  
                 
LIABILITIES AND SHAREHOLDERS' EQUITY                
Current liabilities                
Accounts payable   $ 211,645     $ 108,111  
Accrued payroll and other expenses     647,203       481,610  
Accrued bonuses to officers     45,750       121,000  
Other current liabilities           8,274  
Current portion - Contracts payable (note 4)           1,000,000  
Billings in excess of revenues     313,399       230,100  
Deferred revenue     48,964       176,422  
Total current liabilities     1,266,961       2,125,517  
                 
Long-term liabilities                
Deferred income taxes     3,055,465       2,956,206  
Total liabilities     4,322,426       5,081,723  
                 
Commitments and contingencies (note 5)                
                 
Shareholders' equity (note 6)                
Preferred stock, $0.001 par value 10,000,000 shares authorized no shares issued and outstanding            
Common stock, $0.001 par value 50,000,000 shares authorized 17,242,510 and 17,225,478 shares issued and outstanding     7,244       7,227  
Additional paid-in capital     11,816,573       11,376,007  
Retained earnings     13,401,671       11,349,360  
Total shareholders' equity     25,225,488       22,732,594  
    $        
Total liabilities and shareholders' equity   $ 29,547,914     $ 27,814,317  

 

The accompanying notes are an integral part of these financial statements.

 

  3  
 

 

SIMULATIONS PLUS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

For the three and nine months ended May 31, 2017 and 2016


    Three months ended     Nine months ended  
    (Unaudited)     (Unaudited)  
    2017     2016     2017     2016  
                         
Net Revenues   $ 6,748,518     $ 6,012,193     $ 17,872,044     $ 16,014,539  
Cost of revenues     1,444,764       1,194,815       4,334,699       3,541,903  
Gross margin     5,303,754       4,817,378       13,537,345       12,472,636  
Operating expenses                                
Selling, general, and administrative     1,954,871       1,680,707       5,766,563       5,079,985  
Research and development     253,799       348,427       952,635       1,161,124  
Total operating expenses     2,208,670       2,029,134       6,719,198       6,241,109  
                                 
Income from operations     3,095,084       2,788,244       6,818,147       6,231,527  
                                 
Other income (expense)                                
Interest income     4,663       4,553       13,548       13,507  
Gain (loss) on currency exchange     (14,913 )     7,733       5,573       (35,490 )
Total other income (expense)     (10,250 )     12,286       19,121       (21,983 )
                                 
Income before provision for income taxes     3,084,834       2,800,530       6,837,268       6,209,544  
Provision for income taxes     (1,004,805 )     (891,191 )     (2,199,914 )     (2,048,383 )
Net Income   $ 2,080,029     $ 1,909,339     $ 4,637,354     $ 4,161,161  
                                 
Earnings per share                                
Basic   $ 0.12     $ 0.11     $ 0.27     $ 0.24  
Diluted   $ 0.12     $ 0.11     $ 0.27     $ 0.24  
                                 
Weighted-average common shares outstanding                                
Basic     17,241,891       17,028,634       17,233,470       17,000,228  
Diluted     17,585,528       17,227,540       17,454,864       17,219,835  

 

The accompanying notes are an integral part of these financial statements.

 

  4  
 

 

SIMULATIONS PLUS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the nine months ended May 31, 2017 and 2016


 

    (Unaudited)  
    2017     2016  
Cash flows from operating activities                
Net income   $ 4,637,354     $ 4,161,161  
Adjustments to reconcile net income to net cash provided by operating activities                
Depreciation and amortization of property and equipment     116,348       148,442  
Amortization of capitalized computer software development costs     864,443       735,579  
Amortization of Intellectual Property     566,250       566,250  
Stock-based compensation     355,365       234,616  
Deferred income taxes     99,259       (4,910 )
(Increase) decrease in                
Accounts receivable     (2,001,072 )     (2,988,866 )
Revenues in excess of billings     (436,023 )     (244,772 )
Prepaid income taxes     313,946       (108,690 )
Prepaid expenses and other assets     106,403       93,554  
Increase (decrease) in                
Accounts payable     103,534       (24,411 )
Accrued payroll and other expenses     165,593       81,212  
Accrued bonus     (75,250 )     (30,250 )
Billings in excess of revenues     83,299       5,911  
Accrued income taxes           (43,602 )
Other liabilities     (8,274 )     (14,894 )
Deferred revenue     (127,458 )     182,321  
Net cash provided by operating activities     4,763,717       2,748,651  
                 
Cash flows used in investing activities                
Purchases of property and equipment     (117,519 )     (32,317 )
Capitalized computer software development costs     (928,460 )     (815,582 )
Net cash used in investing activities     (1,045,979 )     (847,899 )
                 
Cash flows used in financing activities                
Payment of dividends     (2,585,043 )     (2,552,175 )
Payments on Contracts Payable     (1,000,000 )     (750,000 )
Proceeds from the exercise of stock options     85,218       129,831  
Net cash used in financing activities     (3,499,825 )     (3,172,344 )
                 
Net increase (decrease) in cash and cash equivalents     217,913       (1,271,592 )
Cash and cash equivalents, beginning of year     8,030,284       8,551,275  
Cash and cash equivalents, end of period   $ 8,248,197     $ 7,279,683  
                 
Supplemental disclosures of cash flow information                
Income taxes paid   $ 1,765,189     $ 2,186,159  

 

The accompanying notes are an integral part of these financial statements.

 

  5  
 

 

Simulations Plus, Inc.

 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

May 31, 2017 and 2016

(Unaudited)

 

NOTE 1: GENERAL

 

This report on Form 10-Q for the quarter ended May 31, 2017, should be read in conjunction with the Company's annual report on Form 10-K for the year ended August 31, 2016, filed with the Securities and Exchange Commission (“SEC”) on November 14, 2016. As contemplated by the SEC under Article 8 of Regulation S-X, the accompanying consolidated financial statements and footnotes have been condensed and therefore do not contain all disclosures required by generally accepted accounting principles. The interim financial data are unaudited; however, in the opinion of Simulations Plus, Inc. ("we", "our", "us"), the interim data includes all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the results for the interim periods. Results for interim periods are not necessarily indicative of those to be expected for the full year.

 

Organization

Simulations Plus, Inc. (“Simulations Plus”, “Lancaster”) was incorporated on July 17, 1996. On September 2, 2014, Simulations Plus, Inc. acquired all of the outstanding equity interests of Cognigen Corporation (“Cognigen”, “Buffalo”) and Cognigen became a wholly owned subsidiary of Simulations Plus, Inc. (collectively, “Company”, “we”, “us”, “our”), pursuant to the terms of that certain Agreement and Plan of Merger, dated as of July 23, 2014, by and between Simulations Plus and Cognigen (the “Merger Agreement”).

 

Subsequent to May 31, 2017, on June 1, 2017 the Company acquired 100% of the stock of DILIsym Systems, Inc.

 

Lines of Business

The Company designs and develops pharmaceutical simulation software to promote cost-effective solutions to a number of problems in pharmaceutical research and in the education of pharmacy and medical students, and it provides consulting services to the pharmaceutical and chemical industries. The Company is also exploring developing software applications for defense and for health care outside of the pharmaceutical industry.

  

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

 

Principles of Consolidation

The consolidated financial statements include the accounts of Simulations Plus, Inc. and its wholly owned subsidiary, Cognigen Corporation. All significant intercompany accounts and transactions are eliminated in consolidation.

 

Estimates

Our condensed consolidated financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. Actual results could differ from those estimates. Significant accounting policies for us include revenue recognition, accounting for capitalized computer software development costs, valuation of stock options, and accounting for income taxes.

 

Reclassifications

Certain numbers in the prior year have been reclassified to conform to the current year's presentation.

 

Revenue Recognition

We recognize revenues related to software licenses and software maintenance in accordance with Financial Accounting Standard Board (“FASB”) Accounting Standard Codification (“ASC”) 985-605, “ Software - Revenue Recognition” . Software product revenue is recorded when the following conditions are met: 1) evidence of arrangement exists, 2) delivery has been made, 3) the amount is fixed, and 4) collectability is probable. Post-contract customer support ("PCS") obligations are insignificant; therefore, revenue for PCS is recognized at the same time as the licensing fee, and the costs of providing such support services are accrued and amortized over the obligation period.

  

As a byproduct of ongoing improvements and upgrades for the new programs and new modules of software, some modifications are provided to customers who have already purchased software at no additional charge. Other software modifications result in new, additional-cost modules that expand the functionality of the software. These are licensed separately. We consider the modifications that are provided without charge to be minimal, as they do not significantly change the basic functionality or utility of the software, but rather add convenience, such as being able to plot some additional variable on a graph in addition to the numerous variables that had been available before, or adding some additional calculations to supplement the information provided from running the software. Such software modifications for any single product have typically occurred once or twice per year, sometimes more, sometimes less. Thus, they are infrequent. The Company provides, for a fee, additional training and service calls to its customers and recognizes revenue at the time the training or service call is provided.

 

 

 

  6  
 

 

Generally, we enter into one-year license agreements with customers for the use of our pharmaceutical software products. We recognize revenue on these contracts when all the criteria are met.

 

Most license agreements have a term of one year; however, from time to time, we enter into multi-year license agreements. We generally unlock and invoice software one year at a time for multiyear licenses. Therefore, revenue is recognized one year at a time.

 

We recognize revenue from collaboration research and revenue from grants equally over their terms. For contract revenues based on actual hours incurred we recognize revenues when the work is performed. For fixed price contracts, we recognize contract study and other contract revenues using the percentage-of-completion method, depending upon how the contract studies are engaged, in accordance with ASC 605-35, “ Revenue Recognition – Construction-Type and Production-Type Contracts” . To recognize revenue using the percentage-of-completion method, we must determine whether we meet the following criteria: 1) there is a long-term, legally enforceable contract, 2) it is possible to reasonably estimate the total project costs, and 3) it is possible to reasonably estimate the extent of progress toward completion.

 

Cash and Cash Equivalents

For purposes of the statements of cash flows, we consider all highly liquid investments purchased with original maturities of three months or less to be cash equivalents.

 

Accounts Receivable

We analyze the age of customer balances, historical bad-debt experience, customer creditworthiness, and changes in customer payment terms when making estimates of the collectability of the Company’s trade accounts receivable balances. If we determine that the financial conditions of any of its customers deteriorated, whether due to customer-specific or general economic issues, an increase in the allowance may be made. Accounts receivable are written off when all collection attempts have failed.

 

Capitalized Computer Software Development Costs

Software development costs are capitalized in accordance with ASC 985-20, “Costs of Software to Be Sold, Leased, or Marketed” . Capitalization of software development costs begins upon the establishment of technological feasibility and is discontinued when the product is available for sale.

 

The establishment of technological feasibility and the ongoing assessment for recoverability of capitalized software development costs require considerable judgment by management with respect to certain external factors including, but not limited to, technological feasibility, anticipated future gross revenues, estimated economic life, and changes in software and hardware technologies. Capitalized software development costs are comprised primarily of salaries and direct payroll-related costs and the purchase of existing software to be used in our software products.

 

Amortization of capitalized software development costs is calculated on a product-by-product basis on the straight-line method over the estimated economic life of the products (not to exceed five years, although all of our current software products have already been on the market for 7-15 years except for our newest PKPlus™ program, and we do not foresee an end-of-life for any of them at this point). Amortization of software development costs amounted to $290,567 and $241,042 for the three months ended May 31, 2017 and 2016 and $864,443 and $735,579 for the nine months ended May 31, 2017 and 2016, respectively. We expect future amortization expense to vary due to increases in capitalized computer software development costs.

 

We test capitalized computer software development costs for recoverability whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.

  

Property and Equipment

Property and equipment are recorded at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over the estimated useful lives as follows:

 

Equipment 5 years
Computer equipment 3 to 7 years
Furniture and fixtures 5 to 7 years
Leasehold improvements Shorter of life of asset or lease

 

Maintenance and minor replacements are charged to expense as incurred. Gains and losses on disposals are included in the results of operations.

 

 

 

  7  
 

 

Goodwill and indefinite-lived assets

Goodwill and indefinite-lived assets are not amortized, but are evaluated for impairment annually or when indicators of a potential impairment are present. Our impairment testing of goodwill is performed separately from our impairment testing of indefinite-lived intangibles. The annual evaluation for impairment of goodwill and indefinite-lived intangibles is based on valuation models that incorporate assumptions and internal projections of expected future cash flows and operating plans.

 

Fair Value of Financial Instruments

Assets and liabilities recorded at fair value in the Condensed Balance Sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The categories, as defined by the standard are as follows:

 

Level Input:   Input Definition:
Level I   Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II   Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III   Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date.

 

For certain of our financial instruments, including accounts receivable, accounts payable, accrued payroll and other expenses, accrued bonus to officer, and accrued warranty and service costs, the amounts approximate fair value due to their short maturities.

 

Research and Development Costs

Research and development costs are charged to expense as incurred until technological feasibility has been established. These costs consist primarily of salaries and direct payroll-related costs. It also includes purchased software and databases that were developed by other companies and incorporated into, or used in the development of, our final products.

  

Income Taxes

We utilize FASB ASC 740-10, “Income Taxes” which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns.

 

Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each year-end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The provision for income taxes represents the tax payable for the period and the change during the period in deferred tax assets and liabilities.

 

We follow guidance issued by the FASB with regard to our accounting for uncertainty in income taxes recognized in the financial statements. Such guidance prescribes a recognition threshold of more likely than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more likely than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. Our policy is to include interest and penalties related to unrecognized tax benefits in income tax expense. Interest and penalties totaled $ -0- and $-0- for fiscal year 2017 and 2016, respectively. We file income tax returns with the IRS and various state jurisdictions and India.

 

Intellectual property

On February 28, 2012, we bought out the royalty agreement with Enslein Research of Rochester, New York. The cost of $75,000 is being amortized over 10 years under the straight-line method. Amortization expense for each of the three-month periods ended May 31, 2017 and 2016 was $1,875, and was $3,750 for each of the nine-month periods ended May 31, 2017 and 2016. Accumulated amortization as of May 31, 2017 and August 31, 2016 was $39,375 and $33,750, respectively.

 

On May 15, 2014, we entered into a termination and non-assertion agreement with TSRL, Inc., pursuant to which the parties agreed to terminate an exclusive software licensing agreement entered into between the parties in 1997. As a result, the company obtained a perpetual right to use certain source code and data, and TSRL relinquished any rights and claims to any GastroPlus products and to any claims to royalties or other payments under that 1997 agreement. We paid TSRL total consideration of $6,000,000, which is being amortized over 10 years under the straight-line method. Amortization expense for each of the three-month periods ended May 31, 2017 and 2016 was $150,000 and was $450,000 for each of the nine-month periods ended May 31, 2017 and 2016. Accumulated amortization as of May 31, 2017 and August 31, 2016 was $1,825,000 and $1,375,000, respectively.

 

 

 

 

  8  
 

 

Total amortization expense for intellectual property agreements for the three months ended May 31, 2017 and 2016 was $151,875, and total amortization expense for the nine months ended May 31, 2017 and 2016 was $455,625. Accumulated amortization as of May 31, 2017 was $1,864,375 and $1,408,750 as of August 31, 2016.

 

Intangible assets

The Company acquired certain intangible assets as part of the acquisition of Cognigen Corporation on September 2, 2014. The following table summarizes those intangible assets as of May 31, 2017:

 

    Amortization Period   Acquisition Value     Accumulated Amortization     Net book value  
Customer relationships   Straight line 8 years   $ 1,100,000     $ 378,125     $ 721,875  
Trade Name-Cognigen   None     500,000             500,000  
Covenants not to compete   Straight line 5 years     50,000       27,500       22,500  
        $ 1,650,000     $ 405,625     $ 1,244,375  

  

Amortization expense for each of the three-and nine-month periods ended May 31, 2017 and 2016 was $36,875 and $110,625, respectively. According to policy in addition to normal amortization, these assets are tested for impairment as needed.

  

Earnings per Share

We report earnings per share in accordance with FASB ASC 260-10. Basic earnings per share is computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The components of basic and diluted earnings per share for the three and nine months ended May 31, 2017 and 2016 were as follows:

 

    Three months ended     Nine months ended  
    5/31/2017     5/31/2016     5/31/2017     5/31/2016  
Numerator:                                
Net income attributable to common shareholders   $ 2,080,029     $ 1,909,339     $ 4,637,354     $ 4,161,161  
                                 
Denominator:                                
Weighted-average number of common shares outstanding during the period     17,241,891       17,028,634       17,233,470       17,000,228  
Dilutive effect of stock options     343,637       198,906       221,394       219,607  
Common stock and common stock equivalents used for diluted earnings per share     17,585,528       17,227,540       17,454,864       17,219,835  

 

Stock-Based Compensation

Compensation costs related to stock options are determined in accordance with FASB ASC 718-10, “Compensation-Stock Compensation”, using the modified prospective method. Under this method, compensation cost is calculated based on the grant-date fair value estimated in accordance with FASB ASC 718-10, amortized on a straight-line basis over the options’ vesting period. Stock-based compensation was $142,879 and $114,367 for the three months ended May 31, 2017 and 2016 respectively and $355,365 and $234,616 or the nine months ended May 31, 2017 and 2016, respectively. This expense is included in the condensed consolidated statements of operations as Selling, General, and Administration (SG&A), and Research and Development expense.

 

 

 

  9  
 

 

 

Recently Issued Accounting Pronouncements

In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The standard will eliminate the transaction- and industry-specific revenue recognition guidance under current U.S. GAAP and replace it with a principles-based approach for determining revenue recognition. ASU 2014-09 is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted for years beginning after December 15, 2016. The revenue recognition standard is required to be applied retrospectively, including any combination of practical expedients as allowed in the standard. We are evaluating the impact, if any, of the adoption of ASU 2014-09 to our financial statements and related disclosures. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting.

 

In November 2015, the FASB issued ASU No 2015-17, Income Taxes (Topic 740). The amendments in ASU 2015-17 change the requirements for the classification of deferred taxes on the balance sheet. Currently, GAAP requires an entity to separate deferred income tax liabilities and assets into current and noncurrent amounts in a classified statement of financial position. To simplify the presentation of deferred income taxes, the amendments in this ASU require that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. The pronouncement is effective for fiscal years and interim periods within those fiscal years beginning after December 15, 2016. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company early adopted ASU No. 2015-17 because it reduced complexity while maintaining the usefulness of the information. The retrospective application resulted in a reclassification of the current deferred tax asset at August 31, 2016 now being presented against the long term deferred tax liability.

 

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in "Leases (Topic 840)" and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company is currently evaluating the impact of the adoption of this standard on its consolidated financial statements.

 

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting. This ASU affects entities that issue share-based payment awards to their employees. The ASU is designed to simplify several aspects of accounting for share-based payment award transactions that include - the income tax consequences, classification of awards as either equity or liabilities, classification on the statement of cash flows, and forfeiture rate calculations. ASU 2016-09 will become effective for the Company in the first quarter of fiscal 2019. Early adoption is permitted in any interim or annual period. The Company early adopted ASU No. 2016-09. The adoption had no material impact on the Company’s financial statements.

  

NOTE 3: Property and Equipment

 

Property and equipment as of May 31, 2017 consisted of the following:

 

Equipment   $ 572,871  
Computer equipment     230,229  
Furniture and fixtures     127,857  
Leasehold improvements     103,599  
Sub total     1,034,556  
Less: Accumulated depreciation and amortization     (777,004 )
Net Book Value   $ 257,552  

  

NOTE 4: CONTRACTS PAYABLE

 

TSRL

Pursuant to the termination and nonassertion agreement with TSRL (See note 2), the Company paid TSRL $2,500,000 over a three-year period. The final payment of $1,000,000 was made in April 2017.

  

 

 

 

  10  
 

 

NOTE 5: COMMITMENTS AND CONTINGENCIES

 

Employment Agreements

 

CEO Employment Agreement

In August 2014, we entered into an employment agreement with Mr. Woltosz for his services as our Chief Executive Officer, which was effective September 1, 2014 and continued until August 31, 2015 (the “September 2014 Agreement”). Under the terms of this employment agreement, Mr. Woltosz was required to devote a minimum of 60% of his productive time to performing the duties as our Chief Executive Officer. The agreement provided for an annual base salary of $180,000, an annual performance bonus of up to 5% of the Company’s net income before taxes of the previous fiscal year, not to exceed $36,000, and the grant of an option to purchase six shares of the Company’s common stock for each $1,000 of net income before taxes that the Company earns at the end of each fiscal year (up to a maximum of 12,000 shares over the term of the agreement) with an exercise price equal to 10% over the market value per share as of the date of grant. In August 2015 this agreement was renewed for another year on the same terms. Under his current employment agreement, we agreed to provide Mr. Woltosz, at 60% of our actual costs, with such health insurance and other benefits which are appropriate to his office and position, adequate to the performance of his duties and not inconsistent with that which we customarily provide to our other management employees. We also agreed to reimburse him for customary, ordinary, and necessary business expenses incurred in connection with the rendering of services. The agreement also provides that we may terminate the agreement without cause upon thirty (30) days written notice, and that upon any such termination our only obligation to Mr. Woltosz would be for a payment equal to the greater of (i) 12 months of salary or (ii) the amount of salary for the remainder of the term of the agreement from the date of notice of termination. Further, the agreement provides that we may terminate the agreement for “cause” (as defined in the agreement) and that our only obligation to Mr. Woltosz upon any such termination would be limited to the payment of Mr. Woltosz’ salary and benefits through and until the effective date of any such termination. On July 9, 2015, the Company entered into a new employment agreement with Mr. Woltosz for another year on the same terms as the September 2014 agreement. A copy of this agreement was filed as an exhibit to the Current Form on Form 8-K filed with the Securities and Exchange Commission on July 15, 2015. On August 8, 2016 the Company entered into a new employment agreement for another year on the same terms as the September 2014 agreement. A copy of this agreement was filed as an exhibit to the Current Form on Form 8-K filed with the Securities and Exchange Commission on August 11, 2016.

 

President’s employment agreement

On September 2, 2014, Thaddeus H. Grasela, Jr., Ph.D., was appointed President of the Company and its wholly owned subsidiary Cognigen (also known as the Buffalo Division of the Company). The Company and Cognigen have entered into an Employment Agreement with Dr. Grasela (the “Grasela Employment Agreement”) that has a three-year term. Pursuant to the Grasela Employment Agreement, Dr. Grasela receives an annual base salary of $250,000, is eligible to receive Company stock options under the 2007 Simulations Plus, Inc. Stock Option Plan, as determined by the Board, and is eligible to receive an annual performance bonus in an amount not to exceed 10% of salary to be determined by the Compensation Committee of the Board. The Compensation Committee awarded Dr. Grasela a $25,000 performance bonus in each of September 2015 and September 2016 for the 2015 and 2016 fiscal years, respectively.

  

License Agreement

The Company executed a royalty agreement with Accelrys, Inc. (“Accelrys”) (the original agreement was entered into with Symyx Technologies in March 2010; Symyx Technologies later merged with Accelrys, Inc.) for access to their Metabolite Database for developing our Metabolite Module within ADMET Predictor™. The module was renamed the Metabolism Module when we released ADMET Predictor version 6 on April 19, 2012. Under this agreement, we pay a royalty of 25% of revenue derived from the sale of the Metabolism/Metabolite module to Accelrys. In 2014, Dassault Systemes of France acquired Accelrys and the Company now operates under the name BIOVIA. We incurred royalty expense of $35,494 and $44,485, respectively, and for the three months ended May 31, 2017 and 2016, respectively and $108,587 and $95,323 for the nine months ended May 31, 2017 and 2016, respectively.

 

Income taxes

Our federal income tax returns for fiscal year 2012 thru 2015 are open for audit, and our state tax returns for fiscal year 2011 through 2015 remain open for audit. In addition our California tax return for the fiscal year 2007 and fiscal year 2008 remains open with regard to R&D tax credits as a result of a previous audit for which we received a letter from the California Franchise Tax Board stating that an audit will not be conducted for those years at this time; however it may be subject to future audit. In 2015 the Company was informed that the IRS was auditing the Company’s tax return for 2014. This audit was completed during FY2016; there were no changes as a result of the audit.

 

Litigation

We are not a party to any legal proceedings and are not aware of any pending legal proceedings of any kind.

 

In June 2014, the Company was served with a complaint in a civil action entitled Sherri Winslow v. Incredible Adventures, Inc., et al. (Los Angeles Superior Court Case No. BC545789) alleging wrongful death and seeking unspecified damages arising out of a May 18, 2012 plane crash in the State of Nevada. The Company’s Chief Executive Officer owned the subject aircraft and is also a named defendant. The complaint alleged that the Company was the owner of the subject aircraft. The Company denied all material allegations against it, including that it owns or has ever owned any interest in the subject aircraft.

 

In June 2017, the Plaintiff settled the case with certain of the Defendants; the case was dismissed on June 20, 2017. The Company incurred no liability as part of the settlement and has been dismissed with prejudice.

 

 

 

 

  11  
 

  

NOTE 6: SHAREHOLDERS’ EQUITY

 

Dividend

The Company’s Board of Directors declared cash dividends during fiscal years 2017 and 2016. The details of the dividends paid are in the following tables:

 

FY2017  
Record Date   Distribution Date     Number of Shares Outstanding on Record Date       Dividend per Share       Total Amount  
11/10/2016   11/17/2016     17,226,478     $ 0.05     $ 861,324  
1/30/2017   2/6/2017     17,233,758     $ 0.05     $ 861,688  
5/08/2017   5/15/2017     17,240,626     $ 0.05     $ 862,031  
Total                       $ 2,585,043  

 

FY2016  
Record Date   Distribution Date     Number of Shares Outstanding on Record Date       Dividend per Share       Total Amount  
11/09/2015   11/16/2015     16,996,001     $ 0.05     $ 849,800  
1/29/2016   02/05/2016     17,018,001     $ 0.05     $ 850,900  
5/02/2016   5/09/2016     17,029,051     $ 0.05     $ 851,475  
8/11/2016   8/18/2016     17,221,978     $ 0.05     $ 861,099  
Total                       $ 3,413,274  

 

Stock Option Plan

In September 1996, the Board of Directors adopted, and the shareholders approved, the 1996 Stock Option Plan (the "Option Plan") under which a total of 1,000,000 shares of common stock had been reserved for issuance. In March 1999, the shareholders approved an increase in the number of shares that may be granted under the Option Plan to 2,000,000. In February 2000, the shareholders approved an increase in the number of shares that may be granted under the Option Plan to 4,000,000. In December 2000, the shareholders approved an increase in the number of shares that may be granted under the Option Plan to 5,000,000. Furthermore, in February 2005, the shareholders approved an additional 1,000,000 shares, resulting in the total number of shares that may be granted under the Option Plan to 6,000,000. The 1996 Stock Option Plan terminated in September 2006 by its term.

 

On February 23, 2007, the Board of Directors adopted, and the shareholders approved, the 2007 Stock Option Plan under which a total of 1,000,000 shares of common stock had been reserved for issuance. On February 25, 2014 the shareholders approved an additional 1,000,000 shares increasing the total number of shares that may be granted under the Option Plan to 2,000,000. This plan terminated in February 2017 by its term.

 

On December 23, 2016 the Board of Directors adopted, and on February 23, 2017 the shareholders approved, the 2017 Equity Incentive Plan under which a total of 1,000,000 shares of common stock has been reserved for issuance. This plan will terminate in December 2026.

 

Qualified Incentive Stock Options (Qualified ISO)

As of May 31, 2017 employees hold Qualified ISO to purchase 1,272,692 shares of common stock at exercise prices ranging from $1.00 to $10.06.

 

Transactions in FY17   Number of Options     Weighted-Average Exercise Price
Per Share
    Weighted-Average Remaining Contractual Life  
Outstanding, August 31, 2016     894,750     $ 7.54       7.72  
Granted     404,582     $ 10.05          
Exercised     (9,892 )   $ 7.00          
Cancelled/Forfeited     (16,748 )   $ 9.24          
Outstanding, May 31, 2017     1,272,692     $ 8.32       7.82  
Exercisable, May 31, 2017     359,000     $ 5.96       5.18  

  

 

 

  12  
 

 

Non-Qualified Stock Options (Non-Qualified ISO)

As of May 31, 2017 the outside members of the Board of Directors and certain employees hold non-qualified options to purchase 47,168 shares of common stock at exercise prices ranging from $4.46 to $10.06.

 

Transactions in FY17   Number of Options     Weighted-Average Exercise Price
Per Share
    Weighted-Average Remaining Contractual Life  
Outstanding, August 31, 2016     52,750     $ 6.88       8.07  
Granted     17,418     $ 10.05          
Exercised     (9,500 )   $ 5.88          
Cancelled/Forfeited     (13,500 )   $ 7.43          
Outstanding, May 31, 2017     47,168     $ 8.10       8.61  
Exercisable, May 31, 2017     13,000     $ 5.78       6.90  

 

The weighted-average remaining contractual life of options outstanding issued under the Plan, both Qualified ISO and Non-Qualified SO, was 7.85 years at May 31, 2017. The exercise prices for the options outstanding at May 31, 2017 ranged from $1.00 to $10.06, and the information relating to these options is as follows:

 

Exercise Price     Awards Outstanding     Awards Exercisable  
Low     High     Quantity     Weighted Average Remaining Contractual Life     Weighted Average Exercise Price     Quantity     Weighted Average Remaining Contractual Life     Weighted Average Exercise Price  
$ 1.00     $ 1.50       67,000       1.85 years     $ 1.00       67,000       1.85 years     $ 1.00  
$ 3.01     $ 4.50       20,000       1.10 years     $ 3.16       20,000       1.10 years     $ 3.16  
$ 4.51     $ 6.00       70,000       1.66 years     $ 5.52       70,000       1.66 years     $ 5.52  
$ 6.01     $ 7.50       341,040       7.28 years     $ 6.86       136,620       7.30 years     $ 6.86  
$ 7.51     $ 9.00       10,000       9.25 years     $ 8.62                 $  
$ 9.01     $ 10.06       811,820       9.26 years     $ 9.89       78,380       8.79 years     $ 9.72  
                  1,319,860       7.85 years     $ 8.32       372,000       5.24 years     $ 5.96  

  

NOTE 7: RELATED PARTY TRANSACTIONS

 

As of May 31, 2017, included in bonus expenses to officers was $45,750, of which $27,000 was an accrued bonus representing an estimated amount of bonus payable to our Chief Executive Officer, Walter Woltosz as part of his current employment agreement, and $18,750 accrued bonus representing as estimated amount of bonus payable to our President, Thaddeus Grasela as part of his current employment agreement.

 

May 1, 2017, Dr. Daniel Weiner was appointed as a member of the Board of Directors of the Company. Dr. Weiner also served on the Board of Directors of DILIsym. Immediately prior to the closing of the acquisition discussed in Subsequent Event Note 11, Dr. Weiner owned 5,000 shares of DILIsym’s common stock (less than one percent of DILIsym’s outstanding shares). At the closing of the Acquisition, Dr. Weiner received approximately $29,000 in cash consideration of the sale of his shares of DILIsym to the Company and may receive up to an additional $35,000 upon any payment of the holdback consideration and/or Earn-out Payments.

 

NOTE 8: CONCENTRATIONS AND UNCERTAINTIES

 

Revenue concentration shows that international sales accounted for 34% and 43.8% of net sales for the nine months ended May 31, 2017 and 2016, respectively. Three customers accounted for 8%, 6% (a dealer account in Japan representing various customers), and 5% of sales for the nine months ended May 31, 2017. Four customers accounted for 8% (a dealer account in Japan representing various customers), 6%, 5% and 5% of sales for the nine months ended May 31, 2016.

 

Accounts receivable concentrations shows that three customers comprised 14%, 12% (a dealer account in Japan representing various customers), and 8% of accounts receivable at May 31, 2017 compared to two customers comprising 15% and 11% (a dealer account in Japan representing various customers) at May 31, 2016.

 

We operate in the computer software industry, which is highly competitive and changes rapidly. Our operating results could be significantly affected by our ability to develop new products and find new distribution channels for new and existing products.

 

The majority of our customers are in the pharmaceutical industry. Consolidation and downsizing in the pharmaceutical industry could have an impact on our revenues and earnings going forward.

 

  13  
 

 

  

NOTE 9: SEGMENT AND Geographic Reporting

 

We account for segments and geographic revenues in accordance with guidance issued by the FASB. Our reportable segments are strategic business units that offer different products and services.

 

Results for each segment and consolidated results are as follows for the three and nine months ended May 31, 2017 and 2016 (in thousands):

 

Three months ended May 31, 2017
    Lancaster     Buffalo     Eliminations     Total  
Net revenues   $ 4,948     $ 1,801             $ 6,749  
Income (loss) from operations     2,681       414               3,095  
Identifiable assets     27,428       9,358     $ (7,238 )     29,548  
Capital expenditures     12       0               12  
Capitalized software costs     278       66               344  
Depreciation and amortization     422       92               514  

 

Three months ended May 31, 2016
    Lancaster     Buffalo     Eliminations     Total  
Net Revenues   $ 4,664     $ 1,348             $ 6,012  
Income (loss) from operations     2,577       211               2,788  
Total assets     26,532       9,504     $ (7,238 )     28,798  
Capital expenditures     3       27               30  
Capitalized software costs     222       48               270  
Depreciation and Amortization     381       98               479  

 

Nine months ended May 31, 2017
    Lancaster     Buffalo     Eliminations     Total  
Net Revenues   $ 12,685     $ 5,187             $ 17,872  
Income (loss) from operations     5,739       1,079               6,818  
Total assets     27,428       9,358     $ (7,238 )     29,548  
Capital expenditures     37       80               117  
Capitalized software costs     809       120               929  
Depreciation and Amortization     1,261       286               1,547  

 

Nine months ended May 31, 2016
    Lancaster     Buffalo     Eliminations     Total  
Net Revenues   $ 11,722     $ 4,293             $ 16,015  
Income (loss) from operations     5,471       760               6,232  
Total assets     26,532       9,504     $ (7,238 )     28,798  
Capital expenditures     4       28               32  
Capitalized software costs     678       138               816  
Depreciation and Amortization     1,171       279               1,450  

  

In addition, the Company allocates revenues to geographic areas based on the locations of its customers. Geographical revenues for the three months and nine months ended May 31, 2017 and 2016 were as follows (in thousands):

 

Three months ended May 31, 2017
    North America     Europe     Asia     South America     Total  
Lancaster   $ 2,533     $ 1,144     $ 1,271     $ 0     $ 4,948  
Buffalo     1,801       0       0       0       1,801  
Total   $ 4,334     $ 1,144     $ 1,271     $ 0     $ 6,749  

 

Three months ended May 31, 2016
    North America     Europe     Asia     South America     Total  
Lancaster   $ 2,444     $ 1,247     $ 973     $ 0     $ 4,664  
Buffalo     1,348       0       0       0       1,348  
Total   $ 3,792     $ 1,247     $ 973     $ 0     $ 6,012  

 

 

  14  
 

 

 

Nine months ended May 31, 2017
    North America     Europe     Asia     South America     Total  
Lancaster   $ 6,261     $ 3,201     $ 3,222     $ 1     $ 12,685  
Buffalo     5,187                         5,187  
Total   $ 11,448     $ 3,201     $ 3,222     $ 1     $ 17,872  

 

Nine months ended May 31, 2016
    North America     Europe     Asia     South America     Total  
Lancaster   $ 5,237     $ 3,651     $ 2,833     $ 1     $ 11,722  
Buffalo     4,293                         4,293  
Total   $ 9,530     $ 3,651     $ 2,833     $ 1     $ 16,015  

 

NOTE 10: EMPLOYEE BENEFIT PLAN

 

We maintain a 401(K) Plan for all eligible employees, and we make matching contributions equal to 100% of the employee’s elective deferral, not to exceed 4% of total employee compensation. We can also elect to make a profit-sharing contribution. Our contributions to this Plan amounted to $64,233 and $61,028 for the three months ended May 31, 2017 and 2016 respectively and $179,123 and $168,654 for the nine months ended May 31, 2017 and 2016, respectively.

 

NOTE 11: SUBSEQUENT EVENTS

 

On May 1, 2017, Simulations Plus, Inc. entered into a Stock Purchase Agreement (the “Agreement”) with DILIsym Services, Inc., a North Carolina corporation (“DILIsym”), the shareholders of DILIsym (the “DILIsym Shareholders”) and Brett A. Howell, the representative of the DILIsym Shareholders (the “DILIsym Shareholders Representative”), each, a “Party,” and collectively, the “Parties.”

 

On June 1, 2017, the Company consummated the acquisition of all outstanding capital stock of DILIsym pursuant to the terms of the Agreement and DILIsym became a wholly owned subsidiary of the Company (the “Acquisition”). Under the terms of the Agreement, the Company: (1) paid to the DILIsym Shareholders Five Million Dollars ($5,000,000) payable at the closing of the Acquisition (the “Closing”) subject to certain adjustments and holdbacks as provided in the Agreement and as more fully described below; and (2) will pay to the DILIsym Shareholders certain earn-out payments, to be measured by the adjusted earnings of DILIsym before income taxes, payable following the Closing, as more particularly described below and in the Agreement:

 

a) On June 1, 2017, the Company paid the DILIsym Shareholders total cash consideration of $4,515,982; which such amount included $515,982 in working capital left in DILIsym’s accounts in excess of the amount required under the Agreement,

 

b) At the holdback release date, eighteen months from the Closing and subject to any offsets, the Company will pay $1,000,000 of holdback consideration; and

 

c) In addition, the Company may pay up to an additional $5,000,000 in Earn-out Payments over the 3 years following the Closing if and when such Earn-out Payments become due and payable, and subject to certain offsets as provided in the Agreement, according to the Agreement.

 

The Company is currently in the process of preparing information for, and assessing the accounting treatment of the transaction.

 

 

 

  15  
 

  

Item 2. Management's Discussion and Analysis or Plan of Operations

 

Forward-Looking Statements

 

This document and the documents incorporated in this document by reference contain forward-looking statements that are subject to risks and uncertainties. All statements other than statements of historical fact contained in this document and the materials accompanying this document are forward-looking statements.

 

The forward-looking statements are based on the beliefs of our management, as well as assumptions made by and information currently available to our management. Frequently, but not always, forward-looking statements are identified by the use of the future tense and by words such as “believes,” expects,” “anticipates,” “intends,” “will,” “may,” “could,” “would,” “projects,” “continues,” “estimates” or similar expressions. Forward-looking statements are not guarantees of future performance and actual results could differ materially from those indicated by the forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by the forward-looking statements.

 

The forward-looking statements contained or incorporated by reference in this document are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”) and are subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. These statements include declarations regarding our plans, intentions, beliefs, or current expectations.

 

Among the important factors that could cause actual results to differ materially from those indicated by forward-looking statements are the risks and uncertainties described under “Risk Factors” in our Annual Report and elsewhere in this document and in our other filings with the SEC.

 

Forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements included in this document are made as of the date of this document and we do not undertake any obligation to update forward-looking statements to reflect new information, subsequent events, or otherwise.

 

General

 

BUSINESS

 

OVERVIEW

 

Simulations Plus, Inc., incorporated in 1996, is a premier developer of groundbreaking drug discovery and development software for mechanistic modeling and simulation, and for machine-learning-based prediction of properties of molecules solely from their structure, and is exploring the application of its machine-learning technologies in other industries, including aerospace/military and general healthcare. Our pharmaceutical/chemistry software is licensed to major pharmaceutical, biotechnology, agrochemical, and food industry companies and to regulatory agencies worldwide for use in the conduct of industry-based research. We also provide consulting services ranging from early drug discovery through preclinical and clinical trial data analysis and for submissions to regulatory agencies. As the result of acquiring our Cognigen division in Buffalo in 2014, we are also a leading provider of population modeling and simulation contract research services for the pharmaceutical and biotechnology industries. Our clinical-pharmacology-based consulting services include pharmacokinetic and pharmacodynamic modeling, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions. In addition, we have developed software for harnessing cloud-based computing in support of modeling and simulation activities and secure data archiving, and we provide consulting services to improve interdisciplinary collaborations and research and development productivity. Simulations Plus is headquartered in Southern California, with additional offices in Buffalo, New York; San Diego, California; Auburn, Alabama; Guerneville, California; and Raleigh-Durham, North Carolina. The Company’s common stock trades on the NASDAQ Capital Market under the symbol “SLP.”

 

We are a global leader focused on improving the ways scientists use knowledge and data to predict the properties and outcomes of pharmaceutical and biotechnology agents, and are one of only two global companies who provide a wide range of preclinical and clinical consulting services and software from early discovery all the way through clinical trials and beyond to post-patent support of generic drug companies. Our innovations in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, physiology, and machine learning into our software have made us the leading software provider for physiologically based pharmacokinetics (PBPK) modeling and simulation and for prediction of molecular properties from structure.

  

We generate revenue by delivering relevant, cost-effective software and creative and insightful consulting services. Pharmaceutical and biotechnology companies use our software programs and scientific knowledge to guide early drug discovery (molecule design and screening), preclinical development, clinical development, and generic product development programs. They use it to enhance their understanding of the properties of potential new medicines and to use emerging data to improve formulations, select and justify dosing regimens, optimize clinical trial design, and simulate outcomes in special populations, such as the elderly and pediatric patients.

 

 

  16  
 

 

PRODUCTS

 

General

 

We currently offer eight software products for pharmaceutical research and development: three simulation programs that provide time-dependent results based on solving large sets of differential equations: GastroPlus™; DDDPlus™; and MembranePlus™; three programs that are based on predicting and analyzing static (not time-dependent) properties of chemicals: ADMET Predictor™; MedChem Designer™; and MedChem Studio™ (the combination of ADMET Predictor, MedChem Designer, and MedChem Studio is called our ADMET Design Suite™); our newest program which is designed for rapid clinical trial data analysis and regulatory submissions called PKPlus™; and one program called KIWI™ from our Cognigen division that provides an integrated platform for data analysis and reporting through our proprietary secure cloud.

 

GastroPlus

Our flagship product, and currently our largest source of revenue, is GastroPlus. GastroPlus simulates the absorption, pharmacokinetics, and pharmacodynamics of drugs administered to humans and animals, and is currently the most widely used commercial software of its type by pharmaceutical companies, the U.S. Food and Drug Administration (FDA), the U.S. National Institutes of Health (NIH), and other government agencies in the U.S. and other countries. The FDA currently has 70 GastroPlus licenses.

 

Because of the widespread use of GastroPlus, we were the only non-European company invited to join the European Innovative Medicines Initiative (IMI) program for Oral Bioavailability Tools (OrBiTo). OrBiTo, begun in 2012, is an international collaboration among 27 industry, academic, and government organizations working in the area of oral absorption of pharmaceutical products. Because we are outside of the European Union, our participation in this project has been at our own expense, while other members are compensated for their work; however, we are a full member with access to all of the data and discussions of all other members. We believe our investment to participate in this initiative has enabled us to benefit from, and to contribute to, advancing the prediction of human oral bioavailability from preclinical data, and ensures that we are well-known to member pharmaceutical companies and regulatory agencies.

 

In September 2016 we announced that Simulations Plus had been invited to join the European SimInhale Consortium and had been admitted to this prestigious group focused on advancing the state of the art for simulation of inhaled dosage forms. As one of only two U.S. participants, Simulations Plus is participating in activities designed to advance particle designs for improved deposition and interaction with lung tissue; promote realistic computer simulations of particle aerosolization, delivery, and deposition; promote patient-tailored inhaled medicines; promote integration of device and formulation design; and promote critical assessment of toxicity issues and related risks.

 

In September 2014, we entered into a research collaboration agreement (RCA) with the FDA to enhance the Ocular Compartmental Absorption and Transit (OCAT™) model within the Additional Dosing Routes Module of GastroPlus. The objective of this agreement is to provide a tool for generic companies and the FDA to assess the likely bioequivalence of generic drug formulations dosed to the eye. Under this RCA, we receive up to $200,000 per year. This RCA may be renewed for up to a total of three years based on the progress achieved during the project. After a successful second year, the RCA was renewed for its third year in September 2016, and will expire in September 2017.

 

We were awarded another RCA by the FDA in September 2015, this one to expand the capabilities of GastroPlus to simulate the dosing of long-acting injectable microspheres. This type of dosage form is usually injected via subcutaneous or intramuscular routes, but can also be used for ocular dosing. Once again, this RCA provides up to $200,000 per year for up to three years. Under this agreement, we are developing simulation models to deal with the very slow dissolution/decomposition of the microsphere carrier material that gradually releases the active drug over periods as long as weeks or months. After a successful first year, the RCA was renewed for the second year in September 2016, and will expire in September 2017 unless further renewed.

 

In addition to the two funded efforts with the FDA described above, we also have an unfunded RCA with the FDA’s Office of Generic Drugs (OGD) that began in 2014. The objective of this RCA, which has a five-year term, is directed toward the FDA’s evaluation of mechanistic IVIVCs ( in vitro-in vivo correlations) to determine whether mechanistic absorption modeling (MAM) can relate laboratory ( in vitro ) dissolution experiment results to the behavior of dosage forms in humans and animals ( in vivo ) better than traditional empirical methods.

  

In April 2017, we released Version 9.5 of GastroPlus after nearly two years of improvements over version 9.0, which was released in April 2015. Version 9.5 is now the largest single upgrade we’ve made to the program. New functionalities that we believe provide the most advanced decision-making tool for preclinical and early clinical trial simulation and modeling analysis available today include:

 

  · ability to simulate the absorption and distribution of antibody-drug conjugates (ADCs), which are antibodies that are used to carry small drug molecules to the intended target tissue
  · ability to dose via intramuscular injection and an improved model for subcutaneous injection
  · several new physiology models, including Chinese and hepatic impairment populations
  · revamped workflows for building in vitro-in vivo correlations (IVIVCs) and performing virtual bioequivalence trial simulations
  · improved reporting capabilities, making it easier for companies wishing to submit results to regulatory agencies

 

 

  17  
 

 

Our goal with GastroPlus is to integrate the most advanced science into user-friendly software to enable pharmaceutical researchers and regulators to perform sophisticated analyses of complex drug behaviors in humans and laboratory animals. Already the most widely used program in the world for physiologically based pharmacokinetics (PBPK), the addition of these new capabilities is expected to expand the user base in the early pharmaceutical research and development process, while also helping us further penetrate the biopharmaceuticals, food, cosmetics, and general toxicology markets.

 

DDDPlus

DDDPlus simulates in vitro (laboratory) experiments that measure the rate of dissolution of a drug and, if desired, the additives (excipients) in a particular dosage form (e.g., powder, tablet, capsule, or injectable solids) under a variety of experimental conditions. This unique software program is used by formulation scientists in industry and the FDA to (1) understand the physical mechanisms affecting the disintegration and dissolution rates of various formulations, (2) reduce the number of cut-and-try attempts to design new drug formulations, and (3) design in vitro dissolution experiments to better mimic in vivo (animal and human) conditions. Version 5.0 of DDDPlus, which added a number of significant enhancements, was released in April 2016. This version added new formulation types (controlled release bilayer tablet, delayed release coated tablet, and immediate release coated beads), expanded formulation specification options, biorelevant solubilities and surfactant effects on dissolution, tablet compression and disintegration models, links with GastroPlus, and updated licensing. Current improvements in development and testing include new capabilities to simulate in vitro dissolution experiments for long-acting injectable microspheres as part of our work under the FDA-funded grant mentioned above.

 

MembranePlus™

MembranePlus was released in October 2014. Similar to DDDPlus, MembranePlus simulates laboratory experiments, but in this case, the experiments are for measuring permeability of drug-like molecules through various membranes, including several different standard cell cultures (Caco-2, MDCK), as well as artificially formulated membranes (PAMPA). The value of such simulations derives from the fact that when the permeabilities of the same molecules are measured in different laboratories using (supposedly) the same experimental conditions, the results are often significantly different. These differences are caused by a complex interplay of factors in how the experiment was set up and run. MembranePlus simulates these experiments with their specific experimental details, and this enables scientists to better interpret how results from specific experimental protocols can be used to predict permeability in human and animals, which is the ultimate goal.

 

PKPlus™

On August 25, 2016, we announced the release of a new standalone software product called PKPlus, based on the internal PKPlus Module in GastroPlus that has been available since 2000. The PKPlus Module in GastroPlus provides quick and easy fitting of compartmental pharmacokinetic (PK) models as well as noncompartmental analysis (NCA) for intravenous and extravascular (oral, dermal, ocular, pulmonary, etc.) doses; however, the PKPlus Module in GastroPlus was not designed to meet all of the requirements for performing these analyses for Phase 2 and 3 clinical trials, nor to produce report-quality output for regulatory submissions. The new standalone PKPlus program has been developed to provide the full level of functionality needed by pharmaceutical industry scientists to perform the analyses and generate the outputs needed to fully satisfy regulatory agency requirements for both NCA and compartmental PK modeling. After receiving considerable feedback on version 1.0, we are modifying the program to include a number of additional features requested by our users and potential users and expect to release the next version later this year. We believe the potential number of eventual users for PKPlus is in the thousands world-wide and that it has the potential to eventually become one of our leading revenue producers.

 

ADMET Predictor™

ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) Predictor is a chemistry-based computer program that takes molecular structures (i.e., drawings of molecules represented in various formats) as inputs and predicts approximately 150 different properties for them at an average rate of over 100,000 compounds per hour on a modern laptop computer. This capability allows chemists to generate estimates for a large number of important molecular properties without the need to synthesize and test the molecules, as well as to generate estimates of unknown properties for molecules that have been synthesized, but for which only a limited number of experimental properties have been measured. Thus, a chemist can assess the likely success of a large number of existing molecules in a company’s chemical library, as well as molecules that have never been made, by providing their molecular structures, either by drawing them using a tool such as our MedChem Designer software, or by automatically generating large numbers of molecules using various computer algorithms, including those embedded in our MedChem Studio software.

  

For many years, ADMET Predictor has been top-ranked for predictive accuracy in multiple peer-reviewed, independent comparison studies, while generating its results at a high throughput rate. Although the state of the art of this type of software does not enable identifying the best molecule in a series, it does allow early screening of molecules that are highly likely to fail as potential drug candidates (i.e., the worst molecules, which is usually the majority of a chemical library) before synthesizing and testing them. Thus, millions of virtual compounds can be created and screened in a day, compared to potentially months or years of work to actually synthesize and test a much smaller number of actual compounds.

 

 

 

  18  
 

 

The most recent release of ADMET Predictor, version 8.0, was released on August 1, 2016. This new version features a completely redesigned and modernized interface as well as a number of new capabilities to enhance the performance and user-friendliness of the program. In addition, we have integrated a number of MedChem Studio features into the new ADMET Predictor, and created a tighter integration between the two programs when a MedChem Studio license is obtained along with an ADMET Predictor license.

 

The optional ADMET Modeler Module™ in ADMET Predictor enables scientists to use their own experimental data to quickly create proprietary high-quality predictive models using the same powerful machine-learning methods we use to build our top-ranked property predictions. Pharmaceutical companies expend substantial time and money conducting a wide variety of experiments on new molecules each year, generating large databases of experimental data. Using this proprietary data to build predictive models can provide a second return on their investment; however, model building has traditionally been a difficult and tedious activity performed by specialists. The automation in ADMET Modeler makes it easy for a scientist to create very powerful models with minimal training.

 

We released version 8.1 in January 2017. This new release includes:

 

  · Both 64-bit and 32-bit executables, making it possible to handle larger data sets
  · Optimization of spreadsheet and model-building functions to improve efficiency
  · Model-building in ADMET Modeler has been streamlined and made much more efficient
  · The MedChem Studio™ Module includes combinatorial substituent and scaffold replacement operations
  · New in silico Ames tests have been added to produce reliable confidence predictions and are more broadly applicable
  · ADMET Risk™ scores are now accessible graphically in histograms

 

Version 8.5 is now well along in development and will add a number of powerful new features, including significant improvements to the ADMET Modeler Module.

  

Potential new markets for machine learning

We are currently investigating applications of our sophisticated machine-learning engine outside of our normal pharmaceutical markets. To date, we have conducted several proof-of-concept studies including: (1) building predictive models for missile aerodynamic force and moment coefficients as a function of missile geometry, Mach number, and angle of attack, (2) classifying/identifying missiles and other objects from radar tracking data, (3) mapping jet engine compressor performance to predict when maintenance might be required, and (4) classifying patients as healthy or experiencing some disease state or genetic disorder evidenced by magnetic resonance imaging (MRI) of the brain. Other potential applications for this modeling engine have also been identified; however, our focus to date has been primarily in these areas.

 

We believe our proprietary machine-learning software engine has a wide variety of potential applications and we intend to pursue funding to develop customized tools to further monetize our investment in this technology by expanding our markets beyond the life sciences and chemistry. In addition, we are examining a variety of expanded capabilities to add to the basic modeling engine to accommodate even larger data sets (“big data analytics”) and new applications.

 

MedChem Designer™

MedChem Designer was launched in 2011. It was initially a molecule-drawing program, or “sketcher”, but now has capabilities exceeding those of other molecule-drawing programs because of its integration with both MedChem Studio and ADMET Predictor. We provide MedChem Designer for free because we believe that in the long run it will help to increase demand for ADMET Predictor and MedChem Studio, and because most other existing molecule-drawing programs are also provided for free. Our free version includes a small set of ADMET Predictor’s best-in-class property predictions, allowing the chemist to modify molecular structures and then see a few key properties very quickly. With a paid ADMET Predictor license, the chemist would see the entire approximately 150 predictions that are available. Over 18,000 copies of MedChem Designer have been downloaded by scientists around the world to date.

 

When used with a license for ADMET Predictor, MedChem Designer becomes a de novo molecule design tool. With it, a researcher can draw one or more molecular structures, then click on the ADMET Predictor icon and have approximately 150 properties for each structure calculated in seconds, including our proprietary ADMET Risk index. Researchers can also click on an icon to generate the likely metabolites of a molecule and then predict all of the properties of those metabolites from ADMET Predictor, including each of their ADMET Risk scores. This is important because a metabolite of a molecule can be therapeutically beneficial (or harmful) even though the parent molecule is not.

  

 

  19  
 

 

Our proprietary ADMET Risk score provides a single number that tells the chemist how many default threshold values for various predicted properties were crossed (or violated) by each structure. Thus, in a single number, the chemist can instantly compare the effects of different structural changes in many dimensions. The ideal score is zero; however, a low score greater than zero might be acceptable, depending on what property(s) caused the points to be assigned. If the number is too high (greater than 5 or 6), the molecule is not likely to be successful as a drug. The default rules can be modified and new rules can be added by the user to include any desired rule set based on any combination of calculated descriptors, predicted properties, and user inputs. As chemists attempt to modify structures to improve one property, they often cause others to become unacceptable. Without ADMET Risk, the chemist would have to individually examine many key properties for each new molecule (and its metabolites) to determine whether any of them became unacceptable as a result of changing the structure.

 

MedChem Studio™

MedChem Studio is a powerful software tool that is used both for data mining and for de novo design of new molecules. In its data-mining role, MedChem Studio facilitates searching large chemical libraries to find molecules that contain identified substructures, and it enables rapid identification of clusters (classes) of molecules that share common substructures. MedChem Studio version 4.0 was released during fiscal year 2014. We have now merged MedChem Studio with the refactoring of ADMET Predictor 8.0, so that either program can be entered through the same interface, and the communication between the two programs is enhanced through the seamless integration of both technologies. We believe this will enhance the attractiveness of both ADMET Predictor and MedChem Studio to medicinal and computational chemists.

  

While MedChem Designer can be used to refine a small number of molecules, MedChem Studio can be used to create and screen (with ADMET Predictor) very large numbers of molecules down to a few promising lead candidates. MedChem Studio has features that enable it to generate new molecular structures using a variety of de novo design methods. When MedChem Studio is used with ADMET Predictor and MedChem Designer (the combination of which we refer to as our ADMET Design Suite), we believe the programs provide an unmatched capability for chemists to search through large libraries of compounds that have undergone high-throughput screening experiments to find the most promising classes (groups of molecules with a large common part of their structures) and molecules that are active against a particular target. In addition, MedChem Studio can take an interesting (but not acceptable) molecule and, using a variety of design algorithms, quickly generate many thousands to millions of high quality analogs (similar new molecules). These molecules can then be screened using ADMET Predictor to find molecules that are predicted to be both active against the target and acceptable in a variety of ADMET properties. We demonstrated the power of the ADMET Design Suite during two NCE (new chemical entity) projects wherein we designed lead molecules to inhibit the growth of the plasmodium falciparum malaria parasite in one study and lead molecules that were combined COX-1 and COX-2 inhibitors. In each case, we announced ahead of time that we were attempting to do this, and we reported the results when the projects were complete. Every molecule we designed and had synthesized hit their targets in both projects.

 

KIWI TM

Drug development programs rely increasingly on modeling and simulation analyses to support decision-making and submissions to regulatory agencies. To ensure high-quality analyses, organizations must not only apply high-quality science, but must also be able to support the science by being able to validate the results. KIWI is a cloud-based web application that was developed to efficiently organize, process, maintain, and communicate the volume of data and results generated by pharmacologists and scientists over the duration of a drug development program. The validated workflow and tools within KIWI promote traceability and reproducibility of results.

 

The pharmaceutical industry has been rapidly adopting cloud technology as a solution to ever-expanding computer processing needs. Leveraging our 20-plus years of experience in providing an architecture supporting modeling and simulation efforts, we have developed KIWI as a secure, validated, enterprise-scale environment, enabling global teams to collaborate on model-based decision making. KIWI has proven to be a valuable platform for encouraging interdisciplinary discussions about the model development process and interpretation of results. We continue to receive positive feedback about the functionality implemented in KIWI and the value of the approach we have taken to harness cloud technology. We continue to improve functionality and collaboration within the KIWI platform, and we expect the licensing fee will be a source of recurring revenue for further development and growth. KIWI Version 1.3 was released in May 2015. This version of KIWI provides our user community with access to new features that accelerate completion of modeling projects by decreasing run times and facilitating the comparison and exporting of results across models. These features include dynamic comparisons of model parameter estimates and diagnostic plots, export of model run records for regulatory submissions, and accelerated infrastructure with the upgrade to the latest versions of NONMEM® and Perl-speaks-NONMEM running in a 64-bit Linux environment.

 

KIWI Version 1.6 was released in September 2016. This new version introduced major enhancements in the functionality of visualization tools offered by the platform. These enhancements include simplifying the creation of plots and comparing them across multiple models, thus accelerating the model refinement process. In addition, analysts can now conveniently copy visualization preferences across projects, improving consistency and facilitating collaboration and communication with clients and colleagues. We are now further enhancing KIWI as part of our five-year, almost-$5 million contract with a leading global research foundation.

  

 

 

  20  
 

 

Contract Research and Consulting Services

Our scientists and engineers have expertise in drug absorption via various dosing routes (oral, intravenous, ocular, nasal/pulmonary, and dermal), pharmacokinetics, and pharmacodynamics. They have attended over 200 scientific meetings worldwide in the past four years, often speaking and presenting. We frequently conduct contracted consulting studies for large customers (including the five largest pharmaceutical companies) who have particularly difficult problems and who recognize our expertise in solving them, as well as for smaller customers who prefer to have studies run by our scientists rather than to license our software and train someone to use it. The demand for our consulting services has been steadily increasing, and we have expanded our consulting teams to meet the increased workload.

 

We continue working on a five-year consulting agreement with a major research foundation to implement a platform for coordinating the data generated by global teams engaged in model-based drug development.

 

We currently are working with the FDA on three different Research Collaboration Agreements (RCAs): two funded efforts for the ocular model and long-acting injectable microspheres and the unfunded IVIVC effort, all described above under “GastroPlus”. We also successfully completed the fifth year of our five-year renewable collaboration with the Center for Food Safety and Nutrition of the FDA to develop predictive toxicity models for food additives and contaminants.

 

Pharmacometric Modeling

We have a reputation for high-quality analyses and regulatory reporting of data collected during preclinical experiments as well as clinical trials of new and existing pharmaceutical products, typically working on 30-40 drug projects per year. The model-based analysis of clinical trial data that we perform is different from the modeling analysis offered by GastroPlus; the former relies more on statistical and semi-mechanistic models, whereas the latter relies on very detailed mechanistic models. Statistical models rely on direct observation and mathematical equations that are used to fit data collected across multiple studies along with describing the variability within and between patients. Mechanistic models are based on a detailed understanding of the human body and the chemistry of the drug and involve mathematical and scientific representation of the phenomena involved in drug dissolution/precipitation, absorption, distribution, metabolism, and elimination. Collectively, the models guide drug formulation design and dose selection.

  

PRODUCT DEVELOPMENT

Development of our software is focused on expanding product lines, designing enhancements to our core technologies, and integrating existing and new products into our principal software architecture and platform technologies. We intend to continue to offer regular updates to our products and to continue to look for opportunities to expand our existing suite of products and services.

 

To date, we have developed products internally, sometimes also licensing or acquiring products, or portions of products, from third parties. These arrangements sometimes require that we pay royalties to third parties. We intend to continue to license or otherwise acquire technology or products from third parties when it makes business sense to do so. We currently have one license agreement, with BIOVIA, a San Diego division of Dassault Systemes in France (formerly known as Accelrys, Inc.), pursuant to which a small royalty is paid to BIOVIA from revenues on each license for the Metabolite module in ADMET Predictor. This license agreement continues in perpetuity and either party has the right to terminate it.

 

In 1997 we entered into an exclusive software licensing agreement with TSRL, Inc. (aka Therapeutic Systems Research Laboratories) (TSRL), pursuant to which TSRL licensed certain software technology and databases to us, and we paid royalties to TSRL. On May 15, 2014, we and TSRL entered into a termination and nonassertion agreement pursuant to which the parties agreed to terminate the 1997 exclusive software licensing agreement. As a result, the Company obtained a perpetual right to use certain source code and data, and TSRL relinquished any rights and claims to any GastroPlus products and to any claims to royalties or other payments under that agreement, and we agreed to pay TSRL total consideration of $6,000,000. All payments have now been made as of April 2017. Our payment obligation is being amortized at a constant rate of $150,000 per quarter until it is completely amortized, after which no further expense will be incurred. To date, this has resulted in expense savings over $900,000 compared to the royalty payments that would have been paid to TSRL if paid consistent with past practices.

  

MARKETING AND DISTRIBUTION

We distribute our products and offer our services in North America, South America, Europe, Japan, Australia, New Zealand, India, Singapore, Taiwan, and the People’s Republic of China.

 

We market our pharmaceutical software and consulting services through attendance and presentations at scientific meetings, exhibits at trade shows, seminars at pharmaceutical companies and government agencies, through our website, and using various communication channels to our database of prospects and customers. At various scientific meetings around the world each year there are numerous presentations and posters presented in which the reported research was performed using our software. Many of these presentations are from industry and FDA scientists; some are from our staff. In addition, more than 50 peer-reviewed scientific journal articles, posters, and podium presentations are typically published each year using our software, mostly by our customers, further supporting its use in a wide range of preclinical and clinical studies.

 

 

 

  21  
 

 

Our sales and marketing efforts are handled primarily internally with our scientific team and several senior management staff assisting our marketing and sales staff with trade shows, seminars, and customer trainings both online and on-site. We believe that this is more effective than a completely separate sales team for several reasons: (1) customers appreciate talking directly with software developers and consulting scientists who can answer a wide range of in-depth technical questions about methods and features; (2) our scientists and engineers gain an appreciation for the customer’s environment and problems; and (3) we believe the relationships we build through scientist-to-scientist contact are stronger than relationships built through salesperson-to-scientist contacts. We also have one independent distributor in Japan and two independent representatives in China who also sell and market our products with support from our scientists and engineers.

 

We provide support to the GastroPlus User Group in Japan, which was organized by Japanese researchers in 2009. In early 2013, a group of scientists in Europe and North America organized another group following the example set in Japan. Over 850 members have joined this group to date. We support this group through coordination of online meetings each month and managing the user group web site for exchange of information among members. These user groups provide us valuable feedback with respect to desired new features and suggested interface changes.

 

PRODUCTION

Our pharmaceutical software products are designed and developed by our development teams in California, North Carolina, and New York, with California locations in Lancaster, Gureneville, San Jose, and San Diego, and in Buffalo, New York. In addition, our Chief Executive Officer works primarily from Auburn, Alabama. Our products and services are now delivered electronically – we no longer provide CD-ROMs and printed manuals or reports.

 

COMPETITION

In our pharmaceutical software and services business, we compete against a number of established companies that provide screening, testing and research services, and products that are not based on simulation software. There are also software companies whose products do not compete directly with, but are sometimes closely related to, ours. Our competitors in this field include some companies with financial, personnel, research, and marketing resources that are larger than ours. Our management believes there is currently no significant competitive threat to GastroPlus; however, in spite of a high barrier to entry, one could be developed over time. Our new PKPlus software product will compete with one major and a few minor software programs; however, the capabilities and design features of PKPlus, along with more affordable licensing, are expected to generate significant interest. MedChem Studio, MedChem Designer, and ADMET Predictor/ADMET Modeler operate in a more competitive environment. Several other companies presently offer simulation or modeling software, or simulation-software-based services, to the pharmaceutical industry.

 

Major pharmaceutical companies conduct drug discovery and development efforts through their internal development staffs and through outsourcing. Smaller companies generally need to outsource a greater percentage of this research. Thus, we compete not only with other software suppliers, but also with the in-house development teams at some of the larger pharmaceutical companies.

 

Although competitive products exist, both new licenses and license renewals for GastroPlus have continued to grow. We believe that we enjoy a dominant market share in this segment. We believe our ADMET Predictor/ADMET Modeler, MedChem Studio, MedChem Designer, DDDPlus, MembranePlus, PKPlus, and KIWI software offerings are each unique in their combination of capabilities and we intend to continue to market them aggressively.

 

We believe the key factors in our ability to successfully compete in this field are our ability to: (1) continue to invest in research and development, and develop and support industry-leading simulation and modeling software and related products and services to effectively predict activities and ADMET-related behaviors of new drug-like compounds, (2) design new molecules with acceptable activity and ADMET properties, (3) develop and maintain a proprietary database of results of physical experiments that serve as a basis for simulated studies and empirical models, (4) attract and retain a highly skilled scientific and engineering team, (5) aggressively our products and services to our global market, and (6) develop and maintain relationships with research and development departments of pharmaceutical companies, universities, and government agencies.

  

In addition, we actively seek strategic acquisitions to expand the pharmaceutical software and services business and to explore opportunities in aerospace and general healthcare.

 

STRATEGY

 

Our business strategy is to do the things we need to do to promote growth both organically (i.e., by expanding our current products and services through in-house efforts) and by acquisition. We believe in the “Built to Last” approach - that the fundamental science and technologies that underlie our business units are the keys both to improving our existing products and to expanding the product line with new products that meet our various customers’ needs. We believe the continued growth of our pharmaceutical software and services business segment is the result of steadily increasing adoption of simulation and modeling software tools across the pharmaceutical industry, as well as the world-class expertise we offer as consultants to assist companies involved in the research and development of new medicines. We have received a continuing series of study contracts with pharmaceutical companies ranging from several of the largest in the world to a number of medium-sized and smaller companies in the U.S. and Europe.

 

 

 

 

  22  
 

  

In the fiscal year ended August 31, 2016 we distributed $0.20 per share in dividends to our shareholders. In November 2016, February 2017, and May 2017 we distributed quarterly dividends of $0.05 per share. We anticipate future dividends to be at least $0.05 per share per quarter; however, there can be no assurances that such dividends will be distributed, or if so, whether the amounts will be more, less, or the same as expected. The Board of Directors must approve each quarterly dividend distribution and may decide to increase, decrease, or eliminate dividend distributions at any time.

   

Results of Operations

 

Comparison of Three Months Ended May 31, 2017 and 2016.

 

The following table sets forth our condensed statements of operations (in thousands) and the percentages that such items bear to net sales (because of rounding, numbers may not foot):

 

    Three Months Ended  
    5/31/17     5/31/16  
Net revenues   $ 6,749       100.0%     $ 6,012       100.0%  
Cost of revenues     1,445       21.4       1,195       19.9  
Gross profit     5,304       78.6       4,817       80.1  
Selling, general and administrative     1,955       29.0       1,681       28.0  
Research and development     254       3.7       348       5.8  
Total operating expenses     2,209       32.7       2,029       33.8  
Income from operations     3,095       45.9       2,788       46.4  
Other income     (10 )     (0.2 )     12       0.2  
Income from operations before taxes     3,085       45.7       2,800       46.6  
(Provision for) income taxes     (1,005 )     (14.9 )     (891 )     (14.8 )
Net income   $ 2,080       30.8%     $ 1,909       31.8%  

 

Net Revenues

Consolidated net revenues increased by 12.2% or $736,000 to $6.75 million in the third fiscal quarter of Fiscal Year 2017 (“3QFY17”) from $6.01 million in the third fiscal quarter of Fiscal Year 2016 (“3QFY16”). This net increase was due to a $284,000 increase in revenues generated by our Lancaster Division, representing a 6.1% increase over 3QFY16, along with an increase of $453,000 or 33.6% in revenues of our Buffalo Division to $1.80 million in 3QFY17 from $1.35 million in 3QFY16. Consolidated software and software-related sales increased $223,000 or 4.9%, while consolidated consulting and analytical study revenues increased $513,000 or 34.9% over 3QFY16.

 

Cost of Revenues

Consolidated cost of revenues increased by $250,000, or 20.9%, in 3QFY17 to $1.45 million from $1.20 million in 3QFY16. Cost of Revenues as a percentage of revenue increased by 1.5% in 3QFY17 to 21.4% as compared to 19.9% in 3QFY16. $209,000 of the increased costs are allocated labor related to increased studies and contracts, and software amortization increase by $50,000.

  

Gross Profit

Consolidated gross profits increased $486,000 or 10.1%, to $5.30 million in 3QFY17 from $4.82 million in 3QFY16. Our Lancaster Division accounted for a $233,000 increase, which came from a mix of increased software license sales and analytical study revenues, while our Buffalo Division showed a $253,000 increase mainly from consulting revenues. Consolidated Gross profit as a percentage of revenues decreased 1.5% to 78.6% in 3QFY17 from 80.1% in 3QFY16.

  

Selling, General and Administrative Expenses

Selling, general, and administrative (SG&A) expenses increased $274,000, or 16.3%, to $1.95 million in 3QFY17, from $1.68 million in 3QFY16.

 

The major increases in SG&A expenses this year compared to last year were:

 

  · Commissions increased $94,000 – higher commissionable sales in Asia
  · Salaries and Wages increased $94,000 – increases in wages over the prior year, higher increased non-cash stock compensation costs, and a higher percentage of allocated G&A labor by scientific staff.
  · Recruitment and Hiring increased $34,000 – hiring fees and moving costs for increased staffing
  · Acquisition Costs DILIsym Services, Inc.—costs of acquisition during the quarter were $144,000 which included legal, M&A, accounting and other direct acquisition related costs

 

The major decreases in SG&A expenses this year compared to last year were:

 

  · Selling expenses decreased by $27,000 web and website redevelopment costs were down over the prior year
  · Professional Fees-Accounting–decreased by $55,000 lower compliance cost associated with Sarbanes-Oxley incurred in the current year

 

 

 

 

  23  
 

 

Research and Development

Total research and development cost decreased $19,000 in 3QFY17 compared to 3QFY16. In 3QFY17 we incurred approximately $598,000 of research and development costs, of which $344,000 was capitalized and $254,000 was expensed. In 3QFY16 we incurred approximately $617,000 of research and development costs, of which $269,000 was capitalized and $348,000 was expensed.

  

Provision for Income Taxes

The provision for income taxes was $1.00 million for 3QFY17 compared to $891,000 for 3QFY16. Our effective tax rate decreased to 32.57% in 3Q17from 34.4% in 3QFY16. This decrease is a result of the effect of tax credits and equity based compensation on earnings in 3QFY17.

 

Net Income

Net income increased by $171,000 or 8.9%, in 3QFY17 to $2.08 million from $1.91 million in 3QFY16. Net earnings from our Lancaster division were up $36,000 or 2.0% to $1.78 million in 3QFY17. Approximately $144,000 in one-time pretax charges related to the acquisition of DILIsym Services, Inc. were expensed to the Lancaster division in this reporting period, which lowered net income by approximately $97,000 for 3QFY17. Net earnings for our Buffalo division increased by $131,000 or 102.3% to $266,000 in 3QFY17.

  

Comparison of Nine Months Ended May 31, 2017 and 2016

 

The following table sets forth our condensed statements of operations (in thousands) and the percentages that such items bear to net sales (because of rounding, numbers may not foot):

 

    Nine Months Ended  
    5/31/17     5/31/16  
             
Net revenues   $ 17,872       100.0%     $ 16,015       100.0%  
Cost of revenues     4,335       24.2       3,542       22.1  
Gross profit     13,537       75.8       12,473       77.9  
Selling, general and administrative     5,767       32.3       5,080       31.7  
Research and development     953       5.3       1,161       7.3  
Total operating expenses     6,719       37.6       6,241       39.0  
Income from operations     6,818       38.2       6,232       38.9  
Other income     19       0.1       (22 )     (0.1 )
Income from operations before taxes     6,837       38.3       6,210       38.8  
(Provision for) income taxes     (2,200 )     (12.3 )     (2,048 )     (12.8 )
Net income   $ 4,637       25.9%     $ 4,161       26.0%  

 

Net Revenues

Consolidated net revenues increased by 11.6% or $1.86 million to $17.87 million in the first nine months of Fiscal Year 2017 (“9moFY17”) from $16.01 million in the first nine months of Fiscal Year 2016 (“9moFY16). $895,000 of this increase was from revenues generated by our Buffalo Division, representing a 20.8% increase over 9moFY16. Net revenues of the Lancaster Division increased $963,000, or 8.2%, to $11.72 million for 9moFY17 from $11.72 million in 9moFY16. Consolidated software and software-related sales increased $751,000, or 6.7%, in 9moFY17, while consolidated consulting and analytical study revenues increased $1.11 million, or 23.2%, over 9moFY16.

 

Cost of Revenues

Consolidated cost of revenues increased by 22.4% or $793,000 in 9moFY17 to $4.33 million from $3.54 million in 9moFY16. The increase came mainly from $472,000 of increased labor related to studies and contracts, $65,000 of increased costs associated with training programs, increased software amortization of $129,000, and $108,000 of direct contract-related expenses. Consolidated cost of revenues as a percentage of revenue increased from 22.1% in 9moFY16 to 24.2% in 9moFY17.

 

Gross Profit

Consolidated gross profit increased $1.06 million or 8.5%, to $13.53 million in 9moFY17 from $12.47 million in 9moFY16. $415,000 of this increase in gross margin is from our Buffalo Division, which showed a 56.9% gross margin on $5.19 million in revenues for 9moFY17. Our Lancaster Division accounted for $649,000 of the increase, showing an 83.4% gross margin for the nine-month period.

 

 

 

  24  
 

 

Selling, General and Administrative Expenses

Selling, general, and administrative (SG&A) expenses increased $687,000 or 13.5%, to $5.77 million in 9moFY17 from $5.08 million in 9moFY16.

 

  · Salaries and Wages increased $183,000 – increases in wages, taxes, and benefits over the prior year, higher annual bonuses paid based on increased profit, increased non-cash stock compensation costs, and a higher percentage of allocated G&A labor by scientific staff
  · Commission expense increased $102,000 – higher commissionable sales in Asia
  · Professional fees increased $316,000 – this increase is the result of the company’s transition to accelerated filer status and the cost of the Company’s Sarbanes-Oxley internal-control-related costs, as well as additional accounting compliance and legal costs associated with reviews of our proxy, 10-K, Equity Incentive Plan, and other corporate documents
  · Acquisition Costs DILIsym Services, Inc.—costs of acquisition during the nine months were $261,000, which included legal, M&A, accounting and other direct acquisition related costs

 

The major decreases in SG&A expenses this year compared to last year were:

 

  · Selling expenses decreased by $53,000 mostly as advertising and website redevelopment costs were down over the prior year
  · Travel and Entertainment decreased by $45,000 – lower cost of conference attendance and foreign travel

  

Research and Development

We incurred approximately $1.89 million of research and development costs during 9moFY17. Of this amount, $928,000 was capitalized software development costs and $952,000 was expensed. We incurred approximately $1.97 million of research and development costs during 9moFY16. Of this amount, $814,000 was capitalized software development costs and $1.16 million was expensed.

 

Other income (expense)

Other income increased $41,000 in 9moFY17 and showed income of $19,000 in 9moFY17 compared to an expense of $21,000 in 9MoFY16. Foreign currency exchange gains accounted for this change due to the dollar strengthening in relation to the Japanese yen.

 

Provision for Income Taxes

The provision for income taxes was $2.20 million for 9moFY17 compared to $2.05 million for 9moFY16. Our effective tax rate decreased to 32.2% in 9moFY17, down from 33.0% in 9moFY16 due mainly to the effect of stock-based compensation.

 

Net Income

Net income increased by $476,000, or 11.4%, to $4.64 million in 9moFY17 from $4.16 million in 9moFY16. The increase comes from revenue growth in both divisions of the Company. Net earnings from our Lancaster division were up $260,000 or 7% to $3.95 million in 9moFY17 from $3.69 million in 9moFY16. Approximately $261,000 in one-time pretax charges related to the acquisition of DILIsym Services, Inc. were expensed to the Lancaster division in 9moFY17, which lowered net income by approximately $177,000. Net earnings for our Buffalo division increased by $216,000 or 45.9% to $687,000 in 9moFY17 from $471,000 in 9moFY16.

 

Liquidity and Capital Resources

 

Our principal sources of capital have been cash flows from our operations. We have achieved continuous positive operating cash flow over the last nine fiscal years. We believe that our existing capital and anticipated funds from operations will be sufficient to meet our anticipated cash needs for working capital and capital expenditures for the foreseeable future. Thereafter, if cash generated from operations is insufficient to satisfy our capital requirements, we may open a revolving line of credit with a bank, or we may have to sell additional equity or debt securities or obtain expanded credit facilities. In the event such financing is needed in the future, there can be no assurance that such financing will be available to us, or, if available, that it will be in amounts and on terms acceptable to us. If cash flows from operations became insufficient to continue operations at the current level, and if no additional financing was obtained, then management would restructure the Company in a way to preserve its pharmaceutical business while maintaining expenses within operating cash flows.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

As of May 31, 2017 and August 31, 2016, we had cash and cash equivalents of $8.25 million and $8.03 million, respectively. We do not hold any investments that are exposed to market risk related to changes in interest rates, which could adversely affect the value of our assets and liabilities, and we do not hold any instruments for trading purposes and investment. Some of our cash and cash equivalents are held in money market accounts; however, they are not exposed to market rate risk.

 

 

 

 

  25  
 

 

In the three months and nine months ended May 31, 2017 and 2016 we sold $795,000 and $466,000, and $1.77 million and $1.73 million, respectively, of software through representatives in certain Asian markets in local currencies. As a result, our financial position, results of operations, and cash flows can be affected by fluctuations in foreign currency exchange rates, particularly fluctuations in the yen and RMB exchange rates. These transactions give rise to receivables that are denominated in currencies other than the entity’s functional currency. The value of these receivables is subject to changes because the receivables may become worth more or less due to changes in currency exchange rates. The majority of our software license agreements are denominated in U.S. dollars. We record foreign gains and losses as they are realized. We mitigate our risk from foreign currency fluctuations by adjusting prices in our foreign markets on a periodic basis. We base these changes on market conditions while working closely with our representatives. We do not hedge currencies or enter into derivative contracts.

  

Item 4. Controls and Procedures

 

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of May 31, 2017. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on this evaluation, management concluded as of May 31, 2017, that our disclosure controls and procedures were effective.

 

Changes in Internal Control over Financial Reporting

 

During the quarter ended May 31, 2017 we had implemented additional measures to remediate the underlying causes of the material weaknesses related to Information Technology General Controls identified in our annual report for the year ended August 31, 2016, including enhancing our internal documentation and monitoring approach to ensure that all GITC procedures designed to restrict access to applications and data are operating in an optimal manner in order to provide management with comfort that access is properly limited to the appropriate internal personnel.

 

Our management, including our CEO, president, and CFO, do not expect that our disclosure controls or internal controls over financial reporting will prevent all errors or all instances of fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the controls. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events, and any design may not succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with policies or procedures. Because of the inherent limitation of a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

   

Part II. Other Information

 

Item 1. Legal Proceedings

 

Except as described below, we are not a party to any legal proceedings and are not aware of pending legal proceedings of any kind.

 

In June 2014, the Company was served with a complaint in a civil action entitled Sherri Winslow v. Incredible Adventures, Inc., et al. (Los Angeles Superior Court Case No. BC545789) alleging wrongful death and seeking unspecified damages arising out of a May 18, 2012 plane crash in the State of Nevada.  The Company’s Chief Executive Officer owns the subject aircraft and is also a named defendant. The complaint alleged that the Company was the owner of the subject aircraft. The Company denied all material allegations against it, including that it owns or has ever owned any interest in the subject aircraft.

 

 

 

 

  26  
 

 

In June 2017 the Plaintiff settled the case with certain of the Defendants; the case was dismissed on June 20, 2017. The Company incurred no liability as part of the settlement and has been dismissed with prejudice.

 

Item 1A. Risk Factors

 

You should carefully consider the risks described below before investing in our publicly traded securities. The risks described below are not the only ones facing us. Our business is also subject to the risks that affect many other companies, such as competition, technological obsolescence, labor relations, general economic conditions, geopolitical changes, and international operations. We operate in a rapidly changing environment that involves a number of risks, some of which are beyond our control. Additional risks not currently known to us or that we currently believe are immaterial also may impair our business operations and our liquidity. The risks described below could cause our actual results to differ materially from those contained in the forward-looking statements we have made in this Quarterly Report on Form 10-Q, the information incorporated herein by reference, and those forward-looking statements we may make from time to time. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties.

 

Risks Relating to the Pending Transactions

 

None pending

 

Certain Risks Related to Our Marketplace and Environment

 

  a) Our ability to sustain or increase revenues will depend upon our success in entering new markets, continuing to increase our customer base, and in deriving additional revenues from our existing customers. Our products are currently used primarily by molecular modeling and simulation specialists in pharmaceutical, biotechnology, agritech, cosmetics, and government research organizations. One component of our overall business strategy is to derive more revenues from our existing customers by expanding their use of our products and services. Such strategy would have our customers utilize our scientific informatics platforms and our tools and components to leverage vast amounts of information stored in both corporate databases and public data sources in order to make informed scientific and business decisions during the research and development process. In addition, we seek to expand into new markets, and new areas within our existing markets, by acquiring businesses in these markets, attracting and retaining personnel knowledgeable in these markets, identifying the needs of these markets, and developing marketing programs to address these needs. If successfully implemented, these strategies would increase the usage of our software and services by biologists, chemists, engineers, and informaticians operating within our existing pharmaceutical, biotechnology, and chemical customers, as well as by new customers in other industries. However, if our strategies are not successfully implemented, our products and services may not achieve market acceptance or penetration in targeted new departments within our existing customers or in new industries. As a result, we may incur additional costs and expend additional resources without being able to sustain or increase revenue.

  

  b) Consolidation within the pharmaceutical and biotechnology industries may continue to lead to fewer potential customers for our products and services . A significant portion of our customer base consists of pharmaceutical and biotechnology companies. Consolidation within the pharmaceutical and biotechnology industries may result in fewer customers for our products and services. Although the industry consolidation that has taken place over the past 20 years has not prevented our business from growing to date, if one of the parties to a consolidation uses the products or services of our competitors, we may lose existing customers as a result of such consolidation.

 

  c) Increasing competition and increasing costs within the pharmaceutical and biotechnology industries may affect the demand for our products and services, which may affect our results of operations and financial condition . Our pharmaceutical and biotechnology customers' demand for our products is impacted by continued demand for their products and by our customers' research and development costs. Demand for our customers' products could decline, and prices charged by our customers for their products may decline, as a result of increasing competition, including competition from companies manufacturing generic drugs. In addition, our customers' expenses could continue to increase as a result of increasing costs of complying with government regulations and other factors. A decrease in demand for our customers' products, pricing pressures associated with the sales of these products and additional costs associated with product development could cause our customers to reduce research and development expenditures. Although our products increase productivity and reduce costs in many areas, because our products and services depend on such research and development expenditures, our revenues may be significantly reduced.

 

 

 

 

  27  
 

 

  d) Health care reform and restrictions on reimbursement may affect the pharmaceutical, biotechnology, and industrial chemical companies that purchase or license our products or services, which may affect our results of operations and financial condition . The continuing efforts of government and third-party payers in the markets we serve to contain or reduce the cost of health care may reduce the profitability of pharmaceutical, biotechnology, and industrial chemical companies, causing them to reduce research and development expenditures. Because some of our products and services depend on such research and development expenditures, our revenues may be significantly reduced. We cannot predict what actions federal, state, or private payers for health care goods and services may take in response to any health care reform proposals or legislation.

 

  e) We face strong competition in the life science market for computer-aided design modeling and simulation software and for cheminformatics products. The market for our computer-aided design modeling and simulation software products for the life science market is intensely competitive. We currently face competition from other scientific software providers, larger technology and solutions companies, in-house development by our customers and academic and government institutions, and the open source community. Some of our competitors and potential competitors have longer operating histories in certain segments of our industry than we do and could have greater financial, technical, marketing, research and development, and other resources. Many of our competitors offer products and services directed at more specific markets than those we target, enabling these competitors to focus a greater proportion of their efforts and resources on these markets. Some offerings that compete with our products are developed and made available at lower cost by government organizations and academic institutions, and these entities may be able to devote substantial resources to product development and also offer their products to users for little or no charge. We could also face competition from open source software initiatives, in which developers provide software and intellectual property free over the Internet. In addition, some of our customers spend significant internal resources in order to develop their own software. Moreover, we intend to leverage our scientific informatics platform in order to enable our customers to more effectively utilize the vast amounts of information stored in both their databases and public data sources in order to make informed scientific and business decisions during the research and development process. This strategy could lead to competition from much larger companies that provide general data storage and management software. There can be no assurance that our current or potential competitors will not develop products, services, or technologies that are comparable to, superior to, or render obsolete, the products, services, and technologies we offer. There can be no assurance that our competitors will not adapt more quickly than we to technological advances and customer demands, thereby increasing such competitors' market share relative to ours. Any material decrease in demand for our technologies or services may have a material adverse effect on our business, financial condition, and results of operations.

  

  f) We are subject to pricing pressures in some of the markets we serve. The market for computer-aided design modeling and simulation products for the life science industry is intensely competitive. Although the average price of our software licenses has increased slightly or remained relatively constant for fiscal 2014, 2015, and 2016, we may experience a decline in the future. In response to increased competition and general adverse economic conditions in this market, we may be required to modify our pricing practices. Changes in our pricing model could adversely affect our revenue and earnings.

 

  g) Our operations may be interrupted by the occurrence of a natural disaster or other catastrophic event at our primary facilities. Our research and development operations and administrative functions are primarily conducted at our facilities in Lancaster, California, and Buffalo, New York. Although we have contingency plans in effect for natural disasters or other catastrophic events, the occurrence of such events could still disrupt our operations. For example, our Lancaster, California facility is located in a state that is particularly susceptible to earthquakes. Any natural disaster or catastrophic event in our facilities or the areas in which they are located could have a significant negative impact on our operations.

 

  h) Our insurance coverage may not be sufficient to avoid material impact on our financial position or results of operations resulting from claims or liabilities against us, and we may not be able to obtain insurance coverage in the future. We maintain insurance coverage for protection against many risks of liability. The extent of our insurance coverage is under continuous review and is modified as we deem it necessary. Despite this insurance, it is possible that claims or liabilities against us may have a material adverse impact on our financial position or results of operations. In addition, we may not be able to obtain any insurance coverage, or adequate insurance coverage, when our existing insurance coverage expires. For example, we do not carry earthquake insurance for our facilities in Lancaster, California, because we do not believe the costs of such insurance are reasonable in relation to the potential risk for our part of California.

 

 

 

 

  28  
 

 

  i) Changes in government regulation or in practices relating to the pharmaceutical or biotechnology industries, including potential health care reform, could decrease the need for the services we provide. Governmental agencies throughout the world, but particularly in the U.S., strictly regulate the drug development process. Our business involves helping pharmaceutical and biotechnology companies, among others, navigate the regulatory drug approval process. Accordingly, many regulations, and often new regulations, are expected to result in higher regulatory standards and often additional revenues for companies that service these industries. However, some changes in regulations, such as a relaxation in regulatory requirements or the introduction of streamlined or expedited drug approval procedures, or an increase in regulatory requirements that we have difficulty satisfying or that make our services less competitive, could eliminate or substantially reduce the demand for our services.

 

  j) Any failure by us to comply with applicable regulations and related guidance could harm our reputation and operating results, and compliance with new regulations and guidance may result in additional costs. Any failure on our part to comply with applicable regulations could result in the termination of ongoing research or the disqualification of data for submission to regulatory authorities. This could harm our reputation, our prospects for future work, and our operating results. If our operations are found to violate any applicable law or other governmental regulations, we might be subject to civil and criminal penalties, damages, and fines. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management's attention from the operation of our business, and damage our reputation.

 

  k) Many of our contracts are fixed-price and may be delayed or terminated or reduced in scope for reasons beyond our control, or we may underprice or overrun cost estimates with these contracts, potentially resulting in financial losses. Many of our contracts provide for services on a fixed-price or fee-for-service with a cap basis and, accordingly, we bear the financial risk if we initially underprice our contracts or otherwise overrun our cost estimates. In addition, these contracts may be terminated or reduced in scope either immediately or upon notice. Cancellations may occur for a variety of reasons, and often at the discretion of the client. The loss, reduction in scope, or delay of a large contract or the loss or delay of multiple contracts could materially adversely affect our business, although our contracts frequently entitle us to receive the costs of winding down the terminated projects, as well as all fees earned by us up to the time of termination. Some contracts also entitle us to a predetermined termination fee and irrevocably committed costs/expenses.

  

  l) We could experience a breach of the confidentiality of the information we hold or of the security of our computer systems. We operate large and complex computer systems that contain significant amounts of client data. As a routine element of our business, we collect, analyze, and retain substantial amounts of data pertaining to the clinical study data analysis we conduct for our clients. Unauthorized third parties could attempt to gain entry to such computer systems for the purpose of stealing data or disrupting the systems. We believe that we have taken appropriate measures to protect them from intrusion, and we continue to improve and enhance our systems in this regard, but in the event that our efforts are unsuccessful, we could suffer significant harm. Our contracts with our clients typically contain provisions that require us to keep confidential the information generated from these studies. In the event the confidentiality of such information was compromised, we could suffer significant harm.

 

  m) Impairment of goodwill or other intangible assets may adversely impact future results of operations. We have intangible assets, including goodwill and other indefinite-lived intangibles, on our balance sheet due to our acquisitions of businesses. The initial identification and valuation of these intangible assets and the determination of the estimated useful lives at the time of acquisition involve use of management judgments and estimates. These estimates are based on, among other factors, input from accredited valuation consultants, reviews of projected future income cash flows and statutory regulations. The use of alternative estimates and assumptions might have increased or decreased the estimated fair value of our goodwill and other intangible assets that could potentially result in a different impact to our results of operations. If the future growth and operating results of our business are not as strong as anticipated and/or our market capitalization declines, this could impact the assumptions used in calculating the fair value of goodwill or other indefinite-lived intangibles. To the extent goodwill or other indefinite-lived intangibles are impaired, their carrying value will be written down to its implied fair value and a charge will be made to our income from continuing operations. Such an impairment charge could materially and adversely affect our operating results. As of August 31, 2016, the carrying amount of goodwill and other intangibles was $6,144,248 on our consolidated balance sheet.

 

Certain Risks Related to Our Operations

 

  a) Software Defects or malfunctions in our products could hurt our reputation among our customers, result in delayed or lost revenue, and expose us to liability. Our business and the level of customer acceptance of our products depend upon the continuous, effective, and reliable operation of our software and related tools and functions. To the extent that defects cause our software to malfunction and our customers' use of our products is interrupted, our reputation could suffer and our revenue could decline or be delayed while such defects are remedied. We may also be subject to liability for the defects and malfunctions of third party technology partners and others with whom our products and services are integrated.

 

 

 

 

  29  
 

 

  b) Delays in the release of new or enhanced products or services or undetected errors in our products or services may result in increased cost to us, delayed market acceptance of our products, and delayed or lost revenue. To achieve market acceptance, new or enhanced products or services can require long development and testing periods, which may result in delays in scheduled introduction. Any delays in the release schedule for new or enhanced products or services may delay market acceptance of these products or services and may result in delays in new customer orders for these new or enhanced products or services or the loss of customer orders. In addition, new or enhanced products or services may contain a number of undetected errors or “bugs” when they are first released. Although we extensively test each new or enhanced software product or service before it is released to the market, there can be no assurance that significant errors will not be found in existing or future releases. As a result, in the months following the introduction of certain releases, we may need to devote significant resources to correct these errors. There can be no assurance, however, that all of these errors can be corrected.

  

  c) We are subject to risks associated with the operation of a global business. We derive a significant portion of our total revenue from our operations in international markets. During the years ended August 31, 2016, 2015 and 2014, 38%, 37% and 48% respectively, of our total revenue was derived from our international operations. Our global business may be affected by local economic conditions, including inflation, recession, and currency exchange rate fluctuations. In addition, political and economic changes, including international conflicts, including terrorist acts, throughout the world may interfere with our or our customers' activities in particular locations and result in a material adverse effect on our business, financial condition, and operating results. Potential trade restrictions, exchange controls, adverse tax consequences, and legal restrictions may affect the repatriation of funds into the U.S. Also, we could be subject to unexpected changes in regulatory requirements, the difficulties of compliance with a wide variety of foreign laws and regulations, potentially negative consequences from changes in or interpretations of US and foreign tax laws, import and export licensing requirements, and longer accounts receivable cycles in certain foreign countries. These risks, individually or in the aggregate, could have an adverse effect on our results of operations and financial condition. For example, we are subject to compliance with the U.S. Foreign Corrupt Practices Act and similar anti-bribery laws, which generally prohibit companies and their intermediaries from making improper payments to foreign government officials for the purpose of obtaining or retaining business. While our employees, distributors, and agents are required to comply with these laws, we cannot be sure that our internal policies and procedures will always protect us from violations of these laws despite our commitment to legal compliance and corporate ethics. The occurrence or allegation of these types of risks may adversely affect our business, performance, prospects, value, financial condition, and results of operations.

 

  d) The drug discovery and development services industry is highly competitive. Our clinical pharmacology division often competes for business not only with other clinical research organization (CROs), but also with internal discovery and development departments within our larger clients, who may have greater resources than ours. We also compete with universities and teaching hospitals for outsourced services. We compete based on a variety of factors, including:

 

  · reputation for on-time quality performance;
  · reputation for regulatory compliance;
  · expertise and experience in multiple specialized areas;
  · scope and breadth of service and product offerings across the drug discovery and development spectrum;
  · ability to provide flexible and customized solutions to support our clients' drug discovery and development needs;
  · price/value;
  · technological expertise and efficient drug development processes;
  · financial stability;
  · accessibility of client data through secure portals; and
  · ability to acquire, process, analyze, and report data in an accurate manner.

 

  e) If we do not compete successfully, our business could suffer. Increased competition might lead to price and other concessions that might adversely affect our operating results. The drug discovery and development services industry has continued to see a trend towards consolidation, particularly among biotechnology companies, who are targets for each other and for larger pharmaceutical companies. If this trend continues, it is likely to produce more competition among the larger companies and CROs generally, with respect to both clients and acquisition candidates. In addition, while there are substantial barriers to entry for large, global competitors with broad-based services, small, specialized entities considering entering the CRO industry will continue to find lower barriers to entry, and private equity firms may determine that there are opportunities to acquire and consolidate these companies, thus further increasing possible competition. More generally, our competitors or others might develop technologies, services, or products that are more effective or commercially attractive than our current or future technologies, services, or products, or that render our technologies, services, or products less competitive or obsolete. If competitors introduce superior technologies, services, or products and we cannot make enhancements to ours to remain competitive, our competitive position, and in turn our business, revenue, and financial condition, would be materially and adversely affected. In the aggregate, these competitive pressures may affect the attractiveness of our technologies, services, or products and could adversely affect our financial results.

 

 

 

 

  30  
 

 

  f) Potential Changes in U.S. and International Tax Law. In the U.S., there are several proposals to reform corporate tax law that are currently under consideration. These proposals include reducing the corporate statutory tax rate, broadening the corporate tax base through the elimination or reduction of deductions, exclusions, and credits, implementing a territorial regime of taxation, limiting the ability of U.S. corporations to deduct interest expense associated with offshore earnings, modifying the foreign tax credit rules, and reducing the ability to defer U.S. tax on offshore earnings. These or other changes in the U.S. tax laws could increase our effective tax rate, which would affect our profitability.

  

  g) Contract research services create a risk of liability. As a CRO, we face a range of potential liabilities which may include:

 

1. Errors or omissions in reporting of study detail in preclinical studies that may lead to inaccurate reports, which may undermine the usefulness of a study or data from the study, or which may potentially advance studies absent the necessary support or inhibit studies from proceeding to the next level of testing; and

 

2. Risks associated with our possible failure to properly care for our clients' property, such as research models, records, work in progress, or other archived materials.

 

Contractual risk transfer indemnifications generally do not protect us against liability arising from certain of our own actions, such as negligence or misconduct. We could be materially and adversely affected if we are required to pay damages or bear the costs of defending any claim that is outside any contractual indemnification provision, or if a party does not fulfill its indemnification obligations, or the damage is beyond the scope or level of insurance coverage. We also often contractually indemnify our clients (subject to a limitation of liability), similar to the way they indemnify us, and we may be materially adversely affected if we have to fulfill our indemnity obligations. Furthermore, there can be no assurance that we nor a party required to indemnify us will be able to maintain such insurance coverage (either at all or on terms acceptable to us).

 

  h) Upgrading our software could result in implementation issues and business disruptions. In recent years we implemented a project to refactor our software programs. In doing so we face the possibility that existing users will find the software unacceptable, or new users may not be as interested as they have been in the past versions. Translation errors might introduce new software bugs that will not be caught.

 

  i) The drug discovery and development industry has a history of patent and other intellectual property litigation, and we might be involved in costly intellectual property lawsuits. The drug discovery and development industry has a history of patent and other intellectual property litigation and these lawsuits will likely continue. Accordingly, we face potential patent infringement suits by companies that have patents for similar products and methods used in business or other suits alleging infringement of their intellectual property rights. Legal proceedings relating to intellectual property could be expensive, take significant time and divert management's attention from other business concerns, whether we win or lose. If we do not prevail in an infringement lawsuit brought against us, we might have to pay substantial damages, including treble damages, and we could be required to stop the infringing activity or obtain a license to use technology on unfavorable terms.

 

  j) We may not be able to successfully develop and market new services and products. We may seek to develop and market new services and products that complement or expand our existing business or service offerings. We cannot guarantee that we will be able to identify new technologies of interest to our customers. Even if we are able to identify new technologies of interest, we may not be able to negotiate license agreements on acceptable terms, or at all. If we are unable to develop new services and products and/or create demand for those newly developed services and products, our future business, results of operations, financial condition, and cash flows could be adversely affected.

 

  k) Ability to incur debt could adversely affect our business and growth prospects. At August 31, 2016, we had no borrowed debt and have no need to do so to fund normal operations in the foreseeable future; however, should circumstance require us to incur debt and a lender could not be found to provide that debt, this could have a significant adverse effect on our business, including making it more difficult for us to obtain financing on favorable terms, limiting our ability to capitalize on significant business opportunities, and making us more vulnerable to rising interest rates.

 

  l) We depend on key personnel and may not be able to retain these employees or recruit additional qualified personnel, which could harm our business. Our success depends to a significant extent on the continued services of our senior management and other members of management. Walter S. Woltosz, our Chief Executive Officer and Chairman of the Board, has held his position since our the founding in 1996. We have an annual employment agreement with Mr. Woltosz. Our President, Thaddeus “Ted” Grasela, has an employment contract that expires in August 2017. No other members of our senior management and scientific personnel are under contract. If Mr. Woltosz, Dr. Grasela, or other members of senior management do not continue in their present positions, our business may suffer. Because of the specialized scientific nature of our business, we are highly dependent upon attracting and retaining qualified scientific and technical and managerial personnel. While we have a strong record of employee retention, there is still significant competition for qualified personnel in the software, pharmaceutical and biotechnology fields. Therefore, we may not be able to attract and retain the qualified personnel necessary for the development of our business. The loss of the services of existing personnel, as well as the failure to recruit additional key scientific, technical, and managerial personnel in a timely manner, could harm our business.

 

 

 

 

  31  
 

 

  m) If we are not successful in selecting and integrating the businesses and technologies we acquire, or in managing our current and future divestitures, our business may suffer. In September 2014, the Company expanded our business through an acquisition. We to continue to search to acquire businesses and technologies and form strategic alliances. However, businesses and technologies may not be available on terms and conditions we find acceptable. We risk spending time and money investigating and negotiating with potential acquisition or alliance partners, but not completing transactions. Even if completed, acquisitions and alliances involve numerous risks which may include: difficulties in achieving business and continuing financial success; difficulties and expenses incurred in assimilating and integrating operations, services, products, technologies, or pre-existing relationships with our customers, distributors, and suppliers; challenges with developing and operating new businesses, including those which are materially different from our existing businesses and which may require the development or acquisition of new internal capabilities and expertise; challenges of maintaining staffing at the acquired entities, including loss of key employees; potential losses resulting from undiscovered liabilities of acquired companies that are not covered by the indemnification we may obtain from the seller(s); the presence or absence of adequate internal controls and/or significant fraud in the financial systems of acquired companies; diversion of management's attention from other business concerns; acquisitions could be dilutive to earnings, or in the event of acquisitions made through the issuance of our common stock to the shareholders of the acquired company, dilutive to the percentage of ownership of our existing shareholders; new technologies and products may be developed which cause businesses or assets we acquire to become less valuable; and risks that disagreements or disputes with prior owners of an acquired business, technology, service, or product may result in litigation expenses and distribution of our management's attention. In the event that an acquired business or technology or an alliance does not meet our expectations, our results of operations may be adversely affected.
     
    Some of the same risks exist when we decide to sell a business, site, or product line. In addition, divestitures could involve additional risks, including the following: difficulties in the separation of operations, services, products, and personnel; and the need to agree to retain or assume certain current or future liabilities in order to complete the divestiture. We evaluate the performance and strategic fit of our businesses. These and any divestitures may result in significant write-offs, including those related to goodwill and other intangible assets, which could have an adverse effect on our results of operations and financial condition. In addition, we may encounter difficulty in finding buyers or alternative exit strategies at acceptable prices and terms and in a timely manner. We may not be successful in managing these or any other significant risks that we encounter in divesting a business, site, or product line, and as a result, we may not achieve some or all of the expected benefits of the divestitures.

  

  n) Our quarterly and annual operating results fluctuate and may continue to fluctuate in the future, and if we fail to meet the expectations of analysts or investors, our stock price and the value of your investment could decline substantially . We believe that operating results for any particular quarter are not necessarily a meaningful indication of future results. Nonetheless, fluctuations in our quarterly operating results could negatively affect the market price of our common stock. Our results of operations in any quarter or annual period have varied in the past and may vary from quarter to quarter or year to year and are influenced by such factors as:

 

  a. changes in the general global economy;
  b. the number and scope of ongoing client engagements; the commencement, postponement, delay, progress, completion, or cancellation of client contracts in the quarter;
  c. changes in customer budget cycles;
  d. the number and scope of ongoing client engagements;
  e. the commencement, postponement, delay, progress, completion, or cancellation of client contracts in the quarter;
  f. changes in the mix of our products and services;
  g. competitive pricing pressures;
  h. the extent of cost overruns;
  i. buying patterns of our clients;
  j. budget cycles of our clients;
  k. the effect of potential acquisitions and consequent integration;
  l. the timing of new product releases by us or our competitors;
  m. general economic factors, including factors relating to disruptions in the world credit and equity markets and the related impact on our customers’ access to capital;
  n. changes in tax laws, rules, regulations, and tax rates in the locations in which we operate;
  o. the timing and charges associated with completed acquisitions and other events;
  p. the financial performance of the limited partnerships in which we invest; and
  q. exchange rate fluctuations.

  

 

 

 

  32  
 

 

  o) We derive a significant percentage of our revenues from a concentrated group of customers and the loss of more than one of our major customers could materially and adversely affect our business, results of operations or financial condition. Three customers accounted for 10% (a dealer account in Japan representing various customers), 7% and 6% of net sales for fiscal year 2016. Three customers accounted for 10% (a dealer account in Japan representing various customers), 8% and 6% of net sales for fiscal year 2015. Two customers accounted for 14% (actually a dealer account in Japan representing various customers), and 8% of net sales for fiscal year 2014 . The loss of any of our major customers could have a material adverse effect on our results of operations and financial condition. We may not be able to maintain our customer relationships, and our customers may delay payment under, or fail to renew, their agreements with us, which could adversely affect our business, results of operations, or financial condition. Any reduction in the amount of revenues that we derive from these customers, without an offsetting increase in new sales to other customers, could have a material adverse effect on our operating results. A significant change in the liquidity or financial position of our customers could also have a material adverse effect on the collectability of our accounts receivable, our liquidity, and our future operating results.

 

  p) A significant portion of our operating expenses is relatively fixed and planned expenditures are based in part on expectations regarding future revenues. Accordingly, unexpected revenue shortfalls may decrease our gross margins and could cause significant changes in our operating results from year to year. As a result, in future quarters our operating results could fall below the expectations of securities analysts or investors, in which event our stock price would likely decrease.

 

  q) If our customers cancel their contracts or terminate or delay their clinical trials, we may lose or delay revenues and our business may be harmed. Certain of our customer contracts are subject to cancellation by our customers at any time with limited notice. Customers engaged in clinical trials may terminate or delay a clinical trial for various reasons, including the failure of the tested product to satisfy safety or efficacy requirements, unexpected or undesired clinical results, decisions to deemphasize a particular product or forgo a particular clinical trial, decisions to downsize clinical development programs, insufficient patient enrollment or investigator recruitment, and production problems resulting in shortages of required clinical supplies. Any termination or delay in the clinical trials would likely result in a consequential delay or termination in those customers’ service contracts. We have experienced terminations and delays of our customer service contracts in the past (although no such past terminations have had a significant impact on our results of operations) and we expect to experience additional terminations and delays in the future. The termination of single-study arrangements could result in decreased revenues and the delay of our customers’ clinical trials could result in delayed professional services revenues, which could materially harm our business.

 

  r) If our security is breached, our business could be disrupted, our operating results could be harmed, and customers could be deterred from using our products and services. Our business relies on the secure electronic transmission, storage, and hosting of sensitive information, including clinical data, financial information, and other sensitive information relating to our customers, company, and workforce. As a result, we face some risk of a deliberate or unintentional incident involving unauthorized access to our computer systems (including, among other methods, cyber- attacks or social engineering) that could result in misappropriation or loss of assets or sensitive information, data corruption, or other disruption of business operations. In light of this risk, we have devoted significant resources to protecting and maintaining the confidentiality of our information, including implementing security and privacy programs and controls, training our workforce, and implementing new technology. We have no guarantee that these programs and controls will be adequate to prevent all possible security threats. We believe that any compromise of our electronic systems, including the unauthorized access, use, or disclosure of sensitive information or a significant disruption of our computing assets and networks, would adversely affect our reputation and our ability to fulfill contractual obligations, and would require us to devote significant financial and other resources to mitigate such problems, and could increase our future cyber security costs. Moreover, unauthorized access, use, or disclosure of such sensitive information could result in contractual or other liability. In addition, any real or perceived compromise of our security or disclosure of sensitive information may result in lost revenues by deterring customers from using or purchasing our products and services in the future or prompting them to use competing service providers.

  

  s) Any failure by us to properly protect customer data we possess or are deemed to possess in connection with the conduct of clinical trials, could subject us to significant liability. Our customers use our solutions to collect, manage, and report information in connection with the conduct of clinical trials. This information may be considered our customers’ proprietary information. Since we receive and process our customers’ data from customers utilizing our hosted solutions, there is a risk that we could be liable if there were a breach of any obligation to a protected person under contract, standard of practice, or regulatory requirement. If we fail to properly protect our customers’ data that is in our possession or deemed to be in our possession, we could be subjected to significant liability and our reputation would be harmed.

 

 

 

 

  33  
 

 

  t) We rely upon a single internal hosting facility and Amazon Web Services to deliver our solutions to our customers and any disruption of or interference with our hosting systems, operations, or use of the Amazon Web Services could harm our business and results of operations. Substantially all of the computer hardware necessary to deliver our CRO and KIWI solutions is located at our internal hosting facility in Buffalo, New York. In addition to our dedicated hosting facility, we utilize third-party cloud computing services from Amazon Web Services ("AWS") to help us efficiently scale our cloud-based solutions and provide training. Because we cannot easily switch our AWS-serviced operations to another cloud provider, any disruption of or interference with our use of AWS would impact our operations, and our business would be adversely impacted. Our systems and operations or those of AWS could suffer damage or interruption from human error, fire, flood, power loss, telecommunications failure, break-ins, terrorist attacks, acts of war, and similar events. The occurrence of a natural disaster, an act of terrorism or other unanticipated problems at our or AWS' hosting facilities could result in lengthy interruptions in our service. Although we and AWS maintain backup facilities and disaster recovery services in the event of a system failure, these may be insufficient or fail. Any system failure, including network, software, or hardware failure, that causes an interruption in our Buffalo data center or our use of AWS or that causes a decrease in responsiveness of our cloud-based solutions could damage our reputation and cause us to lose customers, which could harm our business and results of operations. Our business may be harmed if our customers and potential customers believe our service is unreliable.

 

  u) Defects or errors in our software applications could harm our reputation, result in significant cost to us and impair our ability to market our solutions. Our software applications are inherently complex and may contain defects or errors, some of which may be material. Errors may result from our own technology or from the interface of our cloud-based solutions with legacy systems and data, which we did not develop. The risk of errors is particularly significant when a new product is first introduced or when new versions or enhancements of existing products are released. The likelihood of errors is increased when we do more frequent releases of new products and enhancements of existing products. We have, from time to time, found defects in our solutions. Although these past defects have not resulted in any litigation against us to date, we have invested significant capital, technical, managerial, and other resources to investigate and correct these past defects and we have needed to divert these resources from other development efforts. In addition, material performance problems or defects in our solutions may arise in the future. Material defects in our cloud-based solutions could result in a reduction in sales, delay in market acceptance of our solutions, or credits or refunds to our customers. In addition, such defects may lead to the loss of existing customers and difficulty in attracting new customers, diversion of development resources, or harm to our reputation. Correction of defects or errors could prove to be impossible or impractical. The costs incurred in correcting any defects or errors or in responding to resulting claims or liability may be substantial and could adversely affect our operating results.

 

  v) If we are not able to reliably meet our data storage and management requirements, or if we experience any failure or interruption in the delivery of our services over the Internet, customer satisfaction and our reputation could be harmed and customer contracts may be terminated. As part of our current business model, we deliver our software over the Internet and store and manage hundreds of terabytes of data for our customers, resulting in substantial information technology infrastructure and ongoing technological challenges, which we expect to continue to increase over time. If we do not reliably meet these data storage and management requirements, or if we experience any failure or interruption in the delivery of our services over the Internet, customer satisfaction and our reputation could be harmed, leading to reduced revenues and increased expenses. Our hosting services are subject to service-level agreements and, in the event that we fail to meet guaranteed service or performance levels, we could be subject to customer credits or termination of these customer contracts. If the cost of meeting these data storage and management requirements increases, our results of operations could be harmed.

 

  w) Some of our software solutions and services utilize open source software, and any failure to comply with the terms of one or more of these open source licenses could adversely affect our business. Some of our software solutions utilize software covered by open source licenses. Open source software is typically freely accessible, usable and modifiable, and is used by our development team in an effort to reduce development costs and speed up the development process. Certain open source software licenses require a user who intends to distribute the open source software as a component of the user's software to disclose publicly part or all of the source code to the user's software. In addition, certain open source software licenses require the user of such software to make any derivative works of the open source code available to others on unfavorable terms or at no cost. This can subject previously proprietary software to open source license terms. While we monitor the use of all open source software in our products, processes and technology and try to ensure that no open source software is used in such a way as to require us to disclose or make available the source code to the related product or solution, such use could inadvertently occur. This could harm our intellectual property position and have a material adverse effect on our business.

 

 

 

  34  
 

 

  x) We may be unable to adequately enforce or defend our ownership and use of our intellectual property and other proprietary rights. Our success is heavily dependent upon our intellectual property and other proprietary rights. We rely upon a combination of trademark, trade secret, copyright, patent, and unfair competition laws, as well as license and access agreements and other contractual provisions, to protect our intellectual property and other proprietary rights. In addition, we attempt to protect our intellectual property and proprietary information by requiring certain of our employees and consultants to enter into confidentiality, non-competition, and assignment-of-inventions agreements. The steps we take to protect these rights may not be adequate to prevent misappropriation of our technology by third parties, or may not be adequate under the laws of some foreign countries, which may not protect our intellectual property rights to the same extent as do the laws of the United States. Our attempts to protect our intellectual property may be challenged by others or invalidated through administrative process or litigation, and agreement terms that address non-competition are difficult to enforce in many jurisdictions and may not be enforceable in any particular case. In addition, there remains the possibility that others will “reverse engineer” our products in order to introduce competing products, or that others will develop competing technology independently. If we resort to legal proceedings to enforce our intellectual property rights or to determine the validity and scope of the intellectual property or other proprietary rights of others, the proceedings could be burdensome and expensive, even if we were to prevail. The failure to adequately protect our intellectual property and other proprietary rights may have a material adverse effect on our business, results of operations or financial condition.

 

  y) Current and future litigation against us, which may arise in the ordinary course of our business, could be costly and time consuming to defend. We are subject to claims that arise in the ordinary course of business, such as claims brought by our customers in connection with commercial disputes and employment claims made by our current or former employees. Third parties may in the future assert intellectual property rights to technologies that are important to our business and demand back royalties or demand that we license their technology. Litigation may result in substantial costs and may divert management’s attention and resources, which may seriously harm our business, overall financial condition, and operating results. Insurance may not cover such claims, may not be sufficient for one or more such claims, and may not continue to be available on terms acceptable to us. A claim brought against us that is uninsured or underinsured could result in unanticipated costs, negatively affecting our business, results of operations, and financial condition.

  

  z) We could incur substantial costs resulting from product liability claims relating to our products or services or our customers’ use of our products or services. Any failure or errors in a customer’s clinical trial caused or allegedly caused by our products or services could result in a claim for substantial damages against us by our customers or the clinical trial participants, regardless of our responsibility for the failure. Although we are generally entitled to indemnification under our customer contracts against claims brought against us by third parties arising out of our customers’ use of our products, we might find ourselves entangled in lawsuits against us that, even if unsuccessful, may divert our resources and energy and adversely affect our business. Further, in the event we seek indemnification from a customer, a court may not enforce our indemnification right if the customer challenges it or the customer may not be able to fund any amounts for indemnification owed to us. In addition, our existing insurance coverage may not continue to be available on reasonable terms or may not be available in amounts sufficient to cover one or more large claims, or the insurer may disclaim coverage as to any future claim.

 

  aa) Our Buffalo Subsidiary (Cognigen) depends on the clinical trial market, and a downturn in this market could cause our revenues to decrease. Our Buffalo business depends entirely on the clinical trials conducted or sponsored by pharmaceutical, biotechnology and medical device companies, CROs, and other entities. Our revenues may decline as a result of conditions affecting these industries, including general economic downturns, increased consolidation, decreased competition, or fewer products under development. Other developments that may affect these industries and harm our operating results include product liability claims, changes in government regulation, changes in governmental price controls or third-party reimbursement practices, and changes in medical practices. Disruptions in the world credit and equity markets may also result in a global downturn in spending on research and development and clinical trials and may impact our customers’ access to capital and their ability to pay for our solutions. Any decrease in research and development expenditures or in the size, scope, or frequency of clinical trials could materially adversely affect our business, results of operations, or financial condition.

 

  bb) As a public company, we may incur significant administrative workload and expenses in connection with new and changing compliance requirements . As a public company with common stock listed on The NASDAQ Stock Market, we must comply with various laws, regulations and requirements. New laws and regulations, as well as changes to existing laws and regulations affecting public companies, including the provisions of the Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, and rules adopted by the SEC and by The NASDAQ Stock Market, may result in increased general and administrative expenses and a diversion of management's time and attention as we respond to new requirements.

 

 

 

 

  35  
 

 

  cc) We have been paying quarterly dividends on our common stock, and although there has been a consistent track record of paying these dividends, the Board of Directors may suspend the dividend, and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock. Should the Board of Directors suspend the dividend and decide to use those funds to invest more into the business, you may not receive any dividends on your investment in our common stock for the foreseeable future and the success of an investment in shares of our common stock will depend upon any future appreciation in its value. Shares of our common stock may depreciate in value or may not appreciate in value.

  

  dd) Risks Related to Our Common Stock - The price of our common stock may fluctuate significantly and investors could lose all or part of their investments. Shares of our common stock were sold in our initial public offering ("IPO") in 1996 at a price of $1.25 per share (on a post-split basis), and our common stock has subsequently traded as high as $13.00 and as low as $0.38 from our IPO through May 31, 2017. However, an active, liquid, and orderly market for our common stock on The NASDAQ Stock Market or otherwise may not be sustained, which could depress the trading price of our common stock. The trading price of our common stock may be subject to wide fluctuations in response to various factors, some of which are beyond our control, including:

 

  a. our quarterly or annual earnings or those of other companies in our industry;
  b. announcements by us or our competitors of significant contracts or acquisitions;
  c. changes in accounting standards, policies, guidance, interpretations, or principles;
  d. general economic and stock market conditions, including disruptions in the world credit and equity markets;
  e. the failure of securities analysts to cover our common stock or changes in financial estimates by analysts;
  f. future sales of our common stock; and
  g. the other factors described in these “Risk Factors.”

 

    In recent years, the stock market in general, and the market for technology-related companies in particular, has experienced wide price and volume fluctuations. This volatility has had a significant impact on the market price of securities issued by many companies, including companies in our industry. The price of our common stock could fluctuate based upon factors that have little to do with our performance, and these fluctuations could materially reduce our stock price.
     
    In the past, some companies, including companies in our industry, have had volatile market prices for their securities and have had securities class action suits filed against them. The filing of a lawsuit against us, regardless of the outcome, could have a material adverse effect on our business, financial condition, and results of operations, as it could result in substantial legal costs and a diversion of our management’s attention and resources.

 

 

Item 2. Changes in Securities

 

None.

 

Item 3. Defaults Upon Senior Securities

 

None.

 

Item 4. Mine Safety Disclosures

 

N/A

 

Item 5. Other Information

 

N/A

  

Item 6. Exhibits

 

EXHIBIT NUMBER   DESCRIPTION
  2.1   Agreement and Plan of Merger, dated July 23, 2014, by and among the Company, Cognigen Corporation and the other parties thereto. (13)^
  3.1   Articles of Incorporation of the Company. (5)
  3.2   Amended and Restated Bylaws of the Company. (5)
  4.1   Articles of Incorporation of the Company. (incorporated by reference to Exhibit 3.1 hereof)
  4.2   Amended and Restated Bylaws of the Company. (incorporated by reference to Exhibit 3.2 hereof)
  4.3   Form of Common Stock Certificate (1)
  4.4   Share Exchange Agreement (1)
  10.1   The Company’s 1996 Stock Option Plan and forms of agreements relating thereto (1) (†)
  10.2(a)   Exclusive License Software Agreement by and between the Company and Therapeutic Systems Research Laboratories dated June 30, 1997. (2)

 

 

 

 

  36  
 

 

  10.2(b)   Termination and Non-Assertion Agreement entered into on May 15, 2014 by and between the Company and TSRL, Inc. (11)
  10.3(a)   The Company’s 2007 Stock Option Plan. (3) (†)
  10.3(b)   The Company’s 2007 Stock Option Plan as amended as of December 6, 2013. (10) (†)
  10.4(a)   Lease dated May 12, 2005 by and between Freeway Ventures, LLC and the Company. (6)
  10.4(b)   Notice of Election to Extend Term of Lease by and between the Company and Crest Development LLC (formerly Freeway Ventures LLC) dated July 29, 2010.(4)
  10.4(c)   One Amendment to Lease by and between the Company and Crest Development LLC entered into as of May 23, 2013. (8)
  10.4(d)   Second Amendment to Lease by and between the Company and Crest Development LLC Entered into as of May 1 2016
  10.5   Stock Purchase Agreement by and among the Company, Words+, Inc., and Prentke Romich Company dated November 15, 2011. (7)
  10.6   Employment Agreement by and between the Company and Walter S. Woltosz, dated as of July 22, 2011. (5) (†)
  10.7   Employment Agreement by and between the Company and Walter S. Woltosz, dated as of August 22, 2013. (9) (†)
  10.8   Employment Agreement by and between the Company and Walter S. Woltosz, dated as of August 28, 2014. (12) (†)
  10.9   Employment Agreement by and between the Company and Thaddeus H Grasela Jr. dated as of September 2, 2014. (12) (†)
  10.10   Employment Agreement by and between the Company and Walter S. Woltosz, dated as of July 9, 2015. (9) (†)
  10.11   Employment Agreement by and between the Company and Walter S. Woltosz, dated as of August 8, 2016. (9) (†)
  10.12   2017 Equity Incentive Plan
  10.13   Stock Purchase Agreement by and among Simulation Plus, Inc., DILIsym Services, Inc., The Shareholders’ Representative and The Shareholders of DILIsym Services, Inc**
  31.1   Section 302 – Certification of the Principal Executive Officer*
  31.2   Section 302 – Certification of the Principal Financial Officer*
  32.1   Section 906 – Certification of the Chief Executive Office and Chief Financial Officer**
  101.INS   XBRL Instance Document.
  101.SCH   XBRL Taxonomy Extension Schema Document.
  101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document.
  101.DEF   XBRL Taxonomy Extension Definition Linkbase Document.
  101.LAB   XBRL Taxonomy Extension Label Linkbase Document.
  101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document.
       

^ Schedules and exhibits omitted pursuant to Item 601(b)(2) of Registration S-K. The registrant agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request. 

† Those exhibits marked with a (†) refer to management contracts or compensatory plans or arrangements

*       Filed herewith 

**     Furnished herewith

 

(1)       Incorporated by reference to the Company’s Registration Statement on Form SB-2 (Registration No. 333-6680) filed on March 25, 1997.

(2)       Incorporated by reference to the Company’s Form 10-KSB for the fiscal year ended August 31, 1997.

(3)       Incorporated by reference to the Company’s Form 10-K for the fiscal year ended August 31, 2009.

(4)       Incorporated by reference to the Company’s Form 10-K for the fiscal year ended August 31, 2010.

(5)       Incorporated by reference to the Company’s Form 10-K for the fiscal year ended August 31, 2011.

(6)       Incorporated by reference to the Company’s Form 10-KSB for the fiscal year ended August 31, 2006.

(7)       Incorporated by reference to the Company’s Form 8-K filed November 16, 2011.

(8)       Incorporated by reference to the Company’s Form 10-Q filed July 10, 2013.

(9)       Incorporated by reference to the Company’s Form 10-K filed November 18, 2013.

(10)     Incorporated by reference to the Company’s Form 10-Q filed April 9, 2014.

(11)     Incorporated by reference to the Company’s Form 8-K filed May 19, 2014.

(12)     Incorporated by reference to the Company’s Form 8-K filed September 4, 2014.

(13)     Incorporated by reference to the Company’s Form 8-K/A filed November 18, 2014.

(14)     Incorporated by reference to the Company’s Form 8-K filed July 15, 2015.

     

 

  37  
 

 

SIGNATURES

 

In accordance with Section 13 or 15 (d) of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Lancaster, State of California, on July 10, 2017.

 

 

    Simulations Plus, Inc.
     
     
Date: July 10, 2017 By: /s/ John R Kneisel
    John R. Kneisel
    Chief Financial Officer

 

 

 

 

 

 

  38  

Exhibit 10.13

 

 

 

 

 

 

 

 

 

 

 

STOCK PURCHASE AGREEMENT

 

by and among

 

SIMULATIONS PLUS, INC.,

 

DILISYM SERVICES, INC.,

 

THE SHAREHOLDERS’ REPRESENTATIVE

 

and

 

THE SHAREHOLDERS OF DILISYM SERVICES, INC.

 

 

 

 

 

 

 

 

 

 

     

 

 

 

TABLE OF CONTENTS
    Page
ARTICLE I PURCHASE AND SALE OF THE PURCHASED SHARES 1
Section 1.1 Transaction 1
Section 1.2 Purchase Price 2
Section 1.3 Payment Procedures 2
Section 1.4 Funds Flow Memorandum 3
Section 1.5 Stock Options 3
Section 1.6 Holdback 3
Section 1.7 Further Assurances 3
Section 1.8 Shareholders’ Representative 4
Section 1.9 Working Capital Adjustment 6
Section 1.10 Repayment of Company Indebtedness and Transaction Expenses 8
Section 1.11 Earn-Out 9
ARTICLE II REPRESENTATIONS AND WARRANTIES OF THE COMPANY AND THE SHAREHOLDERS 12
Section 2.1 Organization and Qualification; Subsidiaries 12
Section 2.2 Certificate of Incorporation and Bylaws 12
Section 2.3 Capitalization 12
Section 2.4 Authority Relative to this Agreement 13
Section 2.5 Governmental Authorization and Consents 13
Section 2.6 Non-contravention 14
Section 2.7 Title to Properties; Absence of Liens; Sufficiency of Assets 14
Section 2.8 Financial Statements; Related Information 14
Section 2.9 Absence of Certain Changes 15
Section 2.10 Related Party Transactions 17
Section 2.11 Material Contracts 17
Section 2.12 No Undisclosed Liabilities 19
Section 2.13 Litigation 20
Section 2.14 Compliance with Laws and Court Orders 20
Section 2.15 Licenses and Permits 20
Section 2.16 Governmental Contracts 20
Section 2.17 Proprietary Rights 20
Section 2.18 Taxes 23
Section 2.19 Real Property 24
Section 2.20 Environmental Matters 25
Section 2.21 Insurance Coverage 26
Section 2.22 Employee Benefit Plans 27
Section 2.23 Employees 28
Section 2.24 Labor Matters 28
Section 2.25 Books and Records 29
Section 2.26 Customers; Suppliers 29
Section 2.27 Customer or Third-Party Approval 29

 

 

 

  i  

 

 

Section 2.28 Absence of Unlawful Payments 30
Section 2.29 International Trade 30
Section 2.30 Service or Product Liability 30
Section 2.31 Finders’ Fees 30
Section 2.32 Bank Accounts and Powers of Attorney 30
Section 2.33 Consortium Agreement 31
Section 2.34 Full Disclosure 31
ARTICLE IIA. REPRESENTATIONS AND WARRANTIES OF COMPANY SHAREHOLDERS 32
Section 2A.1. Valid Title 32
Section 2A.2. Authorization; Binding Effect 32
Section 2A.3. Governmental Authorization and Consents 32
Section 2A.4. Non-contravention 32
ARTICLE III REPRESENTATIONS AND WARRANTIES OF PURCHASER 33
Section 3.1 Corporate Existence and Power 33
Section 3.2 Corporate Authorization; Binding Effect 33
Section 3.3 Governmental Authorization 33
Section 3.4 Non-contravention 33
Section 3.5 Litigation 33
ARTICLE IV CONDUCT OF BUSINESS 34
Section 4.1 Conduct of Business by the Company Pending the Transaction 34
Section 4.2 Filing of Tax Returns 36
ARTICLE V COVENANTS 39
Section 5.1 Access to Information; Confidentiality 39
Section 5.2 Consents; Approvals 39
Section 5.3 Litigation and Investigations Support 39
Section 5.4 No Solicitation of Competing Transaction 40
Section 5.5 Notification of Certain Matters 40
Section 5.6 Further Action 41
Section 5.7 Preliminary Closing Balance Sheet; Interim Balance Sheet 41
Section 5.8 Updating of Company Disclosure Schedule 41
ARTICLE VI CONDITIONS TO THE CLOSING 42
Section 6.1 Conditions to Obligation of Each Party to Effect the Transaction 42
Section 6.2 Additional Conditions to Obligation of Purchaser to Effect the Transaction 42
Section 6.3 Additional Conditions to Obligation of the Company and the Shareholders to Effect the Transaction 45
ARTICLE VII TERMINATION 46
Section 7.1 Termination 46
Section 7.2 Effect of Termination 46
ARTICLE VIII INDEMNIFICATION 47
Section 8.1 Indemnification by Shareholders 47
Section 8.2 No Contribution; Shareholders’ Representative 49
Section 8.3 Indemnification by Purchaser 49

 

 

 

  ii  

 

 

Section 8.4 Survival 49
Section 8.5 Certain Limitations 50
Section 8.6 Notice of Indemnification Claims; Notice of Claims 51
Section 8.7 Determination of Losses 53
Section 8.8 Right of Set-Off 53
ARTICLE IX MISCELLANEOUS PROVISIONS 54
Section 9.1 Amendment and Modifications 54
Section 9.2 Waiver of Compliance 54
Section 9.3 Expenses 54
Section 9.4 Waiver 54
Section 9.5 Dispute Resolution 55
Section 9.6 Notices 55
Section 9.7 Assignment 56
Section 9.8 Publicity 56
Section 9.9 Governing Law 57
Section 9.10 Counterparts 57
Section 9.11 Headings 57
Section 9.12 Incorporation of NDA 57
Section 9.13 Entire Agreement 57
Section 9.14 Assignments, Successors, and No Third-Party Rights 57
Section 9.15 Further Assurances 58
Section 9.16 Representation by Counsel; Interpretation 58
Section 9.17 Certain Definitions 58
Section 9.18 Rules of Construction 64

 

 

Company Disclosure Schedule

Schedule 1.11 – Earn-Out Schedule

Exhibit A – Form of Non-Competition Agreement

Exhibit B – Form of General Release of Claims

 

 

 

 

  iii  

 

 

 

 

DEFINED TERMS

 

Acquisition Proposal, 58

Adjusted EBT, 58

Adjustment Amount, 8

Affiliate, 58

Agreement, 1

Articles, 64

Assuming Party, 52

Audited Financial Statements, 58

Basket, 50

Board, 1

Business Day, 59

Cap, 50

Cash Consideration, 2

Claims, 47

Closing, 1

Closing Balance Sheet, 6

Closing Date, 2

Closing Statements, 6

COBRA, 59

Code, 59

Company, 26

Company Adjustment Amount, 8

Company Common Stock, 59

Company Data Site, 59

Company Disclosure Schedule, 12

Company Indemnitees, 49

Company IP Rights, 20

Company Policies, 26

Company’s Knowledge, 61

Contemplated Transactions, 59

Control, 59

Dispute, 55

Dispute Notice, 55

Earn-Out Calculation, 9

Earn-Out Calculation Statement, 9

Earn-Out Payment, 9

Earn-Out Years, 59

Employee Plans, 27

Environmental Laws, 26

Environmental Permits, 26

ERISA, 27

ERISA Affiliate, 27

 

Extended Representations, 49

FCPA, 30

Financial Statements, 14

Flow of Funds Memorandum, 2

Fundamental Representations, 49

GAAP, 59

Government Agency, 60

Government Contract, 60

Government Contract Proposal, 60

Governmental Authority, 60

Governmental Authorization, 60

Holdback Amount, 2

Holdback Release Date, 60

Indebtedness, 60

Indemnification Notice, 51

Indemnification Objection Notice, 52

Indemnitees, 49

Independent Accountant, 7

Independent Firm, 61

Intellectual Property Rights, 61

Interim Balance Sheet, 61

Interim Balance Sheet Date, 61

Interim Financials Certificate, 41

JAMS, 61

Knowledge, 61

Law or Laws, 61

Licensed Intellectual Property, 61

Liens, 61

Losses, 62

Majority Shareholders, 62

Material Adverse Effect, 62

Material Contract, 17

Materials of Environmental Concern, 26

NDA, 62

Net Working Capital, 62

Non-Competition Agreement, 43

Off-the-Shelf Software, 62

Order, 62

Other Securities, 44

Owned Intellectual Property, 21

Ownership Rights, 48

Payoff Letters, 8

 

 

 

  4  

 

 

Payroll Company, 28

Permits, 20

Permitted Indemnification Claims, 52

Person, 62

Preliminary Cash Consideration, 2

Preliminary Closing Balance Sheet, 6

Preliminary Working Capital Statement, 6

Pro Rata Portion, 63

Purchase Price, 2

Purchased Shares, 1

Purchaser, 1

Purchaser Adjustment Amount, 8

Purchaser Deficit, 8

Purchaser Indemnitee, 47

Real Property Leases, 17

Related Parties, 17

Related Party Agreements, 17

Sections, 64

Securities Act, 63

Shareholder Excess, 8

 

Shareholder Release, 45

Shareholders, 1

Shareholders’ Representative, 4

Stock, 13

Stock Options, 13

Subsidiary, 63

Target Net Working Capital, 63

Tax, 63

Tax Return, 63

Tax Sharing Agreement, 63

Taxes, 63

Terminating Breach, 46

Termination Liability, 64

Transaction, 1

Transaction Documents, 64

Transaction Expense Schedule, 2

Transaction Expenses, 64

WARN, 64

Working Capital Statement, 6

 

 

 

 

 

 

 

 

 

 

  v  

 

 

 

STOCK PURCHASE AGREEMENT

 

THIS STOCK PURCHASE AGREEMENT (this “ Agreement ”), dated as of May 1, 2017, is entered into by and among DILISYM SERVICES, INC., a North Carolina corporation (the “ Company ”), SIMULATIONS PLUS, INC., a California corporation (“ Purchaser ”), the shareholders of the Company listed on the signature pages hereto (the “ Shareholders ”), and Brett A. Howell (“ Shareholders’ Representative ”).

 

WHEREAS, the Company, the Shareholders and Purchaser have determined that it is advisable and in the best interest of their respective shareholders for Purchaser to acquire all of the Company’s outstanding capital stock (the “ Purchased Shares ”), upon the terms and subject to the conditions set forth in this Agreement (the “ Transaction ”);

 

WHEREAS, the Board of Directors of the Company (the “ Board ”) has approved this Agreement and the Contemplated Transactions and declared the advisability and resolved to recommend approval of the Transaction and adoption of this Agreement by the Shareholders;

 

WHEREAS, the Company, Purchaser, the Shareholders and the Shareholders’ Representative desire to make certain representations, warranties, covenants and agreements in connection with this Agreement;

 

WHEREAS, in connection with this Agreement, it is contemplated that, subject to the terms and conditions set forth in this Agreement, on the date hereof or at the Closing, the Shareholders, or the Shareholders’ Representative on their behalf, and the Purchaser will enter into the Transaction Documents; and

 

NOW, THEREFORE, subject to and in consideration of the foregoing and the mutual covenants and agreements, terms and conditions herein contained, and intending to be legally bound hereby, the Company, Purchaser, the Shareholders and the Shareholders’ Representative hereby agree as follows:

 

Article I
PURCHASE AND SALE OF THE PURCHASED SHARES

 

Section 1.1 Transaction .

 

(a)        Purchase and Sale . On the terms and subject to the conditions set forth in this Agreement, at the Closing, the Shareholders shall sell, convey, assign, transfer and deliver to the Purchaser, and the Purchaser shall purchase, acquire and accept from the Shareholders, all of the Shareholders’ right, title and interest in and to the Purchased Shares, free and clear of all Liens.

 

(b)        Closing . Unless this Agreement shall have been terminated and the transactions herein contemplated shall have been abandoned pursuant to Section 7.1 and subject to the satisfaction or waiver of the conditions set forth in Article VI, the closing of the Transaction (“ Closing ”) will take place as promptly as practicable (and in any event within five (5) Business Days) after satisfaction or waiver of the conditions set forth in Article VI, at the principal offices of Procopio, Cory, Hargreaves & Savitch LLP, 12544 High Bluff Drive, Suite 300, San Diego, California 92130, unless another date and time or place is agreed to in writing by the parties hereto (the “ Closing Date ”).

 

 

 

  1  

 

 

Section 1.2 Purchase Price .

 

(a)        Subject to the terms and conditions of this Agreement and to the adjustments set forth herein, the aggregate Transaction consideration (the “ Purchase Price ”) shall consist of:

 

(i)        cash in amount equal to the sum of (A) Five Million Dollars ($5,000,000), minus (x) the Transaction Expenses set forth on the Transaction Expense Schedule, minus (y) the amount of Indebtedness of the Company, (collectively, the “ Preliminary Cash Consideration ”), minus (B) the Purchaser Adjustment Amount, if any, plus (C) the Company Adjustment Amount, if any, minus (iv) One Million Dollars ($1,000,000) (the “ Holdback Amount ”), subject to adjustment as provided herein (collectively, the “ Cash Consideration ”); and

 

(ii)        the Earn-Out Consideration.

 

(b)        Not less than two (2) Business Days prior to the Closing Date, the Company shall deliver to Purchaser a schedule (the “ Transaction Expense Schedule ”) of the Company signed by the President of the Company and the Shareholders’ Representative, which schedule shall set forth the Transaction Expenses to be paid at Closing by Purchaser on behalf of the Company as provided herein, along with wire transfer instructions for any such payments. At Closing Purchaser shall pay, on behalf of the Company, to the parties identified in the Transaction Expense Schedule the amounts identified in the Transaction Expense Schedule (which amounts shall reduce the Preliminary Cash Consideration payable to Shareholders at Closing).

 

Section 1.3 Payment Procedures . The Purchase Price which shall be paid by Purchaser on the Closing Date as follows in the form of wire transfers to the accounts set forth in a flow of funds memorandum to be provided by the Shareholders’ Representative to the Purchaser at the Closing, in a form satisfactory to the Purchaser (the “ Flow of Funds Memorandum ”):

 

(a)        the Holdback Amount shall be withheld by the Purchaser as security for certain potential adjustments to the Purchase Price pursuant to Section 1.9 below and for the indemnification obligations set forth in Article VIII;

 

(b)        an amount equal to the Indebtedness, on behalf of the Company, as directed by and in accordance with the terms of payoff letters;

 

(c)        the Transaction Expenses, on behalf of the Company, the Shareholders and their Affiliates, as applicable, as directed by and in accordance with the Payoff Letters; and

 

 

 

  2  

 

 

(d)        the balance of the Closing Consideration, after making the payments set forth in clauses (a) through (c) hereof to the Shareholders.

 

Section 1.4 Funds Flow Memorandum . Notwithstanding anything to the contrary in this Agreement or elsewhere, Purchaser shall not be in any way responsible for or liable in connection with any aspect or component of the Closing Funds Flow Memorandum provided to Purchaser by the Shareholders’ Representative on or prior to the Closing Date, including: (i) any determination or calculation of any amounts payable pursuant to the Funds Flow Memorandum; (ii) the inclusion of any amount payable in or the omission of any amount payable from the Funds Flow Memorandum; or (iii) any error or omission with respect to the third parties to whom payments are to be made pursuant to the Funds Flow Memorandum.

 

Section 1.5 Stock Options . Prior to the Closing, the Shareholders shall take, or shall cause the Company to take, all actions necessary to cancel, rescind and/or exercise all Stock Options outstanding, whether or not exercisable, whether or not vested as of the Closing, and which are outstanding immediately prior to the Closing. As of the Closing, the Shareholders shall have taken all actions necessary to ensure that there is no further or continuing obligation or liability of any kind with respect to the exercise, cash out or other disposition of any Stock Options, including any payroll or other Taxes with respect thereto.

 

Section 1.6 Holdback . At the Closing, the Holdback Amount shall be withheld by Purchaser from the Purchase Price otherwise payable to the Shareholders, and Purchaser shall hold such Holdback Amount in accordance with the terms of this Agreement until the Holdback Release Date. Notwithstanding anything in this Agreement to the contrary, if Purchaser has given written notice to the Shareholders’ Representative of one or more Claims made prior to the Holdback Release Date pursuant to Section 8.6 of this Agreement or any other section of this Agreement providing for payment of Losses from the remaining Holdback Amount and all such Claims have not been finally resolved prior to the Holdback Release Date, Purchaser shall withhold from its delivery of the portion of the remaining Holdback Amount otherwise required to be remitted on the Holdback Release Date, pending resolution of such Claims, an amount of cash that represents Purchaser’s good faith estimate of the amount to which it would be entitled if it prevailed with respect to such Claims. If, upon final resolution of all such Claims, the aggregate amount withheld by the Purchaser is greater than the Shareholders’ aggregate liability with respect to all such Claims, then the Purchaser shall deliver to the Shareholders’ Representative, for the benefit of the Shareholders, the Holdback Amount in an amount equal to such difference. Subject to the terms and conditions herein, each Shareholder shall be entitled to receive from the Shareholders’ Representative, on behalf of Purchaser, as promptly as practicable following the Holdback Release Date and if applicable, such later date as all Claims are finally resolved, such Shareholder’s Pro Rata Portion of the remaining Holdback Amount as set forth in Section 8.8.

 

Section 1.7 Further Assurances . If, at any time after the Effective Time, the Purchaser considers or is advised that any deeds, bills of sale, assignments, consents, assurances or any other actions or things are necessary or desirable to vest, perfect or confirm of record or otherwise in the Purchaser its right, title or interest in, to or under any of the rights, properties, or assets of the Company, or otherwise to carry out the intent and purposes of this Agreement, the Shareholders will execute and deliver all such deeds, bills of sale, assignments, consents and assurances and to take and do, all such other actions and things as Purchaser may determine to be necessary or desirable to vest, perfect or confirm any and all right, title and interest in, to and under such rights, properties or assets in Purchaser and the Company to carry out the intent and purposes of this Agreement.

 

 

  3  

 

 

Section 1.8 Shareholders’ Representative .

 

(a)        Through signature on this Agreement and/or approval of this Agreement, each of the Shareholders hereby appoints Brett A. Howell as such Shareholder’s exclusive agent and attorney-in-fact (the “ Shareholders’ Representative ”) to give and receive notices and communications with respect to the provisions of this Agreement, and to agree to, negotiate, enter into settlements or compromises of matters arising under this Agreement, and to take any and all actions necessary or appropriate in the judgment of the Shareholders’ Representative to be taken on behalf of the Shareholders under this Agreement. Such agency is irrevocable other than as set forth in this Agreement and coupled with an interest. Notices or communications to or from the Shareholders’ Representative shall constitute notice to or from the Shareholders in respect of matters under this Agreement. The Shareholders agree that a decision, act, consent or instruction of the Shareholders’ Representative shall constitute a decision of all Shareholders, and shall be final, binding and conclusive upon each Shareholder, and Purchaser may rely upon any decision, act, consent or instruction of the Shareholders’ Representative as being the decision, act, consent or instruction of all Shareholders. Purchaser and its Affiliates shall not be liable in any way to the Shareholders based on any act or omission of the Shareholders’ Representative relating to this Agreement.

 

(b)        The Shareholders’ Representative shall be liable to the Shareholders only for his proven bad faith, willful misconduct, or gross negligence, as determined in light of all the circumstances, including the time and facilities available to him in the ordinary conduct of business. In determining the occurrence of any event or contingency, the Shareholders’ Representative may request from any of the Shareholders or any other Person such reasonable additional evidence as the Shareholders’ Representative in his sole discretion may deem necessary to determine any fact relating to the occurrence of such event or contingency, and may at any time inquire of and consult with others, including any of the Shareholders, and may obtain legal advice, and the Shareholders’ Representative shall not be liable to any Shareholder for any damages resulting from his delay in acting hereunder pending his receipt and examination of additional evidence, counsel or advice requested by him.

 

(c)        The Shareholders’ Representative is authorized, in his sole discretion, to comply with final, nonappealable orders issued or process entered by any court of competent jurisdiction with respect to the Holdback Amount. If any portion of the Holdback Amount is disbursed to the Shareholders’ Representative and is at any time attached, garnished or levied upon under any court order, or in case the payment, assignment, transfer, conveyance or delivery of any such property shall be stayed or enjoined by any court order, or in case any order, writ, judgment or decree shall be made or entered by any court affecting such property or any part thereof, then and in any such event, the Shareholders’ Representative is authorized, in his sole discretion, but in good faith, to rely upon and comply with any such order, writ, judgment or decree which he is advised by legal counsel selected by him is binding upon it without the need for appeal or other action; and if the Shareholders’ Representative complies with any such order, writ, judgment or decree, he shall not be liable to any Shareholder or to any other Person by reason of such compliance even though such order, writ, judgment or decree may be subsequently reversed, modified, annulled, set aside or vacated.

 

 

 

  4  

 

(d)        In no event shall the Shareholders’ Representative be liable to any Shareholder for incidental, indirect, special, consequential or punitive damages.

 

(e)        The Shareholders’ Representative shall be entitled to reimbursement for expenses (including attorneys’ fees) that are incurred by Shareholders’ Representative in connection with his performance hereunder. Each Shareholder shall be liable for its pro rata share (based on their respective Pro Rata Portion of the Purchased Shares immediately prior to the Closing Date) of such excess expenses (including attorneys’ fees).

 

(f)        In the event that any Shareholder pays Purchaser and/or Shareholders’ Representative any amounts pursuant to this Agreement in excess of such Shareholder’s Pro Rata Portion of such amount, such Shareholder shall be entitled to reimbursement for the amount of any such payments in excess of such Shareholder’s Pro Rata Portion of such amount out of (and any such amounts shall be deducted by the Shareholders’ Representative from) any future Holdback Amount that is distributed to the Shareholders’ Representative for future distribution to the Shareholders prior to Shareholders’ Representative’s distribution of such Holdback Amount to the Shareholders.

 

(g)        If the Shareholders’ Representative resigns (by giving at least sixty (60) days’ written notice of such resignation to Purchaser) or dies or becomes incapable of continuing to act as the Shareholders’ Representative for any reason, a successor Shareholders’ Representative (who shall either be a Shareholder or another Person reasonably acceptable to Purchaser) shall be appointed in writing by a majority in interest of the Shareholders (which for purposes of this Agreement shall be based on their respective Pro Rata Portion of the Purchased Shares immediately prior to the Closing Date), such appointment to become effective upon the delivery of executed counterparts of such writing to Purchaser, together with an acknowledgement signed by the successor Shareholders’ Representative named in such writing that he, she or it accepts the responsibility of successor Shareholders’ Representative and agrees to perform and be bound by all provisions of this Agreement applicable to the Shareholders’ Representative. Pending the election of a successor Shareholders’ Representative, the Shareholder that has the largest aggregate stake in the Purchase Price immediately following the Effective Time (excluding any former Shareholders’ Representative) shall act as the interim Shareholders’ Representative. Failing such appointment, Purchaser or any Shareholder may apply to a court of competent jurisdiction for the appointment of a successor Shareholders’ Representative.

 

 

 

  5  

 

 

(h)        A majority in interest of the Shareholders (based on their respective Pro Rata Portion of Purchased Shares immediately prior to the Closing Date) shall have the right at any time during the term of this Agreement to remove the then-acting Shareholders’ Representative and to appoint a successor Shareholders’ Representative (who shall either be a Shareholder or another Person reasonably acceptable to Purchaser); provided, however, that such removal of the then-acting Shareholders’ Representative shall not be effective until the delivery to Purchaser of executed counterparts of a writing signed by a majority in interest of the Shareholders with respect to such removal and appointment, together with an acknowledgement signed by a successor Shareholders’ Representative appointed in such writing that he, she or it accepts the responsibility of successor Shareholders’ Representative and agrees to perform and be bound by all of the provisions of this Agreement applicable to the Shareholders’ Representative.

 

(i)        Each interim and successor Shareholders’ Representative shall have all the power, authority, rights and privileges conferred by this Agreement upon the original Shareholders’ Representative, and the term Shareholders’ Representative as used herein shall be deemed to include any interim or successor Shareholders’ Representative.

 

(j)        Any notices given by Purchaser while there is no Shareholders’ Representative shall be sufficiently given if given to the Shareholder with the largest stake in the Holdback Amount immediately following the Effective Time (excluding the former Shareholders’ Representative). A copy of all such notices shall be delivered to the successor Shareholders’ Representative upon his, her or its appointment and he, she or it shall have five (5) days thereafter to take such actions as may be required under the terms of this Agreement in connection with any such notice.

 

Section 1.9 Working Capital Adjustment .

 

(a)        No later than three (3) Business Days prior to the Closing Date, and as one of the conditions to Closing described in Section 6.2 hereof, the Shareholders’ Representative shall cause to be delivered to Purchaser a preliminary balance sheet of Company dated as of the Closing Date (the “ Preliminary Closing Balance Sheet ”), together with a written statement setting forth in reasonable detail its determination of the Company’s current assets and its current liabilities as of that date and an estimate of the Company’s Net Working Capital (the “ Preliminary Working Capital Statement ”). The Preliminary Closing Balance Sheet and the Preliminary Working Capital Statement shall be prepared in accordance with GAAP and Section 1.9.

 

(b)        Within ninety (90) calendar days after the Closing Date, Purchaser will prepare or cause to be prepared, and will provide to the Shareholders’ Representative, a balance sheet of the Company as of the Closing Date (the “ Closing Balance Sheet ”), together with a working capital statement setting forth in reasonable detail its determination of the Company’s Net Working Capital as of the Closing Date (“ Working Capital Statement ”). The Closing Balance Sheet and Working Capital Statement (collectively, the “ Closing Statements ”) will be prepared in accordance with GAAP. Subject to a customary confidentiality agreement being in effect (which agreement shall allow the Shareholders’ Representative to discuss these matters with the Shareholders), Purchaser shall provide to Shareholders’ Representative reasonable supporting documentation for the Closing Statements concurrently with the delivery thereof and access to the appropriate books, records, employees and agents of the Company (including by electronic means, to the extent available) and Purchaser to allow Shareholders’ Representative to properly review the Closing Statements (upon reasonable notice); provided, that Purchaser shall not be required to provide any attorney-client privileged documents or communications.

 

 

 

  6  

 

(c)        The Closing Statements shall be final and binding on the parties unless Shareholders’ Representative, within thirty (30) calendar days following its receipt thereof, delivers to Purchaser written notice of disagreement with any of the Closing Statements, which notice shall describe in reasonable detail the nature of such disagreement, and shall identify the specific items involved and the dollar amount of the disagreement. If Shareholders’ Representative shall raise any objections within the aforesaid thirty (30) calendar day period, then the disputed matters shall be resolved by Shareholders’ Representative, on behalf of the Shareholders, and Purchaser, in good faith. If Shareholders’ Representative and Purchaser are unable to resolve all disagreements within thirty (30) calendar days after receipt by Purchaser of a written notice of disagreement, or such longer period as may be agreed by Purchaser and Shareholders’ Representative, then, either Shareholders’ Representative or Purchaser may initiate procedures to finally resolve such disputes by providing written notice of such intent to the non-initiating party. Promptly following such written notice (but in any event within ten (10) Business Days), Shareholders’ Representative and Purchaser shall jointly select a nationally recognized independent public accounting firm that does not have an existing business relationship with any of Purchaser, Shareholders’ Representative, the Shareholders, or the Company (the “ Independent Accountant ”); provided, however, that if Purchaser and Shareholders’ Representative are unable to select an Independent Accountant within such time period, JAMS shall make such selection as promptly as practicable thereafter. The Independent Accountant so selected will consider only those items and amounts set forth in the Closing Statements as to which Purchaser and Shareholders’ Representative have disagreed within the time periods and on the terms specified above and must resolve the matter in accordance with the terms and provisions of this Agreement. The Independent Accountant may not assign a value greater than the greatest value for any such item claimed by either Purchaser, on the one hand, or Shareholders’ Representative, on the other hand, or smaller than the value assigned to the disputed item by Purchaser, on the one hand, or Shareholders’ Representative, on the other hand, in the Closing Statements. In submitting a dispute to the Independent Accountant, each of the parties shall concurrently furnish, at its own expense, to the Independent Accountant and the other party, such documents and information as the Independent Accountant may reasonably request; provided, that neither party shall be required to provide any attorney-client privileged documents or communications. Each party may also furnish to the Independent Accountant such other information and documents as it deems relevant, with copies of such submission and all such documents and information being concurrently given to the other party. The Independent Accountant shall issue a written report that sets forth the resolution of all items in dispute and that contains, as applicable, (i) a final Closing Balance Sheet and/or (ii) a final Working Capital Statement, according to the dispute(s) noticed. The report shall be final and binding upon Purchaser, the Company, Shareholders’ Representative and the Shareholders. The fees and expenses of the Independent Accountant incurred in connection with the determination of the disputed items by the Independent Accountant shall be allocated equally between Purchaser and Shareholders’ Representative (solely on behalf of the Shareholders). Purchaser and Shareholders’ Representative shall, and Purchaser shall cause the Company to, cooperate fully with the Independent Accountant and respond on a timely basis to all requests for information or access to documents or personnel made by the Independent Accountant or by other parties hereto, all with the intent to fairly and in good faith resolve all disputes relating to the Closing Statements as promptly as reasonably practicable; provided, that neither party shall be required to provide any attorney-client privileged documents or communications.

 

 

 

  7  

 

(d)        After the Closing Statements have been finally determined in accordance with Section 1.09 (c), if the finally determined Net Working Capital of the Company as of the Closing is less than the Target Net Working Capital (the difference between such Net Working Capital of the Company as of the Closing minus the Target Net Working Capital is referred to herein as the “ Purchaser Deficit ”), then the Purchase Price shall be reduced by the amount of Purchaser Deficit (“ Purchaser Adjustment Amount ”). Purchaser shall be entitled to receive cash in an amount equal to the Purchaser Adjustment Amount, from the Shareholders and, may either (i) elect to offset the Purchaser Adjustment Amount against the Holdback Amount (without regards to the limitations of Article VIII), or (ii) recover such amount directly from the Shareholders (in which case, the Shareholders shall deliver such amount to Purchaser within five (5) Business Days following such determination). If the finally determined Net Working Capital of the Company as of the Closing is greater than the Target Net Working Capital (the difference between such Net Working Capital of the Company as of the Closing minus the Target Net Working Capital is referred to herein as the “ Shareholder Excess ”), then the Purchase Price shall be increased by the amount of the Shareholder Excess (“ Company Adjustment Amount ”, and together with the Purchaser Adjustment Amount, as applicable, the “ Adjustment Amount ”). The Shareholders shall be entitled to receive cash in the amount of the Company Adjustment Amount, if any, from Purchaser. In the event of a Company Adjustment Amount, Purchaser shall deliver such amount to the Shareholders within five (5) Business Days following such determination.

 

Section 1.10 Repayment of Company Indebtedness and Transaction Expenses . At or prior to the Closing, the Company shall repay and discharge, or cause to be repaid and discharged, any and all Transaction Expenses not being paid directly by the Shareholders and Indebtedness of the Company outstanding as of the Closing Date, together with accrued and unpaid interest thereon. Prior to the Closing Date, the Company shall submit reasonably satisfactory documentation (“ Payoff Letters ”) setting forth (a) the amount of all Indebtedness outstanding as of the Closing Date, including the identity of each lender thereof, dollar amounts, wire instructions and any other information necessary to effect payment therefore, and (b) an estimate of the Transaction Expenses, including in each case the identity of each service provider, dollar amounts and any other information necessary to effect payment therefore. The Company and the Shareholders understand that all amounts of Indebtedness and Transaction Expenses are the sole responsibility of the Company and the Shareholders, and the amounts paid pursuant to this Section 1.10 are being made on the Company and the Shareholders’ behalf and shall reduce the Preliminary Cash Consideration and Purchase Price payable to the Shareholders under this Agreement. In no event shall Purchaser or the Company have any liability or obligation regarding the Indebtedness or Transaction Expenses. In connection with the repayment of Indebtedness hereunder, the Company shall obtain releases of all Liens on the assets, properties or capital stock of the Company securing any such Indebtedness of the Company. At the Closing, the Company shall provide evidence in writing reasonably satisfactory to Purchaser of such repayment of Indebtedness of the Company and release of any and all Liens contemplated by this Section 1.10, including, without limitation, Payoff Letters that are reasonably acceptable to Purchaser and its lenders and UCC-3 termination statements.

 

 

 

  8  

 

Section 1.11 Earn-Out .

 

(a)        Earn-Out Payment . Following the Closing, the Shareholders shall be entitled to a payment (each, an “ Earn-Out Payment ”) equal to the Adjusted EBT for each of the Earn-Out Years, as more fully set forth in this Section 1.11. For avoidance of doubt, all items with respect to the Earn-Out Payment shall be calculated in accordance with GAAP and Schedule 1.11.

 

(b)        Limitation . No Earn-Out Payment shall be due or payable for any Earn-Out Year in which Adjusted EBT is a negative number. In no event will the aggregate amount of all of the Earn-out Payments exceed Five Million Dollars ($5,000,000). The Earn-out Payments, if any, shall be considered part of the Purchase Price to the extent permitted by Law.

 

(c)        Procedures Applicable to Determination of the Earn-Out Payments .

 

(i)        Purchaser shall consult with Shareholders’ Representative from time to time during the period of the Earn-Out Years with regards to Adjusted EBT and, no later than the date that is ninety (90) days after the last day of each Earn-Out Year, Purchaser shall prepare and deliver to the Shareholders’ Representative a written statement (the “ Earn-Out Calculation Statement ”) setting forth in reasonable detail its determination the Adjusted EBT, and its calculation of the resulting Earn-Out Payment, if any (the “ Earn-Out Calculation ”).

 

(ii)        The Earn-Out Calculation Statement shall be final and binding on the parties unless Shareholders’ Representative, within thirty (30) calendar days following its receipt thereof, delivers to Purchaser written notice of disagreement with any of the Earn-Out Calculation Statement, which notice shall describe in reasonable detail the nature of such disagreement, and shall identify the specific items involved and the dollar amount of the disagreement. If Shareholders’ Representative shall raise any objections within the aforesaid thirty (30) calendar day period, then the disputed matters shall be resolved by Shareholders’ Representative, on behalf of the Shareholders, and Purchaser, in good faith. If Shareholders’ Representative and Purchaser are unable to resolve all disagreements within thirty (30) calendar days after receipt by Purchaser of a written notice of disagreement, or such longer period as may be agreed by Purchaser and Shareholders’ Representative, then, either Shareholders’ Representative or Purchaser may initiate procedures to finally resolve such disputes by providing written notice of such intent to the non-initiating party. Promptly following such written notice (but in any event within ten (10) Business Days), Shareholders’ Representative and Purchaser shall jointly select an Independent Accountant; provided, however, that if Purchaser and Shareholders’ Representative are unable to select an Independent Accountant within such time period, JAMS shall make such selection as promptly as practicable thereafter. The Independent Accountant so selected will consider only those items and amounts set forth in the Earn-Out Calculation Statement as to which Purchaser and Shareholders’ Representative have disagreed within the time periods and on the terms specified above and must resolve the matter in accordance with the terms and provisions of this Agreement. The Independent Accountant may not assign a value greater than the greatest value for any such item claimed by either Purchaser, on the one hand, or Shareholders’ Representative, on the other hand, or smaller than the value assigned to the disputed item by Purchaser, on the one hand, or Shareholders’ Representative, on the other hand, in the Earn-Out Calculation Statement. In submitting a dispute to the Independent Accountant, each of the parties shall concurrently furnish, at its own expense, to the Independent Accountant and the other party, such documents and information as the Independent Accountant may reasonably request; provided, that neither party shall be required to provide any attorney-client privileged documents or communications. Each party may also furnish to the Independent Accountant such other information and documents as it deems relevant, with copies of such submission and all such documents and information being concurrently given to the other party. The Independent Accountant shall issue a written report that sets forth the resolution of all items in dispute and that contains, as applicable, (i) a final Earn-Out Calculation Statement and/or (ii) a final Earn-Out Calculation, according to the dispute(s) noticed. The report shall be final and binding upon Purchaser, the Company, Shareholders’ Representative and the Shareholders. The fees and expenses of the Independent Accountant incurred in connection with the determination of the disputed items by the Independent Accountant shall be allocated equally between Purchaser and Shareholders’ Representative (solely on behalf of the Shareholders). Purchaser and Shareholders’ Representative shall, and Purchaser shall cause the Company to, cooperate fully with the Independent Accountant and respond on a timely basis to all requests for information or access to documents or personnel made by the Independent Accountant or by other parties hereto, all with the intent to fairly and in good faith resolve all disputes relating to the Earn-Out Calculation Statement as promptly as reasonably practicable; provided, that neither party shall be required to provide any attorney-client privileged documents or communications.

 

 

 

  9  

 

(d)        Timing and Tax Treatment of Earn-Out Payments . Subject to Section 1.11(f) and Section 1.11(g) below, any Earn-Out Payment that Purchaser is required to pay pursuant to Section 1.11(a) hereof shall be paid in full no later than five (5) Business Days following the date upon which the determination of the amount of any Earn-Out Payment becomes final and binding upon the parties as provided in Section 1.11(c) (including any final resolution of any dispute raised by the Shareholders’ Representative). Purchaser shall pay to the Shareholders the applicable Earn-Out Payment in cash by wire transfer of immediately available funds to the bank account(s) designated by the Shareholders’ Representative. Any Earn-Out Payment shall be treated as an adjustment to the Purchase Price by the parties for all applicable income tax purposes, unless otherwise required by Law.

 

(e)        Post-Closing Operation of the Company . Subsequent to the Closing, Purchaser shall have sole discretion with regard to all matters relating to the operation of the Company and any Subsidiary and shall operate the Company in any way it deems appropriate; provided, however, that from the Closing through the Earn-Out Years: (i) Purchaser shall not intentionally take any action the purpose of which is to decrease the Earnout Payment; provided that any action taken to comply with GAAP or upon the advice of Purchaser’s auditors shall not be deemed to be an action intentionally taken to decrease the Earnout Payment; (ii) Purchaser shall not sell, liquidate or otherwise dispose of the operations or equity interest in the Company unless the party acquiring such operations or ownership interest expressly agrees in writing to be bound by the post-Closing terms of this Agreement (including this Section 1.11) and to assume, and does in fact assume, all of Purchaser’s obligations under this Agreement (including this Section 1.11). For avoidance of doubt, Purchaser has no obligation to operate the Company or any Subsidiary in order to achieve any Earn-Out Payment or to maximize the amount of any Earn-Out Payment.

 

 

 

  10  

 

 

(f)        Audit Correction . Notwithstanding the foregoing, including Sections 1.11(c) and (d), if the Company’s final audit for any Earn-Out Year indicates the Earn-Out Calculation for such Earn-Out Year was incorrect, Purchaser shall provide notice of such error, together with a duly corrected Earn-Out Calculation to the Shareholders’ Representative setting forth any overpayment or underpayment to the Shareholders for such Earn-Out Year, and such corrected Earn-Out Calculation shall be final and binding on the parties hereto.  The Shareholders shall pay to Purchaser any such overpayment, and the Purchaser shall pay to the Shareholders any such underpayment, within five Business Days of such notice under this Section 1.11(f) by wire transfer of immediately available funds to the bank account(s) designated by Purchaser.

 

(g)        Right of Set-Off . Purchaser shall have the right to withhold and set off any amount otherwise due to be paid to the Shareholders pursuant to this Section 1.11 against the amount of (i) any Adjustment Amount owed to it pursuant to Section 1.9 of this Agreement, and (ii) any Losses that any Purchaser Indemnitee may be finally entitled to under Article VIII of this Agreement.

 

(h)        No Security . The Parties understand and agree that (i) the contingent rights to receive any Earn-Out Payment shall not be represented by any form of certificate or other instrument, are not transferable, except by operation of Laws relating to descent and distribution, divorce and community property, and do not constitute an equity or ownership interest in Purchaser or the Company or any Subsidiary, (ii) the Shareholders shall not have any rights as a securityholder of Purchaser or the Company or any Subsidiary as a result of any Shareholder’s contingent right to receive any Earn-Out Payment hereunder, and (iii) no interest is payable with respect to any Earn-Out Payment.

 

(i)        Condition of Non-Competition Agreement . Notwithstanding anything contained in this Section 1.11 or otherwise in this Agreement, no Shareholder shall be entitled to receive any Earn-out Payment otherwise payable to such Shareholder pursuant to this Section 1.11 to the extent of Losses caused by such Shareholder from the breach or other violation of the Non-Competition Agreement.

 

 

 

  11  

 

 

Article II
REPRESENTATIONS AND WARRANTIES OF THE COMPANY
AND THE SHAREHOLDERS

 

The Company and each of the Shareholders hereby, jointly and severally, represent and warrant to Purchaser that on the date hereof and as of the Closing Date that the following statements are true, correct and complete, except as specifically set forth in the section of the written disclosure schedule delivered on or prior to the date hereof by the Shareholders to Purchaser (the “ Company Disclosure Schedule ”) which shall identify by section number the provision of this Article II to which each exception relates, as follows:

 

Section 2.1 Organization and Qualification; Subsidiaries . The Company is a corporation duly incorporated, validly existing and in good standing under the law of its jurisdiction of incorporation, and the Company has the requisite power and authority and is in possession of all franchises, grants, authorizations, licenses, permits, easements, consents, certificates, approvals and orders necessary to own, lease and operate the properties it purports to own, lease or operate and to carry on its business as it is now being conducted. The Company is duly qualified or licensed as a foreign corporation to do business, and is in good standing, in each jurisdiction where the character of its properties owned, leased or operated by it or the nature of its activities makes such qualification or licensing necessary. The Company does not own or lease property in any jurisdiction other than its jurisdiction of incorporation and the jurisdictions referred to in the previous sentence. Except as set forth on Section 2.1 of the Company Disclosure Schedule, no jurisdiction has claimed, in writing or otherwise, that the Company is required to qualify as a foreign corporation or other entity therein, and (except as aforesaid) the Company does not file any franchise, income or other tax returns in any other jurisdiction based upon the ownership or use of property therein or the derivation of income therefrom. The Company has no subsidiaries and does not own, directly or indirectly, (a) any capital stock (including ordinary share or preference share capital), partnership or membership interest, unit of participation or other similar interest (however designated) in any other Person and (b) any option, warrant, purchase right, conversion right, exchange right or other contractual obligation which would entitle the Company to acquire any such interest in any Person or otherwise entitle the Company to share in the equity, profits, earnings, losses or gains of such Person (including stock appreciation, phantom stock, profit participation, change of Control bonus or other similar rights), in any other corporation, partnership or other Person.

 

Section 2.2 Certificate of Incorporation and Bylaws . The Company has heretofore furnished to Purchaser a true, complete and correct copy of its Certificate of Incorporation and Bylaws, each as amended to date. Such Certificate of Incorporation and Bylaws are in full force and effect. The Company is not in violation of any material provisions of its Certificate of Incorporation or Bylaws.

 

Section 2.3 Capitalization . The authorized capital stock of the Company consists of One Million (1,000,000) shares of Common Stock. As of the date of this Agreement, Seven Hundred Sixty-Six Thousand Twenty-Seven (766,027) shares of Common Stock are issued and outstanding, all of which are validly issued, fully paid and nonassessable, and none of which are held in treasury. There are no shares of capital stock of the Company outstanding other than the Purchased Shares. Except as set forth on Section 2.3 of the Company Disclosure Schedule, no shares of Common Stock are issued, granted, outstanding or reserved for future issuance for outstanding option to purchase shares of Company Common Stock (each a “ Stock Option ” and, collectively, the “ Stock Options ”) and the Company has no Company stock option or other equity or incentive plan. Section 2.3 of the Company Disclosure Schedule sets forth a true and complete list of all shareholders of the Company, and the number of shares held by each. There are no options, warrants or other similar rights, agreements, arrangements, commitments or understanding, whether or not in writing, of any character relating to the issued or unissued capital stock or other securities of the Company or obligating the Company to issue (whether upon conversion, exchange or otherwise) or sell any share of capital stock of, or other equity interests in or other securities of, the Company. There are no obligations, contingent or otherwise, of the Company to repurchase, redeem or otherwise acquire any shares of Common Stock or capital stock or any other securities of the Company or to provide funds to or make any investment (in the form of a loan, capital contribution or otherwise) in any other entity. Except as set forth on Section 2.3 of the Company Disclosure Schedule, there are no voting trusts or agreements, stockholder agreements, pledge agreements, buy-sell agreements, rights of first refusal, preemptive rights or proxies relating to any securities of the Company.

 

 

 

  12  

 

 

Section 2.4 Authority Relative to this Agreement . The Company has all necessary corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder and to consummate the Contemplated Transactions. The execution and delivery of this Agreement by the Company, the Transaction Documents and the consummation by the Company of the Contemplated Transactions have been duly and validly authorized by all necessary corporate action on the part of the Company, and no other corporate proceedings on the part of the Company are necessary to authorize this Agreement, the Transaction Documents or to consummate the Contemplated Transactions, including, if necessary, the approval of this Agreement by all Shareholders in accordance with the Governing Corporate Law and the Company’s Certificate of Incorporation and Bylaws, as amended to date. The Board has unanimously approved this Agreement and the Contemplated Transactions and declared their advisability. This Agreement has been duly and validly executed and delivered by the Company and, when duly authorized, executed and delivered to all other parties hereto, will constitute a legal, valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except as enforceability against the Company may be limited by applicable bankruptcy, insolvency, reorganization, fraudulent conveyance or transfer, moratorium or similar laws affecting the enforcement of creditors' rights and by general principles of equity relating to enforceability (regardless of whether considered in a proceeding at law or in equity).

 

Section 2.5 Governmental Authorization and Consents . Except for obtaining those consents, approvals, authorizations, filings or notices set forth in Section 2.5 of the Company Disclosure Schedule, no Governmental Authorization of, filing with, or notice to, any Governmental Authority or any lenders, lessors, creditors, shareholders or any other Person, is required by the Company in connection with the execution, delivery and performance by the Company of this Agreement or any document, agreement, instrument or certificate contemplated hereby and the consummation by the Company of the Contemplated Transactions. Additionally, no Governmental Authorization of, filing with, or notice to, any Governmental Authority was required by the Company or, to the Company’s Knowledge, the Hamner Institute in connection with (i) the Hamner Institute’s contribution or assignment of Intellectual Property to the Company, or (ii) the issuance of any equity securities of the Company to or from the Hamner Institute.

 

 

  13  

 

 

Section 2.6 Non-contravention . The execution and delivery of this Agreement and all of the Transaction Documents and, the performance by the Company of the obligations hereunder and thereunder, and the consummation of the Transaction and all related transactions, do not and will not (a) breach, contravene or conflict with the Certificate of Incorporation, Bylaws or other charter documents of the Company, (b) assuming compliance with the matters referred to in Section 2.5, contravene or conflict with any applicable provision of any Law, regulation, rule, judgment, injunction, Order or decree binding upon or applicable to the Company, (c) except as set forth in Section 2.5 or Section 2.6 of the Company Disclosure Schedule, require notice, consent or approval or constitute a default under, or impair or alter the rights of the Company or, to the Company’s Knowledge, any third party, (d) give rise to a right of termination, cancellation, amendment or acceleration of any right or obligation of the Company or to a loss of any benefit to which the Company is entitled under, any provision of any contract (including any Material Contract) or other instrument binding upon the Company or by which any of the Company’s assets or properties may be bound or subject, or any license, franchise, Permit or other similar authorization held by the Company or (e) result in the creation or imposition of any Lien on any assets or properties of the Company.

 

Section 2.7 Title to Properties; Absence of Liens; Sufficiency of Assets . The Company has good, valid, and marketable title to or, in the case of leased property and assets, valid and subsisting leasehold interests in, all of its assets and property, whether real, personal, mixed, tangible, including, without limitation, all of the assets and properties reflected in the Interim Balance Sheet, free and clear of all Liens, except for such Liens as are set forth in Section 2.7 of the Company Disclosure Schedule. The Company does not own or lease any vehicles. As of the Closing, the assets and property owned or leased by the Company (i) will constitute all of the property and assets used or held for use in connection with the Company’s business, (ii) will constitute all of the property and assets necessary to conduct the Company’s business, (iii) will be in good operating condition and repair (normal wear and tear excepted), (iv) will be adequate for the uses to which they are being put and (v) will be free and clear of all Liens.

 

Section 2.8 Financial Statements; Related Information .

 

(a)        A correct and complete copy of the Audited Financial Statements, together with the related auditor’s reports thereon, and Interim Balance Sheet (collectively, the “ Financial Statements ”) are, or will be at the time of Closing (with respect to the Audited Financial Statements) attached to Section 2.8(a) of the Company Disclosure Schedule. The Financial Statements were prepared in accordance with GAAP applied on a consistent basis throughout all periods involved, are accurate and complete and present fairly, the financial position and the results of operations and cash flows of the Company, in each case as of the dates and for the periods referred to therein, subject, in the case of the Interim Balance Sheet, to (i) normally recurring year-end adjustments in accordance with the Company’s ordinary course of business consistent with past practices which are not material either individually or in the aggregate and (ii) the absence of footnote disclosures.

 

  14  

 

 

(b)        The Company has not entered into any off balance sheet financial arrangement, including any transaction involving a hedge or derivative financial instrument.

 

(c)        The net property and equipment balance reflected in the Audited Financial Statements and Interim Balance Sheet represents the sum of all personal property and assets that are owned by the Company and not fully depreciated, and any depreciation with respect to such assets has been made in accordance with GAAP as historically applied by the Company on a consistent basis.

 

(d)        The Company maintains a system of internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) revenue is recognized in accordance with GAAP; and (iii) access to assets is permitted only in accordance with management’s general or specific authorization.

 

Section 2.9 Absence of Certain Changes . Except as disclosed in Section 2.9 of the Company Disclosure Schedule, since December 31, 2015, the Company has conducted its business in the ordinary course consistent with past practice, including making all payments and discharging all commitments and, except as disclosed in Section 2.9 of the Company Disclosure Schedule, there has not been:

 

(a)        any event, occurrence, development of a state of circumstances or facts, or change in the business, properties, assets, prospects, operations or condition (financial or otherwise) of the Company which, individually or in the aggregate, has had or could reasonably be expected to have a Material Adverse Effect and no such event, occurrence, development or change is threatened;

 

(b)        (i) any declaration, setting aside or payment of any dividend or other distribution with respect to any shares of capital stock of the Company, or (ii) any sale of issuance of, or any repurchase, redemption or other acquisition by the Company of, any outstanding shares of capital stock or other securities of, or other ownership interests in, the Company;

 

(c)        (i) any acquisition by the Company of stock or other equity interests, from any Person, (ii) any acquisition of assets of another Person incident to the acquisition of a business, (iii) any sale, lease, license or other disposition of assets or property of the Company or (iv) any other acquisition by the Company of assets of another Person;

 

(d)        any amendment of any term of any outstanding security of the Company;

 

(e)        any incurrence, assumption or guarantee by the Company of any Indebtedness or any creation or assumption by the Company of any Lien on any asset;

 

 

 

 

  15  

 

(f)        any extension of a loan, advance or capital contribution to or investment in any Person by the Company;

 

(g)        any condemnation, seizure, damage, destruction or other casualty loss (whether or not covered by insurance) affecting the assets, properties, business, prospects, operations or condition (financial or otherwise) of the Company and, to the Company’s Knowledge, no such loss is threatened;

 

(h)        any material transaction or commitment made, or any material contract or agreement entered into, amended or terminated by the Company or any waiver or relinquishment by the Company of any contract or other right, other than in the ordinary course of business consistent with past practices;

 

(i)        any change in any method of accounting or accounting practice by the Company;

 

(j)        any capital expenditure, or commitment for a capital expenditure, for additions or improvements to property, plant and equipment by the Company that, individually or in the aggregate, involve payments in excess of $15,000;

 

(k)        except for capital expenditures and commitments referred to in paragraph (j) above, any acquisition or disposition by the Company of any assets or property (real, personal or mixed, tangible or intangible) in one or more transactions, or any commitment by the Company in respect thereof, that, individually or in the aggregate, involved or involve payments of $15,000 or more;

 

(l)        any write-down or write-off of accounts receivable of the Company or any cancellation of any debts or waiver of any Claims or rights, in each case, other than in the ordinary course of business consistent with past practices;

 

(m)        any incurrence by the Company of any material liability or obligation of any nature (whether accrued, absolute, contingent or otherwise);

 

(n)        any disposal by the Company or lapse of any rights to the use of any Intellectual Property Rights, or disposal of or disclosure to any Person by the Company other than representatives of Purchaser of any trade secret, formula, process, know-how or other Intellectual Property Rights not theretofore a matter of public knowledge;

 

(o)        any write-down by the Company of the value of any inventory (including write-downs by reason of shrinkage or mark-down) or write-off by the Company as uncollectible of any notes or accounts receivable, except for immaterial write-downs and write-offs in the ordinary course of business and consistent with past practice all of which are reflected in the Interim Balance Sheet;

 

(p)        any payment, discharge or satisfaction of any claim, liability or obligation by the Company (whether absolute, accrued, contingent or otherwise) other than the payment, discharge or satisfaction in the ordinary course of business and consistent with past practice of liabilities and obligations reflected or reserved against in the Balance Sheet or incurred in the ordinary course of business and consistent with past practice since the Interim Balance Sheet Date; or

 

 

 

  16  

 

 

(q)        any agreement by the Company, whether in writing or otherwise, to take any action described in this Section 2.9.

 

Section 2.10 Related Party Transactions . Except as set forth in Section 2.10 of the Company Disclosure Schedule, (a) no Shareholder, (b) no officer, director or Affiliate of the Company, and (c) no immediate family member of any Person identified in (a) or (b) above (collectively, the “ Related Parties ”) and no former director or current employee: (i) owns, directly or indirectly, any interest in (excepting not more than 5% stock holdings for investment purposes in securities of publicly held and traded companies), or is an officer, director, employee or consultant of, any Person which is, or is engaged in business as, a competitor, lessor, lessee, customer, distributor, sales agent, or supplier of the Company; (ii) owns, directly or indirectly, in whole or in part, any tangible or intangible property that the Company uses or the use of which is reasonably necessary or desirable for the conduct of the business of the Company; (iii) owes any amount to the Company; or (iv) on behalf of the Company, has made any payment or commitment to pay any commission, fee or other amount to, or purchase or obtain or otherwise contract to purchase or obtain any goods or services from, any Person of which any officer or director of the Company, or an immediate family member of the foregoing, is a partner or shareholder (excepting stock holdings solely for investment purposes in securities of publicly held and traded companies). Section 2.10 of the Company Disclosure Schedule contains a correct and complete description of all transactions, contracts, agreements and understandings (oral or written) between the Company and any Related Party (collectively, the “ Related Party Agreements ”).

 

Section 2.11 Material Contracts .

 

(a)        Except as disclosed in the corresponding subsection of Section 2.11(a) of the Company Disclosure Schedule, the Company is not a party to or bound by any of the following (whether oral or written) (each a “ Material Contract ”):

 

(i)        any (A) lease, sublease, license or other agreement under which the Company uses or has the right or obligation to use or pay rent or other fees for use thereof, now or in the future, any real property (“ Real Property Leases ”) or (B) lease for personal property;

 

(ii)        any partnership, joint venture or limited liability company agreement;

 

(iii)        other than the Transaction Documents, any agreement relating to the (A) acquisition or disposition of any business (whether by sale of stock, sale of assets or otherwise) or (B) acquisition or disposition of assets outside the ordinary course of business;

 

(iv)        any agreement relating to Indebtedness of the Company or Indebtedness of any other Person to the Company;

 

(v)        any agreement that restricts the freedom of the Company to compete in any line of business, in any market or customer segment or with any Person;

 

(vi)        any contract or other agreement with any current or former officer, director, employee, consultant, agent or other representative or any agreement or understanding pursuant to which the Company may be liable for any severance or termination pay or obligations;

 

 

 

 

  17  

 

(vii)        any contracts or other agreements for the sale of any of its assets or properties other than in the ordinary course of business or the grant to any Person of any preferential rights to purchase any of the assets or properties of the Company;

 

(viii)        any outstanding contracts or agreements with any Government Agency;

 

(ix)        any agreement for the purchase of more than $10,000 of materials, software, supplies, goods, services, equipment or other assets, whether individually or in the aggregate;

 

(x)        any agreement (A) providing for the sale by the Company of materials, supplies, goods, services, equipment and involving more than $10,000, or (B) which will result in any loss to the Company upon completion of performance thereof, or any outstanding bids or proposals that will not result in a normal profit;

 

(xi)        any option to license, license (including software licenses, other than licenses for Off-the-Shelf Software with aggregate license fees of under $5,000) or franchise agreement;

 

(xii)        any commission, agency, dealer, sales representative or marketing agreement;

 

(xiii)        any agreement containing any right of first refusal or right of first negotiation;

 

(xiv)        any agreement pursuant to which the Company is subject to confidentiality or non-disclosure obligations;

 

(xv)        any agreement under which the Company agrees to indemnify any party other than in the ordinary course of business, or in which the Company agrees to indemnify any Person for consequential or incidental damages or lost profits;

 

(xvi)        any contract or agreement to provide goods or services to any Person on a preferential or most-favored basis;

 

(xvii)        any agreement which encumbers any Company Intellectual Property Rights other than agreements listed in (xi) above;

 

(xviii)        any outstanding proposal related to the Company’s business;

 

 

 

  18  

 

 

(xix)        any other agreement or series of related agreements, which, individually or in the aggregate, is material to the Company; and

 

(xx)        the Consortium Agreements.

 

(b)        True and complete copies of all Material Contracts, in each case as amended to date, have been made available to Purchaser on the Company Data Site. Each Material Contract constitutes a valid and binding obligation of the Company and is in full force and effect in all material respects. Each Material Contract is enforceable against the Company, as applicable, and, to the Company’s Knowledge, the other parties thereto in accordance with its terms, subject to general equitable principles (regardless of whether such enforceability is considered in a proceeding at equity or at Law), and except as enforceability thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws of general application relating to creditors’ rights. The Company is not in default under or breach of any Material Contract, and no event or circumstance has occurred that, with notice or lapse of time or both, would (i) constitute any default or breach thereunder by the Company or, to the Company’s Knowledge, any other party to such Material Contract, (ii) impair or alter the rights of the Company or, to the Company’s Knowledge, any third party, (iii) give rise to a right of termination, cancellation, amendment or acceleration against the Company or (iv) result in the creation or imposition of any Lien on any assets or properties of the Company.

 

(c)        Neither the Company, nor, to the Company’s Knowledge, any other Person intends to terminate (whether for cause or convenience) or default under any Material Contract before the expiration of its stated term, if any, and, to the Company’s Knowledge, no Person intends not to renew such contract, if renewable by its terms. Except as set forth in Section 2.11(c) of the Company Disclosure Schedule, no Claim for non-performance of any Material Contract is pending or, to the Company’s Knowledge, threatened. There are no pending renegotiations of, attempts to renegotiate or outstanding rights to renegotiate any material amounts paid or payable under any Material Contract, and no Person has requested any such renegotiation. Except as separately identified in Section 2.5 of the Company Disclosure Schedule, no approval or consent of any Person is needed in order that the Material Contracts continue in full force and effect following the consummation of the Transactions.

 

Section 2.12 No Undisclosed Liabilities . There are no liabilities of the Company of the kind required to be disclosed on the face of a balance sheet in accordance with GAAP (whether accrued or unaccrued, actual or contingent, matured or unmatured, conditional or absolute, determined, determinable, unliquidated or otherwise), and there are no existing conditions, situations or circumstances which, individually or in the aggregate, reasonably could be expected to result in such a liability or obligation, other than: (a) liabilities or obligations to the extent disclosed or provided for in the Interim Balance Sheet; (b) liabilities (other than an Indebtedness) that have arisen after the Interim Balance Sheet Date in the ordinary course of business; and (c) liabilities disclosed in Section 2.12 of the Company Disclosure Schedule.

 

 

 

  19  

 

 

Section 2.13 Litigation . There is no action, suit, investigation or proceeding pending against or, to the Company’s Knowledge, threatened against or affecting the Company or any of its officers or directors in such capacity before any court or arbitrator or any governmental body, agency or official nor is there any valid basis for any such action, suit, investigation or proceeding. The Company is not subject to any judgment, order or decree. The Company has not instituted or had instituted on its behalf any legal proceeding against any other Person.

 

Section 2.14 Compliance with Laws and Court Orders . The Company is in material compliance with all applicable Laws, Orders or other requirements of each Governmental Authority applicable to its business, properties, assets and operations (including those Laws relating to wages and hours, classification of employees, record keeping, customs, export and sanctions compliance, possession of classified information or zoning). The Company has not been given written notice of any alleged violation or non-compliance of any such Law, Order or requirement. The Company is not and has not been under investigation with respect to, and has not been given notice of any violation of any applicable Law, order or requirement or, to the Company’s Knowledge, threatened to be charged with any such violation of any applicable Law, order or requirement.

 

Section 2.15 Licenses and Permits . The Company has all Governmental Authorizations, license, franchise, permit, Order, registration, certificate, approval or other similar authorization issued to the Company affecting, or relating in any way to, the assets or business of the Company (collectively, the “ Permits ”) necessary to carry on its business as now conducted. Section 2.15 of the Company Disclosure Schedule correctly sets forth a list of each Permit, and each pending application for any Permit, together with the name of the Government Agency or entity issuing such Permit or with which such application is pending. Except as set forth in Section 2.15 of the Company Disclosure Schedule, (a) the Permits are valid and in full force and effect, (b) the Company has not been in violation of or default under, and no condition exists that with notice or lapse of time or both would constitute a violation of or default under, the Permits, (c) no proceeding is pending or, to the Shareholders’ Knowledge, threatened, to revoke or limit any Permit and (d) none of the Permits will be terminated or impaired or become terminable, in whole or in part, as a result of the Contemplated Transactions. The Company is in compliance in all material respects with the terms of such Permits.

 

Section 2.16 Governmental Contracts . The Company (i) is not a party to, nor is the Company or any of its assets bound or affected by, any Government Contract, and (ii) has not submitted any Government Contract Proposal.

 

Section 2.17 Proprietary Rights .

 

(a)        Company IP Rights . Section 2.17(a) of the Company Disclosure Schedule sets forth a list of the all Intellectual Property Rights that are used in or necessary to the operation of the Company or its business (the “ Company IP Rights ”), including without limitation all: (i) patents and patent applications, along with, for any and all of the foregoing, any and all inventions described in the patents or patent applications, in the United States, its territorial possessions and all foreign countries, and in any and all continuations-in-part, continuations, divisions, substitutes, reissues, extensions thereof, together with all Claims for damages or injunctive relief by reason of infringements of any patents issuing from such patent applications, with the right to sue for past infringement and collect for same; (ii) trademarks and applications therefor; (iii) copyrights and applications therefor; (iv) Internet domain names, (v) Licensed Intellectual Property, excluding Off-the-Shelf Software having aggregate perpetual license fees of under $5,000; (vi) trade secrets and know-how; and (vii) software (in both object code and source code form), specifications, drawings, and other technical documentation related to the Company business.

 

 

 

  20  

 

 

(b)        Ownership . Subject to Section 2.17(b) of the Company Disclosure Schedule, the Company is the sole and exclusive owner of the right, title and interest in and to all Company IP Rights (with the exception of the Licensed Intellectual Property) (the “ Owned Intellectual Property ”). All patents, registrations and applications for Owned Intellectual Property (i) are valid, subsisting and in proper form, and have been duly maintained, including the timely submission of all necessary filings, fees and Taxes in accordance with the legal and administrative requirements of the appropriate jurisdictions and (ii) have not lapsed, expired or been abandoned, and no patent, registration or application therefor is the subject of any opposition, interference, cancellation proceeding or other legal or governmental proceeding before any Governmental Authority in any jurisdiction.

 

(c)        Licenses to Company . The Licensed Intellectual Property is licensed pursuant to valid and binding agreements that are enforceable by the Company in accordance with their terms and, other than as set forth in Section 2.17(c) of the Company Disclosure Schedule, in connection with the Contemplated Transactions, are not deemed to be assigned or otherwise are freely assignable under such agreements without consent or approval of any third party. The Company, and, to the Company’s Knowledge, any other party to any such agreement is not in default or breach in any material respect under the terms of any such agreements and no event or circumstance has occurred that, with notice or lapse of time or both, would constitute a material breach or default thereunder. The computer software used by the Company in the conduct of its business was either (i) developed by employees of the Company within the scope of their employment, (ii) developed on behalf of the Company by a third party, and in each case all ownership rights therein have been assigned or otherwise transferred to or vested in the Company pursuant to written agreements, (iii) licensed or acquired from a third party pursuant to a written license, assignment, or other contract that is in full force and effect and of which the Company is not in material breach or (iv) open source software.

 

(d)        Licenses from Company to Third Parties . Except as set forth in Section 2.17(d) of the Company Disclosure Schedule, the Company has not has granted any licenses to another Person with respect to the Owned Intellectual Property. The Company has not granted any Person an exclusive license under any Owned Intellectual Property. Except as set forth in Section 2.17(d) of the Company Disclosure Schedule, the Company has not entered into any consent, indemnification, forbearance to sue, settlement agreement or cross-licensing arrangement with any Person relating to any Intellectual Property Rights.

 

(e)        Government Rights . Except as disclosed in Section 2.17(e) of the Company Disclosure Schedule, the Company has not provided to the U.S. Government any ownership rights in the Owned Intellectual Property. Except as disclosed in Section 2.17(e) of the Company Disclosure Schedule, the Company has not provided to the U.S. Government greater intellectual property rights to use third-party materials than have been granted to the Company.

 

 

 

  21  

 

 

(f)        Adverse Effect . The Contemplated Transactions will not result in any termination, loss or impairment of any Company IP Right nor require payment by the Company of any fee to owners of any Licensed Intellectual Property.

 

(g)        Encumbrances . The Company has not assigned, hypothecated or otherwise encumbered title in and to any of the Owned Intellectual Property and other than as disclosed on Section 2.17(g) of the Company Disclosure Schedule, is not obligated to pay any further sums to another Person for the use of the Licensed Intellectual Property or Owned Intellectual Property equal to or greater than $10,000 in the aggregate. The Company has no agreement or obligation to pay any employee or consultant any sums for the use by the Company of any Intellectual Property Rights. The Owned Intellectual Property was written and created solely by either (i) current and former employees of the Company acting within the scope of their employment who have validly and irrevocably assigned all of their rights, including all Intellectual Property Rights therein, to the Company pursuant to the agreements set forth in Section 2.17(g) of the Company Disclosure Schedule or (ii) by third parties who have validly and irrevocably assigned all of their rights in and to the Owned Intellectual Property, including all Intellectual Property rights therein, to the Company.

 

(h)        Infringement . Except as disclosed in Section 2.17(h)(1) of the Company Disclosure Schedule, (i) to the Company’s Knowledge, there are no infringements by any other party of any of the Owned Intellectual Property, (ii) there are no pending or, to the Company’s Knowledge, threatened Claims against any Person, who would be entitled to indemnification by the Company for such Claims, that the Owned Intellectual Property infringes any other Person’s Intellectual Property, (iii) making, using or selling the Company’s products and/or services, as currently designed, does not infringe any third party’s Intellectual Property Rights in existence as of the Closing and (iv) except as disclosed in Section 2.17(h) of the Company Disclosure Schedule, there are no facts, conditions, situations or set of circumstances that would reasonably be expected to result in or be the basis for any such liability in the future. Except as disclosed in Section 2.17(h)(2) of the Company Disclosure Schedule, the Company has not entered into any agreement to indemnify any Person against any charge of infringement of any of the Company’s Intellectual Property, and neither the Company nor to the Company’s Knowledge, such other Person has received any written communication alleging that the Company or such Other Person, by making, using or selling the Company’s Intellectual Property, has violated or infringed the Intellectual Property of any other Person. The Company has not been sued at any time for infringing any Intellectual Property of another Person.

 

(i)        Know-How . Except as disclosed in Section 2.17(i) of the Company Disclosure Schedule, there have been no disclosures by the Company or any of their Affiliates, to any other Person, other than disclosures to Government Agencies or Persons who are bound to hold such information in confidence pursuant to confidentiality agreements or otherwise by operation of Law, of any algorithm, process, technique, formula, research and development results, financial results, price or cost data or other know-how relating to the business of the Company, the unauthorized public disclosure or use of which could have individually or, in the aggregate, a Material Adverse Effect on the Company. Except as disclosed in Section 2.17(i) of the Company Disclosure Schedule, to the Company’s Knowledge, no employee or former employee has used any algorithm, process, technique, formula, research and development results, financial results, price or cost data or other know-how constituting Intellectual Property of the Company for any purpose other than for the benefit of the Company.

 

 

 

  22  

 

 

(j)        Open Source Software . The Intellectual Property Rights used by the Company do not include any open source software.

 

Section 2.18 Taxes .

 

(a)        Except as otherwise set forth on Section 2.18(a) of the Company Disclosure Schedule: (i) the Company has timely filed (taking into account any properly granted extensions of time to file) all Tax Returns with the appropriate taxing authorities required to have been filed, and each such Tax Return is correct and complete in all material respects; (ii) all material Taxes due and owed by the Company, whether or not shown on any Tax Return, have been timely paid; (iii)  the Company and its officers, directors or employees responsible for Tax matters have complied with all rules and regulations relating to the withholding of Taxes and the remittance of withheld Taxes in connection with any amounts paid or owing to any employee, independent contractor, creditor, shareholder or other third party; (iv) the Company has not waived any statute of limitations in respect of its Taxes or agreed to any extension of time with respect to a Tax assessment of deficiency, which waiver or extension is currently in effect; (v) no withholding is required under Section 1445 of the Code, in connection with the consummation of the Contemplated Transactions; (vi) the Company has not engaged in any transaction that would constitute a “reportable transaction,” a transaction substantially similar to a “reportable transaction,” or a “tax shelter” within the meaning of Sections 6011, 6111, 6662 or 6707A of the Code and the Treasury Regulations thereunder, and that has not been disclosed on an applicable Tax Return; (vii) the Company has no outstanding ruling requests to the Internal Revenue Service or a state tax authority; (viii) the Company has at no time made, changed or rescinded any express or deemed material election relating to Taxes that is not reflected in any Tax Return; (ix) the Company will not be required to include any item of income in, or exclude any item of deduction from any Tax period ending after the Closing Date as a result of any (a) change in method of accounting for a taxable period (or portion thereof) ending on or prior to the Closing Date (including installment sale or open transaction), (b) ”closing agreement” as described in Section 7121 of the Code or similar state or local Tax Law, or (c) material prepaid amount received on or prior to the Closing Date; (x) the Company has not been a member of an Affiliate group of corporations within the meaning of Section 1504(a) of the Code that has filed or at any time was required to file a consolidated federal income tax return for any taxable period, and the Company has not been a member of an Affiliate group of corporations that has filed or at any time was required to file a consolidated, combined or unitary income tax return under provisions of state, local or foreign tax Law comparable to Section 1504(a) of the Code for any taxable period; (xi) the Company has no obligation under any agreement or arrangement with any other Person with respect to which it has agreed to accept liability for Taxes of such other Person (including pursuant to Treasury Regulations Section 1.1502-6 or comparable provision of state, local or foreign tax Law), including any liability for Taxes as a transferee or successor, by contract or otherwise; (xii) the unpaid Taxes of the Company do not exceed the reserve for Tax liability (excluding any reserve for deferred Taxes established to reflect temporary difference between book and Tax income) set forth or included in the Interim Balance Sheet; (xiii) no payments by the Company to employees required under or contemplated by this Agreement will be non-deductible under Sections 162(a), 162(m) or 280(G) or other similar provisions of the Code concerning non-deductibility of expenses; (xiv) the Company is not the beneficiary of any extension of time within which to file any Tax Returns; (xv) there are no liens for Taxes (other than Taxes not yet due and payable) upon any of the assets of the Company; (xvi) the Company has not received any written notice from any Tax authority that such Tax authority currently plans to assess any additional Taxes for any period for which Tax Returns have been filed; (xvii) no Tax audits or administrative or judicial Tax proceedings are pending or being conducted with respect to the Company; (xviii) the Company has not received from any taxing authority (including jurisdictions in which the Company has not filed Tax Returns) any currently unresolved (A) written notice indicating an intent to open an audit or other review, (B) written request for information related to Tax matters or (C) written notice of deficiency or proposed adjustment for any amount of Tax, proposed, asserted or assessed by any taxing authority against the Company; (xix) the Company has not distributed stock of another Person or had its stock distributed by another Person in a transaction that was purported or intended to be governed in whole or in party by Sections 354, 355 or 361 of the Code; (xx) at no time has a nonresident alien (as defined in Section 7701(b)(1)(B) of the Code) been a shareholder of the Company; (xxi) no liability can be imposed on the Company under Section 4979A of the Code; and (xxii) the Company has not been requested to or participated in an “International Boycott” within the meaning of Section 999 of the Code.

 

 

 

  23  

 

 

(b)        Tax Returns . The Company has made available to Purchaser on the Company Data Site (i) complete copies of all Tax Returns of the Company requested by Purchaser, and of all examination reports and statements of deficiencies assessed against or agreed to by the Company for all taxable periods for which the applicable statute of limitations has not yet expired, and (ii) complete copies of all private letter rulings, revenue agent reports, information documents requests, notices of proposed deficiencies, deficiency notices, protests, petitions, closing agreements, settlement agreements, pending ruling requests, and any similar documents, submitted by, received by, agreed to by or on behalf of or otherwise relating to the Company with respect to a taxable period for which the statute of limitations has not yet expired. Section 2.18(b) of the Company Disclosure Schedule lists each state, local, county, municipal or foreign jurisdiction in which the Company files or is or has been determined by any Governmental Agency to be required to file a Tax Return or is or has been determined by any Governmental Agency to be liable for any Tax on a “nexus” basis at any time for a taxable period for which the statute of limitations has not expired.

 

(c)        Partnerships . The Company does not own and has not owned an interest in any Person treated as a partnership for Tax purposes.

 

Section 2.19 Real Property . The Company has never owned any real property or interest therein. Section 2.11(a)(i) of the Company Disclosure Schedule sets forth a true and complete list of all Real Property Leases and other than the property under the Real Property Leases, the Company has never leased any other real property or interest therein. No third-party claim has been made against the Company or against the landlord under any Real Property Lease based on an event or circumstance occurring on the leased real property or relating to use and occupancy by the Company of the leased real property.

 

 

 

 

  24  

 

Section 2.20 Environmental Matters .

 

(a)        Except as identified in Section 2.20(a) of the Company Disclosure Schedule:

 

(i)        no notice, notification, demand, request for information, citation, summons or order has been received, no penalty has been assessed, and no investigation, action, Claim or review (or any basis therefor) is pending or, to the Company’s Knowledge, is threatened by any Governmental Authority or other Person with respect to any matters relating to the Company or any Person for which the Company has retained or assumed liability either contractually or by operation of Law, and relating to or arising out of any Environmental Law;

 

(ii)        no complaint has been filed with respect to any matters relating to the Company and relating to or arising out of any Environmental Law;

 

(iii)        there are no liabilities of or relating to the Company, of any kind whatsoever whether accrued, contingent, absolute, determined or otherwise, arising under or relating to any Environmental Law, and to the Company’s Knowledge there are no facts, conditions, situations or set of circumstances that would reasonably be expected to result in or be the basis for any such liability;

 

(iv)        the Company is and has been in compliance with all Environmental Laws in all material respects, and has obtained and is in compliance with all Environmental Permits in all material respects; and

 

(v)        the Company has never performed or subcontracted for the performance of, at its own facilities or otherwise, any activity involving the disturbance, abatement, repair or removal of any Material of Environmental Concern.

 

(b)        The Company has not used or disposed of any Materials of Environmental Concern.

 

(c)        The Company is not subject to any Environmental Laws requiring (i) the performance of site assessment by the Company for Materials of Environmental Concern, (ii) the removal or remediation by the Company of Materials of Environmental Concern, (iii) the giving of notice to, or receiving the approval of, any Governmental Authority by the Company, or (iv) the recording or delivery by the Company to any other Person of any disclosure document or statement pertaining to matters of environmental concern by virtue of the Transactions or as a condition to the effectiveness of any of the Transactions.

 

(d)        There has been no environmental investigation, study, audit, test, review or other analysis conducted in relation to the current or prior business of the Company or any property or facility now or previously owned, leased or operated by the Company which has not been made available to Purchaser on the Company Data Site at least fifteen (15) days prior to the date of this Agreement.

 

 

 

 

  25  

 

For purposes of this Section 2.20, the following terms shall have the meanings set forth below:

 

Company ” shall include the Company and any entity which is, in whole or in part, a predecessor of the Company.

 

Environmental Laws ” means any Law (including common law), treaty, judicial decision, regulation, rule, judgment, order, decree, injunction, permit or governmental restriction or requirement or any agreement or contract with any Governmental Authority or other third party, whether now or hereinafter in effect, relating to human health and safety, the environment or to pollutants, contaminants, wastes or chemicals or any toxic, radioactive, ignitable, corrosive, reactive or otherwise hazardous substances, wastes or materials.

 

Environmental Permits ” means all permits, licenses, franchises, certificates, approvals and other similar authorizations of Governmental Authorities relating to or required by Environmental Laws and affecting the business of the Company as currently conducted.

 

Materials of Environmental Concern ” shall mean chemicals, pollutants, contaminants, toxic or hazardous substances, petroleum and petroleum products, asbestos and asbestos-containing materials, polychlorinated biphenyls, lead and lead-based paints and materials, and radon.

 

Section 2.21 Insurance Coverage . Section 2.21 of the Company Disclosure Schedule sets forth (a) a true and complete list and description of all insurance policies, fidelity bonds and other insurance arrangements and other contracts or arrangements for the transfer or sharing of insurance risks by the Company with respect to the business, assets, properties, operations, employees, officers or directors of the Company (the “ Company Policies ”), together with a statement of the aggregate amount of Claims paid out, and Claims pending, under each such insurance policy or other arrangement through the date hereof, (b) the dates from which such policies or other arrangements have been in effect, and (c) a description of such risks that the Company has designated as being self-insured. True and complete copies of all such Company Policies have been made available to Purchaser on the Company Data Site. The Company has policies of insurance of the type and, to the Company’s Knowledge, in amounts customarily carried by Persons conducting businesses or owning assets similar to those of the Company. All such Company Policies are in full force and effect, all premiums due thereon have been timely paid, and the Company is otherwise in compliance in all material respects with the terms and provisions of such policies and arrangements. Furthermore, (i) the Company has not received any notice of cancellation or non-renewal of any such policy or arrangement, nor is the termination of any Company Policy or arrangements threatened, (ii) there is no claim pending under any of such policies or arrangements as to which coverage has been questioned, denied or disputed by the underwriters of such policies or arrangements or in respect of which the underwriters have reserved their rights, (iii) the Company has not received any notice or indication from any of its insurance carriers that any insurance premiums will be increased in the future or that any insurance coverage presently provided for will not be available to the Company in the future on substantially the same terms as now in effect and (iv) none of such Company Policies provide for any retrospective premium adjustment, experienced-based liability or loss sharing arrangement affecting the Company.

 

 

 

 

  26  

 

Section 2.22 Employee Benefit Plans .

 

(a)        Section 2.22(a) of the Company Disclosure Schedule contains a correct and complete list identifying (i) each “employee benefit plan”, as defined in Section 3(3) of the Employee Retirement Income Security Act of 1974 (“ ERISA ”), and (ii) each employment, severance or similar contract, plan, arrangement or policy and each other plan, agreement or arrangement (written or oral) providing for compensation, bonuses, profit-sharing, stock option or other stock-related rights or other forms of incentive or deferred compensation, vacation benefits, insurance coverage (including any self-insured arrangements), health or medical benefits, disability benefits, workers’ compensation, supplemental unemployment benefits, severance benefits and post-employment or retirement benefits (including compensation, pension, health, medical or life insurance benefits) which is maintained, administered, contributed to or required to be contributed to by the Company or any ERISA Affiliate and covers any employee or former employee of the Company, or with respect to which the Company or any ERISA Affiliate has any liability, whether direct or indirect, actual or contingent, and whether formal or informal (collectively, the “ Employee Plans ”). Copies of each such plan (and, if applicable, any related trust agreement and all amendments to such requested plans), together with the most recent annual report (Form 5500 including, if applicable, Schedule B thereto) prepared in connection with any such plan, have been furnished to Purchaser. For purposes of this Section 2.22, “ ERISA Affiliate ” of any Person means any other Person that, together with such Person, would be treated as a single employer under Section 414 of the Code or Section 4001 of ERISA.

 

(b)        Neither the Company nor any ERISA Affiliate maintains, or has ever maintained, any Employee Plan that (i) constitutes or constituted a “multiemployer plan,” as defined in Section 3(37) of ERISA, (ii) is or was subject to Title IV of ERISA, (iii) is or was intended to be qualified under Section 401(a) of the Code or any trust forming a part thereof; (iv) is or was a “nonqualified deferred compensation plan” (within the meaning of Section 409A of the Code). Neither the Company nor any ERISA Affiliate is a party to, or otherwise obligated under, any contract, agreement, plan or arrangement that provides for the gross-up of interest and/or taxes imposed by Section 409A(a)(1)(B) of the Code.

 

(c)        Each Employee Plan has been maintained in compliance with its terms and with the requirements prescribed by any and all statutes, orders, rules and regulations, including ERISA and the Code, which are applicable to such Employee Plan, including timely adoption of all amendments required to maintain each such Employee Plan’s compliance with applicable Law. All contributions and payments accrued under each Employee Plan have been discharged and paid on or prior to the Closing Date, other than with respect to any accrued during the payroll period which includes the Closing Date.

 

 

 

 

  27  

 

(d)        Except as set forth in Section 2.22(d) of the Company Disclosure Schedule, neither the execution of this Agreement or any other Transaction Documents, nor the consummation of the Contemplated Transactions will (i) entitle any employee or independent contractor of the Company to severance pay or any increase in severance pay upon any termination of employment after the date of this Agreement or (ii) accelerate the time of payment or vesting or result in any payment or funding (through a grantor trust or otherwise) of compensation or benefits under, increase the amount payable, or result in any other material obligation pursuant to, any Employee Plan. The Company does not have any liability with respect to post employment or retiree health, medical or life insurance benefits for retired, former or current employees of the Company.

 

(e)        There is no pending or, to the Company’s Knowledge, threatened or contingent Claim against the Company relating to any Employee Plans. No Employee Plan or fiduciary thereof is under review or investigation by any Government Agency or Governmental Authority. No fiduciary of any Employee Plan has breached any fiduciary duty it owes to such Employee Plan or any of its participants.

 

Section 2.23 Employees .

 

(a)        Set forth in Section 2.23 of the Company Disclosure Schedule is a true and complete list as of the date of this Agreement of (i) the names and titles of all employees, directors and officers of the Company and (ii) the names of all independent contractors or consultants. Except as set forth in Section 2.23 of the Company Disclosure Schedule, the Company has not entered into an employment agreement, oral or written, with any Person and all employees are “at will” and will not be owed any severance, termination or other special payments or benefits upon termination of employment. Set forth in Section 2.23 of the Company Disclosure Schedule is a list of the names of Persons with whom the Company has entered into a separation agreement and general release or similar agreements within the last seven (7) years.

 

(b)        The Company has engaged CBIZ- Flex-Pay (“ Payroll Company ”) to facilitate employment tax administration and payroll processing. Notwithstanding the foregoing, all personnel of the Company processed through Payroll Company are employees of the Company, and all references in this Agreement to Company employees, and/or Persons employed by the Company, shall include personnel processed by Payroll Company on behalf of the Company.

 

Section 2.24 Labor Matters . The Company is in material compliance with all Laws respecting terms and conditions of employment and employment practices, equal employment opportunity, nondiscrimination, immigration, wages, hours, benefits, collective bargaining, the payment of social security and similar taxes, occupational safety and health and plant closing. Each Person employed by the Company who was or is classified by the Company as exempt from overtime requirements under applicable Law was and is properly classified as exempt, and no such Person has any Claim against the Company for wages or benefits relating to being classified as exempt under applicable Law. There exists no basis for the assessment of any unpaid wages with respect to any employees of the Company. All Persons treated as independent contractors or consultants by the Company are not employees under applicable Law, and no such Person has any Claim against the Company for wages or benefits relating to being classified as an independent contractor under applicable Law. There is no unfair labor practice complaint pending or, to the Company’s Knowledge, threatened against the Company before the National Labor Relations Board or any state or local authority or agency. The Company is not and has not been bound by or party to any collective bargaining agreement. There is no labor strike, slowdown, lockout or stoppage or union organization campaign, election or similar action pending or, to the Company’s Knowledge, threatened against or affecting the Company. The Company has not incurred any liability or obligation under the Worker Adjustment and Retraining Notification Act, as it may be amended from time to time, or similar applicable state Law. The Company has never employed any illegal aliens and has complied with all immigration laws. To the Company’s Knowledge, no employee of the Company has (a) breached any agreement to keep in confidence information acquired by that employee in confidence or in trust prior to that employee’s employment with the Company by disclosing such information to the Company, or (b) through his or her employment by the Company, breached any noncompetition, nonsolicitation or noninterference agreement or used trade secrets of any other Person. During the past three (3) years, no significant accidents or injuries have occurred in the workplace or in work-related activities involving the Company or any of its employees, officers, consultants, directors or contractors.

 

 

 

 

  28  

 

Section 2.25 Books and Records . The Company has maintained business records, including books of account, minute books and stock record books, with respect to the assets and its business and operations which are true, accurate and complete in all material respects, and there are no material deficiencies in such business records. True and complete copies of all minute books and all stock record books of the Company have heretofore been made available to Purchaser on the Company Data Site. None of the records, systems, controls, data or information which are material to the operation of the Company’s business are recorded, stored, maintained, operated or otherwise wholly or partly dependent upon or held by any means (including any electronic, mechanical or photographic process, whether or not computerized) which (including all means of access thereto and therefrom) are not under the exclusive ownership and direct Control of the Company.

 

Section 2.26 Customers; Suppliers . Since January 1, 2016, there has not been (a) any adverse change in the business relationship of the Company with any customer or supplier of the Company’s business or (b) any adverse change in any material term (including payment terms) of the customer or supplier agreements or related agreements with any such customer or supplier. To the Company’s Knowledge, no customer or supplier of the Company’s business intends to cease doing business with the Company or materially decrease the amount of business it does with the Company.

 

Section 2.27 Customer or Third-Party Approval . All work substantially completed by the Company prior to the Closing Date which will require either customer or third-party approval or acceptance but which has not yet received the required customer or third-party approval or acceptance will meet all material requirements and specifications of the applicable contract as modified through the Closing Date in all material respects.

 

 

 

 

  29  

 

Section 2.28 Absence of Unlawful Payments . The Company (including any of its officers, directors, agents, distributors, employees or other Person associated with or acting on its behalf) has not, directly or indirectly, taken any action which would cause it to be in violation of the Foreign Corrupt Practices Act of 1977, as amended, or any rules or regulations thereunder or any similar anti-corruption or anti-bribery Laws applicable to the Company in any jurisdiction other than the United States (in each case, as in effect at the time of such action) (collectively, the “ FCPA ”) or used any corporate funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity, made, offered or authorized any unlawful payment to foreign or domestic government officials or employees, whether directly or indirectly, or made, offered or authorized any unlawful bribe, rebate, payoff, influence payment, kickback or other similar unlawful payment, whether directly or indirectly, except for any of the foregoing which is no longer subject to potential claims of violation as a result of the expiration of the applicable statute of limitations. The Company has established reasonable internal controls and procedures intended to ensure compliance with the FCPA.

 

Section 2.29 International Trade . The Company has not unlawfully exported, disclosed, released or otherwise provided access to information, software, technical data or technical assistance that is Controlled for export under, and has at all times been in compliance with, the International Traffic in Arms Regulations (ITAR), Export Administration Regulations (EAR) and/or other applicable export or sanction Law.

 

Section 2.30 Service or Product Liability . There is no action or suit, proceeding, or to the Company’s Knowledge, inquiry or investigation, by or before any court or Governmental Authority pending or, to the Company’s Knowledge, threatened against or involving the Company relating to any services performed by the Company that are alleged to have been defective or improperly rendered or not in compliance with contractual requirements or relating to any products or software manufactured, sold, leased, licensed or delivered by the Company which are alleged to be defective or not in compliance with contractual requirements; nor, to the Company’s Knowledge, is there any basis for or any event or circumstances that might give rise to any such action, suit or proceeding, inquiry or investigation, Claim or notice. The Company has no liability (and to the Company’s Knowledge, there is no basis for any present or future action, suit, proceeding, inquiry, investigation, charge, complaint, Claim, notice or demand against it giving rise to any liability) arising out of injury to individuals or property as a result of the ownership, possession, or use of any services, products or software designed, manufactured, sold, leased, licensed or delivered by the Company.

 

Section 2.31 Finders’ Fees . No broker, finder, agent or similar intermediary has acted on behalf of the Company or the Shareholders in connection with this Agreement or the Contemplated Transactions, and there are no brokerage commissions, finders’ fees or similar fees or commissions payable by the Company in connection therewith based on any agreement, arrangement or understanding with the Company or the Shareholders.

 

Section 2.32 Bank Accounts and Powers of Attorney . Set forth in Section 2.32 of the Company Disclosure Schedule is an accurate and complete list showing (a) the name and address of each bank or other depository with which the Company has an account and/or safe deposit box, the number of any such account or any such box and the names of all Persons authorized to draw thereon or to have access thereto, and (b) the names of all Persons, if any, holding powers of attorney from the Company and a summary statement of the terms thereto.

 

 

 

 

  30  

 

Section 2.33 Consortium Agreement. True and complete copies of all Consortium Agreements, in each case as amended to date, have been made available to Purchaser on the Company Data Site. Each Consortium Agreement constitutes a valid and binding obligation of the Company and is in full force and effect in all material respects. Each Consortium Agreement is enforceable against the Company, as applicable, and, to the Company’s Knowledge, the other parties thereto in accordance with its terms, subject to general equitable principles (regardless of whether such enforceability is considered in a proceeding at equity or at Law), and except as enforceability thereof may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or other similar laws of general application relating to creditors’ rights. The Company is not in default under or breach of any Consortium Agreement, and no event or circumstance has occurred that, with notice or lapse of time or both, would (i) constitute any default or breach thereunder, (ii) impair or alter the rights of the Company or any third party, (iii) give rise to a right of termination, cancellation, amendment or acceleration, or (iv) result in the creation or imposition of any Lien on any assets or properties of the Company. Neither the Company, nor, to the Company’s Knowledge, any other Person intends to terminate (whether for cause or convenience) or default under any Consortium Agreement before the expiration of its stated term, if any, and, no Person intends not to renew such contract, if renewable by its terms. Except as set forth in Section 2.33 of the Company Disclosure Schedule, no Claim for non-performance of any Consortium Agreement is pending or, to the Company’s Knowledge, threatened. There are no pending renegotiations of, attempts to renegotiate or outstanding rights to renegotiate any material amounts paid or payable under any Consortium Agreement, and no Person has requested any such renegotiation. Except as separately identified in Section 2.5 of the Company Disclosure Schedule, no approval or consent of any Person is needed in order that the Consortium Agreements continue in full force and effect following the consummation of the Transactions.

 

Section 2.34 Full Disclosure . No representation, warranty or other statement of the Company or the Shareholders contained in this Agreement contains an untrue statement of material fact or omits to state a material fact necessary in order to make such representation, warranty or other statement, in light of the circumstances under which it was made, not misleading. Neither the Company nor any of the Shareholders has withheld from Purchaser any documents or other information in its possession that, taken as a whole with all other documents and information in the Company’s or the Shareholders’ possession, (i) would lead a reasonable Person in Purchaser’s position to conclude that any such representation, warranty or other statement is untrue in any material respect, or (ii) would be material to the decision of a reasonable Person in Purchaser’s position to execute this Agreement and consummate the Transaction. The Company or the Shareholders have made available on the Company Data Site true, correct and complete copies of the Certificate of Incorporation, Bylaws, and all other material organizational and constituent documents and minute books of the Company (including stock ledger) and all Material Contracts, Financial Statements, Tax Returns and insurance policies referred to in this Agreement.

 

 

 

  31  

 

 

ARTICLE IIA.
REPRESENTATIONS AND WARRANTIES OF
COMPANY SHAREHOLDERS

 

Each Shareholder, severally and not jointly, represents and warrants to Purchaser as of the date of this Agreement and as of the Closing Date as follows:

 

Section 2A.1   Valid Title . Such Shareholder is the sole, true, and lawful owner of the type and number of shares of Company Common Stock in the amount set forth in Section 2.3 of the Company Disclosure Schedule, free and clear of any and all Claims, Liens, and any other limitation or restriction (including any restriction on the right to vote, sell or otherwise dispose of such shares). Except as set forth on Section 2.3 of the Company Disclosure Schedule, such Shareholder owns no securities of the Company or options to purchase or rights to subscribe for or otherwise acquire any securities of the Company and has no other interest in or voting rights with respect to any securities of the Company. Except as set forth on Section 2.3 of the Company Disclosure Schedule, none of such Shareholder's shares of Company Common Stock is subject to any voting trust or other agreement or arrangement with respect to the voting of such stock.

 

Sectioin 2A.2   Authorization; Binding Effect . Such Shareholder has the legal capacity to enter into this Agreement and the Transaction Documents contemplated hereby to which such Shareholder is a party and to consummate the Contemplated Transactions and thereby. This Agreement, the Transaction Documents and each such document to which such Shareholder is or will be a party have been (and as to those yet to be executed, will be) duly executed and delivered by such Shareholder and, when duly authorized, executed and delivered all other parties thereto, will constitute a valid and binding agreement of such Shareholder enforceable against such Shareholder in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws affecting the enforcement of creditors’ rights generally and by general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at Law).

 

Section 2A.3   Governmental Authorization and Consents . No Governmental Authorization of, filing with, or notice to, any Governmental Authority or any lenders, lessors, creditors, stockholders or any other Person, is required by such Shareholder in connection with the execution, delivery and performance by such Shareholder of this Agreement and each of the documents, agreements, instruments and certificates to which such Shareholder is a party in connection with the Contemplated Transactions, and the consummation by such Shareholder of the transactions contemplated hereunder and thereunder.

 

Section 2A.4   Non-contravention . The execution and delivery of this Agreement, and each of the documents, agreements, instruments and certificates to which such Shareholder is a party, by such Shareholder, the performance by such Shareholder of his or her respective obligations hereunder and thereunder, and the consummation of the Contemplated Transactions, do not and will not (a) contravene or conflict with any applicable provision of any Law, regulation, rule, judgment, injunction, Order or decree binding upon or applicable to the Shareholder, or (b) contravene or constitute a default under any written agreement or obligation to which such Shareholder is a party by which any of his or her properties or assets are bound.

 

 

 

  32  

 

 

Article III
REPRESENTATIONS AND WARRANTIES OF PURCHASER

 

Purchaser represents and warrants to the Company and the Shareholders as of the date of this Agreement as follows:

 

Section 3.1 Corporate Existence and Power . Purchaser is a corporation duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation, and has all corporate powers and all material governmental licenses, authorizations, permits, consents and approvals required to carry on its business as now conducted and to own the properties and assets it now owns.

 

Section 3.2 Corporate Authorization; Binding Effect . Purchaser has all requisite corporate power and corporate authority required to enter into this Agreement and all documents, agreements, instruments and certificates contemplated hereby to which it is or will be a party and to consummate the Contemplated Transactions to be consummated by it. The execution and delivery of such documents to which each of Purchaser is or will be a party by Purchaser, and the consummation of the transactions to be consummated by Purchaser hereunder, have been duly authorized by all necessary corporate action on the part of Purchaser. This Agreement and the Transaction Documents to which each is a party have and/or will be duly executed and delivered by Purchaser, and, when duly authorized, executed and delivered all other parties thereto, such agreements will constitute a valid and binding agreement of such Purchaser enforceable against Purchaser in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and other similar laws affecting the enforcement of creditors’ rights generally and by general principles of equity (regardless of whether such enforceability is considered in a proceeding in equity or at Law).

 

Section 3.3 Governmental Authorization . No Governmental Authorization of, filing with, or notice to, any Governmental Authority or any other Person is required by Purchaser in connection with the execution, delivery and performance by Purchaser of this Agreement or any document to which it is a party in connection herewith and the consummation by Purchaser of the transactions contemplated hereunder to be consummated by it.

 

Section 3.4 Non-contravention . Except for the approval of the Board of Directors of Purchaser, which has not yet been obtained and which is not required to be obtained in order to make this Agreement a legally binding Agreement of Purchaser, the execution and delivery by Purchaser of this Agreement and the documents, instruments, agreements and certificates contemplated hereby to which it is or will be a party, the performance by Purchaser of its obligations hereunder and thereunder and the consummation of the Contemplated Transactions do not and will not (a) contravene or conflict with the Certificate (or Articles) of Incorporation or Bylaws of Purchaser, or (b) contravene or conflict with any applicable provision of any Law, regulation, rule, judgment, injunction, Order or decree binding upon or applicable to Purchaser in any material respect.

 

Section 3.5 Litigation . There is no action, suit, investigation or proceeding pending against or, to Purchaser’s Knowledge, threatened against or affecting Purchaser before any court or arbitrator or any governmental body, agency or official, which in any manner challenges or seeks to prevent, enjoin, alter or materially delay any of the Contemplated Transactions.

 

 

 

  33  

 

 

Article IV
CONDUCT OF BUSINESS

 

Section 4.1 Conduct of Business by the Company Pending the Transaction . The Company and the Shareholders covenant and agree that, during the period from the date of this Agreement and continuing until the earlier of the termination of this Agreement or the Closing Date, unless Purchaser shall otherwise agree in writing, the Company shall in all material respects conduct its business only in the ordinary course of business, and the Company shall use reasonable efforts to preserve substantially intact the business organization of the Company, to keep available the services of the present officers, employees and consultants of the Company and to preserve the present relationships of the Company with customers, suppliers and other Persons with which the Company has significant business relations, with the intent that such goodwill and ongoing business relationships shall be unimpaired at the Closing Date, provided , however that prior to Closing the Company shall, notwithstanding anything herein to the contrary, be permitted to distribute to the Shareholders any cash or cash equivalents of the Company, subject to the effects of Section 1.9 hereof. By way of amplification and not limitation, except as contemplated by this Agreement, the Company shall not, during the period from the date of this Agreement and continuing until the earlier of the termination of this Agreement or the Closing Date, directly or indirectly, undertake any of the following actions without the prior written consent of Purchaser, unless otherwise expressly provided for in this Agreement:

 

(a)        amend or otherwise change the Certificate of Incorporation or Bylaws of the Company;

 

(b)        issue, sell, pledge, dispose of or encumber, or authorize the issuance, sale, pledge, disposition or encumbrance of, any shares of capital stock of any class other than pursuant to the exercise of Stock Options outstanding on the date of this Agreement, or any options, warrants, convertible securities, exchangeable securities or other rights of any kind to acquire any shares of capital stock of any class, or any other ownership interest (including, without limitation, any phantom interest) in the Company, any of its Affiliates;

 

(c)        sell, pledge, dispose or encumber any assets of the Company (other than sales and dispositions in the ordinary course of business);

 

(d)        (i) split, combine or reclassify any of its capital stock or issue or authorize or propose the issuance of any other securities in respect of, in lieu of or in substitution for shares of its capital stock, or (ii) amend the terms or change the period of exercisability of, purchase, repurchase, redeem or otherwise acquire any of its securities, including, without limitation, shares of Common Stock or any option, warrant, convertible or exchangeable securities or other right, directly or indirectly, to acquire shares of Common Stock, or propose to do any of the foregoing, except for the termination of any arrangement providing for the issuance of shares thereunder;

 

 

 

  34  

 

 

(e)        (i) acquire (by consolidation, or acquisition of stock or assets) any material property or assets, make any investment in, or make any capital contributions to, any corporation, partnership or other business organization or division thereof, (ii) incur any Indebtedness, make any loans or advances, (iii) enter into, terminate or amend any Material Contract or agreement other than in the ordinary course, (iv) authorize any capital expenditures or purchases of fixed assets which are, in the aggregate, in excess of $15,000; or (v) enter into or amend any contract, agreement, commitment or arrangement to effect any of the matters prohibited by this Section 4.1(e);

 

(f)        (i) increase the compensation or fringe benefits payable or to become payable to its directors, officers or employees, other than increases consistent with past practices; provided such increases in the aggregate, shall not exceed four percent (4%), (ii) grant any severance or termination pay to, or enter into any severance agreement or other agreement providing for severance payments with, any director, officer or other employee of the Company, (iii) establish, adopt, enter into or amend any collective bargaining, bonus, profit sharing, thrift, compensation, stock option, restricted stock, pension, retirement, deferred compensation, employment, termination, severance or other plan, agreement, trust, fund, policy or arrangement for the benefit of any current or former directors, officers or employees, (iv) enter into any employment or consulting agreement, (v) except as otherwise expressly contemplated by this Agreement, accelerate the payment, right to payment or vesting of any bonus, severance, profit sharing, retirement, deferred compensation, stock option, insurance or other compensation or benefits, or (vi) enter into, amend, waive or terminate any agreement or arrangement with any director, officer, employee or consultant, which limits or restricts the director, officer, employee or consultant from engaging or competing in any business or in any geographic area;

 

(g)        take any action to change material accounting policies or procedures (including, without limitation, procedures with respect to revenue recognition, payments of accounts payable and collection of accounts receivable);

 

(h)        make any material Tax election inconsistent with past practice, or settle or compromise any material federal, state, local or foreign Tax liability, or agree to an extension of a statute of limitations;

 

(i)        pay, discharge or satisfy any Claims, liabilities or obligations (absolute, accrued, asserted or unasserted, contingent or otherwise), other than the payment, discharge or satisfaction in the ordinary course of business and consistent with past practice of liabilities reflected or reserved against in the Financial Statements or incurred in the ordinary course of business and consistent with past practice;

 

(j)        enter into any compromise or settlement of, or take any material action with respect to, any litigation, action, suit, claim, proceeding or investigation;

 

 

 

  35  

 

 

(k)        adopt or enter into a plan of complete or partial liquidation, dissolution, consolidation, restructuring, recapitalization or other material reorganization (other than the Transaction);

 

(l)        enter into any agreement, understanding or commitment that restrains, limits or impedes the Company’s ability to compete with or conduct any business or line of business;

 

(m)        plan, announce, implement or effect any reduction in force, lay-off, early retirement program, severance program or other program or effort concerning the termination of employment of employees of Company;

 

(n)        enter into any new agreement in an amount in excess of $15,000 (other than contracts with customers entered into in the ordinary course of business consistent with past practice) or which will remain in effect for longer than one year from the date hereof or with terms other than ordinary course of business terms consistent with past practice;

 

(o)        assign, license, transfer or impair in any way the Owned Intellectual Property of the Company, such prohibited activities to include, without limitation, licensing of the Company’s software, technology or Owned Intellectual Property to any third party, disclosure of any trade secrets to any third party with or without a non-disclosure agreement or pledging the Company’s software, technology or Owned Intellectual Property as collateral in any manner (except for non-exclusive licenses of Owned Intellectual Property of the Company to customers of the Company in the ordinary course of customer contracts consistent with Company’s past practice); or

 

(p)        take, or agree in writing or otherwise to take, any of the actions described in Section 4.1(a) through (o) above, or any action which would make any of the representations or warranties of the Company and/or Shareholders contained in this Agreement untrue or incorrect in any material respect, prevent the Company from performing, or cause the Company not to perform, its covenants hereunder or that would or could reasonably be expected to, result in any of the conditions of the Transaction set forth in Article VI not being satisfied.

 

Section 4.2 Filing of Tax Returns .

 

(a)        The Company shall prepare or cause to be prepared and file or cause to be filed all Tax Returns of the Company that are required to be filed on or prior to the Closing Date (taking into account, for these purposes, any extension of the time to file any such Tax Return), including any amended Tax Returns required for such periods. Unless otherwise required by applicable Law, every material position taken on such Tax Returns shall be reasonably consistent with the methodology and elections employed by the Company in prior years. The Company shall provide Purchaser with copies of any Tax Returns described in the preceding sentence that have not been provided to Purchaser prior to the date hereof.

 

 

 

  36  

 

 

(b)        Purchaser shall prepare or cause to be prepared and file or cause to be filed any Tax Returns of the Company for taxable periods ending on or prior to the Closing Date that are required to be filed after the Closing Date. For the avoidance of doubt, the foregoing Tax Returns shall include, without limitation, all applicable federal, state, and local payroll filings of the Company, as well as any Forms W-2 and Forms 1099 or other documents provided to any current or former employee or consultant of the Company with respect to any payments made to such Persons through and including the Closing Date. Unless otherwise required by applicable Law, every material position taken on such Tax Returns shall be reasonably consistent with the methodology and elections employed by the Company in prior years. Purchaser shall permit the Shareholders’ Representative to review and comment on each such Tax Return prior to filing as provided herein. Not less than thirty (30) days before the earlier of the due date of any such Tax Return or the date on which such Tax Returns are to be filed, Purchaser shall furnish a draft of such Tax Return (as proposed to be filed) to Shareholders’ Representative for his review. Not less than fifteen (15) days before the earlier of the due date of any such Tax Return or the date on which any such Tax Return is to be filed, the Shareholders’ Representative shall forward to Purchaser any comments he may have relating to such Tax Return, and Purchaser and the Shareholders’ Representative agree to resolve in good faith any disputes regarding such Tax Return. Not less than five (5) days before the earlier of the due date of such Tax Return or the date on which such Tax Return is to be filed, Purchaser shall forward to the Shareholders’ Representative the Tax Return to be filed. Any dispute regarding such Tax Returns that cannot be resolved by negotiation between Purchaser and the Shareholders’ Representative shall be resolved by the Independent Firm; provided , that , in resolving a dispute with respect to a Tax Return, the Independent Firm shall be bound by the requirement that the Tax Return be prepared in a manner consistent with past reporting practices of the Company unless otherwise required by applicable law only (it being understood that a position is in accordance with applicable law only if there is substantial authority for such position). The fees and expenses of the Independent Firm (a) shall be borne one-half (1/2) severally by the Shareholders in accordance with each Shareholder’s Pro Rata Portion, and (b) shall be borne one-half (1/2) by Purchaser. Purchaser and the Shareholders’ Representative shall make available to the Independent Firm and to each other all relevant books and records and working papers relating to the Tax Return under dispute and all other items reasonably requested by the Independent Firm; provided, that neither party shall not be required to provide any attorney-client privileged documents or communications. If any dispute with respect to a Tax Return is not resolved prior to the due date of such Tax Return, such Tax Return shall be filed in the manner Purchaser deems correct and the Tax shown as due on such Tax Return shall be paid in accordance with this Section 4.2(b), and if the dispute is subsequently resolved by the Independent Firm in a manner that differs from the manner in which the Tax Return was filed, Purchaser shall file an amended Tax Return in a manner consistent with the resolution of the dispute. Any Tax refund or Tax credit that relates to the portion of a Tax period covered by the Tax Return ending on or before the Closing Date shall be paid to the Shareholders; provided , that to the extent such refund or credit is attributable to a carryback of Tax losses from Tax periods following the Closing Date, it shall belong to Purchaser (it being agreed that Purchaser shall have no obligation to carryback any such losses). All other Tax refunds or credits shall belong solely to Purchaser. Likewise, to the extent not reflected in the Closing Balance Sheet and paid by way of adjustment to the Purchase Price as provided in Section 1.8, such portion of any Taxes paid by Purchaser which relates to the portion of any such taxable period ending on the Closing Date shall be reimbursable to Purchaser by the Shareholders, jointly and severally. For purposes of this Section 4.2(b), in the case of any Taxes that are imposed on a periodic basis and are payable for a taxable period that includes (but does not end on) the Closing Date, the portion of such Tax which relates to the portion of such taxable period ending on the Closing Date shall (x) in the case of any Taxes other than Taxes based upon or related to income or receipts, be deemed to be the amount of such Tax for the entire taxable period multiplied by a fraction the numerator of which is the number of days in the taxable period ending on the Closing Date and the denominator of which is the number of days in the entire taxable period, and (y) in the case of any Tax based upon or related to income or receipts be deemed equal to the amount which would be payable if the relevant taxable period ended on the Closing Date. All determinations necessary to give effect to the foregoing allocations shall be made in a manner consistent with prior practice of the Company.

 

 

 

  37  

 

 

(c)        Purchaser and the Shareholders’ Representative shall cooperate fully, as and to the extent reasonably requested by the other party, in connection with the filing of Tax Returns pursuant to this Section 4.2 and any audit, litigation or other proceeding with respect to Taxes. Such cooperation shall include the retention and (upon the other party’s request) the provision of records and information which are reasonably relevant to any such audit, litigation or other proceeding and making employees available on a mutually convenient basis to provide additional information and explanation of any material provided hereunder. Purchaser and Shareholders’ Representative agree to (i) retain all books and records with respect to Tax matters pertinent to the Company relating to any taxable period beginning before the Closing Date until the expiration of the statute of limitations (and, to the extent notified by Purchaser or Shareholders’ Representative, any extensions thereof) of the respective taxable periods, and to abide by all record retention agreements entered into with any taxing authority, and (ii) give the other party reasonable written notice prior to transferring, destroying or discarding any such books and records and, if the other party so requests, the Company or Shareholders’ Representative, as the case may be, shall allow the other party to take possession of such books and records. In addition, Purchaser and the Shareholders’ Representative will, to the maximum extent allowed by applicable Law, elect with the relevant taxing authorities to treat the portion any Tax periods described in Section 4.2(b) that begins before the Closing Date as a short taxable period that ends on the Closing Date.

 

(d)        All transfer, documentary, sales, use, stamp, registration and other similar such Taxes and fees (including any penalties and interest) incurred in connection with this Agreement shall be promptly paid by Shareholders in accordance with their respective Pro Rata Portion. Any such Taxes of the Company not paid by the Shareholders shall be reimbursed to Purchaser out of the Holdback Amount. Purchaser shall file all necessary Tax Returns and other documentation with respect to all such transfer, documentary, sales, use, stamp, registration and other Taxes and fees, and, if required by applicable Law, the other parties shall, and shall cause their Affiliates to, join in the execution of any such Tax Returns and other documentation. The expense of such filings shall be paid by the Shareholders by way of prompt offset/reimbursement out of the Holdback Amount.

 

 

 

 

  38  

 

(e)        Purchaser shall have full responsibility for and discretion in handling any Tax controversy relating to a Tax period ending on or prior to or subsequent to the Closing Date. The Shareholders’ Representative shall furnish to Purchaser or give Purchaser access to all material relevant information in its possession concerning the Tax controversy that is the subject of such proceeding. The Shareholders’ Representative shall have the right to participate in the defense or settlement of such straddle proceeding, at its sole cost and expense, through its own legal counsel. Purchaser shall not settle or compromise a claim or consent to the entry of any judgment that would adversely affect the Shareholders (or the Company for any period or portion thereof ending on or before the Closing Date) without the prior written consent of the Shareholders’ Representative, which consent shall not be unreasonably withheld, conditioned or delayed.

 

Article V
COVENANTS

 

Section 5.1 Access to Information; Confidentiality . Upon reasonable notice the Company and the Shareholders shall afford, to the officers, employees, accountants, counsel, financial advisors and other representatives of Purchaser reasonable access during normal business hours, during the period prior to the Effective Time, to all its properties, books, contracts, commitments and records and, during such period, the Company shall furnish promptly to Purchaser all information concerning its business, properties and personnel as Purchaser may reasonably request, and the Company and the Shareholders shall make available to Purchaser the appropriate individuals (including attorneys, accountants and other professionals) for discussion of its business, properties and personnel as Purchaser may reasonably request.

 

Section 5.2 Consents; Approvals . The Company and the Shareholders shall each use their best efforts to take all appropriate action to do or cause to be done all things necessary, proper or advisable under applicable Laws to consummate the Transaction and the other Contemplated Transactions, including, without limitation, using their best efforts to obtain all consents, waivers, approvals, authorizations or orders of Governmental Authorities and parties to contracts (including Material Contracts) with the Company, and the Company shall make all filings including, without limitation, all filings with Governmental Authorities required in connection with the authorization, execution and delivery of this Agreement by the Company and the Shareholders, and the consummation by the Company and the Shareholders of the Contemplated Transactions and to fulfill the conditions to the Transaction.

 

Section 5.3 Litigation and Investigations Support . If and for so long as any party hereto is actively contesting or defending against any action, suit, proceeding, hearing, investigation, charge, complaint, claim, or demand involving a third party in connection with (a) the Contemplated Transactions, or (b) any fact, situation, circumstance, status, condition, activity, practice, plan, occurrence, event, incident, action, failure to act, or transaction on or prior to the Closing Date involving the Company, or its business or properties, including audits or reviews of pricing data, product quality, product failure or government property instituted by any Governmental Authority or current or former customer of the Company or Purchaser, the Shareholders’ Representative will cooperate with the contesting or defending party and its counsel in the contest or defense, and provide such testimony and access to its books and records as shall be reasonably necessary in connection with the contest or defense, all at the sole cost and expense of the contesting or defending party (unless the contesting or defending party is entitled to indemnification therefor as provided in this Agreement).

 

 

 

  39  

 

 

Section 5.4 No Solicitation of Competing Transaction . Until the earlier of the Closing Date or the termination of this Agreement in accordance with Article VII, the Company and the Shareholders shall not (and the Company and the Shareholders shall cause their Affiliates, officers, directors, employees, representatives and agents, including investment bankers, attorneys and accountants, not to), directly or indirectly, encourage, solicit, initiate or participate in discussions or negotiations with, or provide any information to, any Person or group (other than Purchaser, any of their Affiliates or representatives) concerning any Acquisition Proposal. The Company and the Shareholders shall not enter into any agreement with respect to any Acquisition Proposal. Upon execution of this Agreement, the Company and the Shareholders shall immediately cease any existing activities, discussions or negotiations with any parties conducted heretofore with respect to any of the foregoing, and the Company and the Shareholders shall request (or if it has the contractual right to do so, demand) the return of all documents, analyses, financial statements, projections, descriptions and other data previously furnished to others in connection with efforts to sell the Company. The Company and the Shareholders shall promptly notify Purchaser of the existence of any proposal or inquiry received by the Company or the Shareholders, and the Company and the Shareholders shall promptly communicate to Purchaser the terms of any proposal or inquiry which any of them may receive (and shall immediately provide to Purchaser copies of any written materials received by the Company or the Shareholders (or a summary of all material terms if oral) in connection with such proposal, discussion, negotiation or inquiry) and the identity of the party making such proposal or inquiry.

 

Section 5.5 Notification of Certain Matters . Until the earlier of the Closing Date or the termination of this Agreement in accordance with Article VII, the Company and the Shareholders shall give prompt notice to Purchaser if any of the following occurs after the date of this Agreement: (a) any notice of, or other communication relating to, a breach, default, or event which with notice or lapse of time or both could become a breach or default, under any Material Contract; (b) receipt of any notice or other communication from any Person alleging that the consent of such Person is or may be required in connection with the Contemplated Transactions, other than a consent disclosed pursuant to Section 2.5 or Section 2.6 of the Company Disclosure Schedules; (c) receipt of any notice or other communication from any Governmental Authority in connection with the Contemplated Transactions; (d) the occurrence or non-occurrence of any fact or event which could reasonably be expected to cause any covenant, condition or agreement hereunder not to be complied with (including those in Article VI) or satisfied in any material respect or any representation or warranty to be breached in any material respect; (e) the commencement or threat of any litigation or government investigation involving or affecting the Company or any of its properties or assets; (f) notice of any cancellation or material change in any insurance maintained by the Company, and (g) the occurrence of any event that, had it occurred prior to the date of this Agreement would have constituted a Material Adverse Effect. The delivery of any notice pursuant to this Section 5.5 or otherwise after execution of this Agreement shall not be deemed to cure any breach of any representation, warranty, or covenant or limit or affect the remedies of the party receiving the notice.

 

 

 

 

  40  

 

Section 5.6 Further Action . Upon the terms and subject to the conditions hereof, each of the parties shall use all reasonable efforts to take, or cause to be taken, all actions, and to do, or cause to be done, all other things necessary, proper or advisable to consummate and make effective as promptly as practicable the Contemplated Transactions, to obtain in a timely manner all necessary waivers, consents and approvals and to effect all necessary registrations and filings, and otherwise to satisfy or cause to be satisfied all conditions precedent to its obligations under this Agreement.

 

Section 5.7 Preliminary Closing Balance Sheet; Interim Balance Sheet .

 

(a)        Concurrently with the Shareholders’ Representative’s delivery of the Preliminary Closing Balance Sheet and Preliminary Working Capital Statement pursuant to Section 1.9(a), the Shareholders’ Representative will deliver a certificate certifying that the Preliminary Closing Balance Sheet and Preliminary Working Capital Statement was prepared in good faith and presents fairly in all material respects the financial position, assets and liabilities of the Company as of the Closing, based on assumptions believed to be true at the time of preparation, and prepared in accordance with GAAP.

 

(b)        The Company shall provide to Purchaser as soon as practicable (but no more than fifteen (15) days) after the end of each calendar month prior to the Closing Date (i) financial statements of the Company, consisting of a balance sheet as of the end of such month and an income statement for that month and for the portion of the year then ended, (ii) a schedule of one-time and personal add-backs, including a brief description of each such add-back, to the income statement included in such interim financial statements that includes the same add-back items that were included in the pro forma financial statements, and (iii) a certificate (each, an “ Interim Financials Certificate ”) certifying that each set of interim financial statements and other financial information to be delivered to Purchaser pursuant to this Section 5.7: (A) presents fairly in all material respects the financial position, assets and liabilities of the Company as of the dates thereof and the revenues, expenses, results of operations and cash flows of the Company for the period covered thereby as of the dates and for the period covered thereby, in each case in conformity with GAAP and, to the extent consistent with GAAP, the Company’s past accounting practices applied consistently during such periods in accordance with the past accounting practices of the Company, subject to the lack of footnote disclosures; (B) is in accordance with the books and records of the Company, does not reflect any transactions which are not bona fide transactions; (C) makes full and adequate disclosure of, and provision for, all material obligations and liabilities of the Company as of the date thereof; and (D) does not include any assets or liabilities of any other Person.

 

Section 5.8 Updating of Company Disclosure Schedule . The Company and the Shareholders shall notify Purchaser of any changes, additions, or events which may cause any change in or addition to the Company Disclosure Schedule delivered by the Company and the Shareholders under Article II promptly after the occurrence of the same and again at the Closing by delivery of appropriate updates to all such Company Disclosure Schedule. No such notification shall cure any misrepresentation or breach of any representation, warranty or covenant of the Company and the Shareholders, nor shall any such notification be considered to constitute or give rise to a waiver by Purchaser of any condition set forth in this Agreement except to the extent Purchaser specifically agrees thereto in writing.

 

 

 

  41  

 

 

Article VI
CONDITIONS TO THE CLOSING

 

Section 6.1 Conditions to Obligation of Each Party to Effect the Transaction . The respective obligations of each party to effect the Transaction shall be subject to the satisfaction or waiver to the extent permissible under Law at or prior to the Closing Date of all the following conditions:

 

(a)        Orders, Injunctions . No foreign or domestic Law, Order, injunction, judgment or decree that prohibits, restrains, enjoins or otherwise prohibits (whether temporarily, preliminarily or permanently) consummation of the Transaction shall have been enacted, issued, promulgated, enforced or entered by any court or Governmental Authority of competent jurisdiction and there shall not be pending any suit, action or proceeding by any Governmental Authority which seeks to restrain, enjoin or otherwise prohibit (whether temporarily, preliminarily or permanently) consummation of the Transaction; provided, that each of the parties hereto shall have used its reasonable best efforts to prevent any such enactment, issuance, promulgation, enforcement or entry and to appeal as promptly as practicable any such Law.

 

Section 6.2 Additional Conditions to Obligation of Purchaser to Effect the Transaction . The obligations of Purchaser to effect the Transaction and consummate the other Contemplated Transactions are also subject to the satisfaction or waiver by Purchaser at or prior to the Closing of the following conditions:

 

(a)        Representations and Warranties . Without giving effect to any supplement to the Company Disclosure Schedule, the representations and warranties of the Company and the Shareholders set forth in this Agreement that are qualified as to materiality shall be true and correct, and the representations and warranties of the Company and the Shareholders set forth in this Agreement that are not so qualified shall be true and correct in all material respects, in each case as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date, except to the extent the representation or warranty is expressly limited by its terms to another date, and Purchaser shall have received a certificate signed on behalf of the Company by an executive officer of the Company and by each of the Shareholders to such effect.

 

(b)        Performance of Obligations of the Company . The Company and, as applicable, the Shareholders shall have performed or complied in all material respects with all obligations, covenants and agreements required to be performed by it or them under this Agreement at or prior to the Closing Date, and Purchaser shall have received a certificate signed on behalf of the Company by an executive officer of the Company to such effect.

 

 

 

 

  42  

 

(c)        Consents and Approvals . All consents and approvals necessary to the consummation of the Contemplated Transactions, including, without limitation, consents from parties to loans, leases and other agreements and consents from any Governmental Authority shall have been duly obtained, each in form and substance reasonably satisfactory to Purchaser.

 

(d)        Board of Directors Approval . The Board of Directors of Purchaser shall have approved this Agreement, the Contemplated Transactions and the Closing.

 

(e)        No Material Adverse Effect . There will not have been any Material Adverse Effect to the Company, and Purchaser will have received a certificate to such effect signed by an executive officer of the Company.

 

(f)        Non-Competition Agreement . Purchaser shall have received a non-competition agreement substantially in the form of Exhibit A hereto (the “ Non-Competition Agreement ”), duly executed by each of the Shareholders.

 

(g)        Employee Retention . Purchaser shall be satisfied in its reasonable judgment that sufficient Company employees shall remain employed by the Company immediately following the Closing Date to continue the business of the Company following the Closing Date.

 

(h)        Delivery of Books and Records . At the Closing, the Company shall deliver to Purchaser physical possession of all of the tangible assets and properties of the Company, including without limitation, its original Certificates of Incorporation, minute books, stock records and other corporate records, Material Contract files and records, and documentation of all Company IP Rights owned or licensed by the Company.

 

(i)        Audited Financial Statements . Purchaser shall have received the Audited Financial Statements, along with a certificate certifying that the Audited Financial Statements: (A) presents fairly in all material respects the financial position, assets and liabilities of the Company as of the dates thereof and the revenues, expenses, results of operations and cash flows of the Company for the period covered thereby as of the dates and for the period covered thereby, in each case in conformity with GAAP and, to the extent consistent with GAAP, the Company’s past accounting practices applied consistently during such periods in accordance with the past accounting practices of the Company, subject to the lack of footnote disclosures; (B) is in accordance with the books and records of the Company, does not reflect any transactions which are not bona fide transactions; (C) makes full and adequate disclosure of, and provision for, all material obligations and liabilities of the Company as of the date thereof; and (D) does not include any assets or liabilities of any other Person.

 

(j)        Resignation of Officers and Directors . The officers and directors of the Company in office immediately prior to the Effective Time will have resigned in writing effective as of the Effective Time.

 

 

 

  43  

 

 

(k)        No Other Securities . All (i) options (including, without limitation, the Stock Options), rights, or other securities that entitle the holders thereof to purchase or otherwise acquire any shares of the capital stock of the Company, and (ii) notes, evidence of indebtedness, stock of other securities issued by the Company that are convertible into or exchangeable for any shares of the capital stock of the Company or any securities set forth in clause (i) above (collectively, “ Other Securities ”), will have been validly terminated or exercised in full and thereby converted into shares of Common Company Stock, in accordance with their current terms and conditions, so that no Other Securities will be outstanding immediately prior to the Effective Time.

 

(l)        Certificates . The original Certificates in respect of all issued and outstanding shares of Company Common Stock shall have been delivered to Purchaser

 

(m)        (or purchaser shall have received an affidavit of lost certificate in form reasonably acceptable to Purchaser). No Claim Regarding Stock Ownership or Sale Proceeds . There must not have been made or threatened by any Person any claim asserting that such Person (a) is the holder or the beneficial owner of, or has the right to acquire or to obtain beneficial ownership of, any stock of, or any other voting, equity, or ownership interest in, the Company, or (b) is entitled to all or any portion of the consideration payable for the Company Common Stock hereunder.

 

(n)        Consortium Agreements. Purchaser shall have received assurances, satisfactory to Purchaser in its sole discretion, that (i) all payments due under the Consortium Payments have been made in full and there are no outstanding balances due under any Consortium Agreement as of the Closing; and (ii) all parties to the Consortium Agreements intend to continue under the Consortium Agreements consistent with past practices following the Closing.

 

(o)        Closing Documents . Purchaser shall have received the following agreements and documents, each of which shall be in full force and effect:

 

(i)        certificates executed by an executive officer on behalf of the Company, and the Shareholders, each dated the date of Closing (the “ Bring-Down Certificate ”), certifying (A) that all representations and warranties set forth in Article II and Article IIA are true, accurate and complete as of the Closing Date as if such representations and warranties were made on the Closing Date (except to the extent that such representations and warranties expressly relate solely to an earlier date in which case such representations and warranties shall have been true, accurate and correct on and as of such earlier date (other than the date of this Agreement, it being understood that any representation or warranty that by its terms speaks as of the date of this Agreement (and words of similar import) shall be made as of the Closing Date under the Bring-Down Certificate)), and (B) the satisfaction of the conditions precedent contained in Sections 6.2(a) and 6.2(b);

 

(ii)        a certificate of the Secretary of the Company attaching a true and complete copy of (A) the Company’s Certificate of Incorporation, as amended to date and certified by the Secretary of State of the State of North Carolina, (B) the Bylaws of the Company, as amended to date, (C) resolutions adopted by the Board and all Shareholders of the Company approving the Agreement, the Transaction and the Contemplated Transactions;

 

 

 

  44  

 

 

(iii)        certificates from appropriate authorities as to the good standing of, and payment of all required fees by the Company in its jurisdiction of organization and each jurisdiction in which it is qualified to do business as a foreign entity, as of a recent date prior to Closing;

 

(iv)        the FIRPTA Certificates;

 

(v)        a General Release of Claims substantially in the form of Exhibit B , (the “ Shareholder Release ”), duly executed by each of the Shareholders;

 

(vi)        a Payoff Letter in form and substance satisfactory to Purchaser from each of the Persons referenced in Section 1.10, confirming amounts due from the Company;

 

(vii)        a copy of the Company Data Site, in a format acceptable to Purchaser in its sole discretion, including any secured folders located therein;

 

(viii)        an IRS Form W-9 or the appropriate version of IRS Form W-8, as applicable, duly executed by each Shareholder; and

 

(ix)        such other documents as Purchaser may reasonably request for the purpose of (A) evidencing the accuracy of any of the Shareholder’s representations and warranties, (B) evidencing the performance by the Shareholder or the Company of, or the compliance by the Shareholder or the Company with, any covenant or obligation required to be performed or complied with by such Shareholder or the Company, (C) evidencing the satisfaction of any condition referred to in Section 6.2, or (D) otherwise facilitating the consummation or performance of any of the Contemplated Transactions.

 

Section 6.3 Additional Conditions to Obligation of the Company and the Shareholders to Effect the Transaction . The obligation of the Company and the Shareholders to effect the Transaction and consummate the other transactions contemplated hereby is also subject to the satisfaction by Purchaser or waiver by the Company and the Shareholders the following conditions:

 

(a)        Representations and Warranties . The representations and warranties of Purchaser set forth in this Agreement that are qualified as to materiality shall be true and correct, and the representations and warranties of Purchaser set forth in this Agreement that are not so qualified shall be true and correct in all material respects, in each case as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date, except to the extent the representation or warranty is expressly limited by its terms to another date, and the Company shall have received a certificate signed on behalf of Purchaser by an executive officer of Purchaser to such effect.

 

(b)        Performance of Obligations of Purchaser . Purchaser shall have performed or complied in all material respects with all obligations required to be performed by it under this Agreement at or prior to the Closing Date, and the Company shall have received a certificate signed on behalf of Purchaser by an executive officer of Purchaser to such effect.

 

 

 

  45  

 

 

Article VII
TERMINATION

 

Section 7.1 Termination . This Agreement may be terminated at any time prior to the Closing, notwithstanding approval thereof by the shareholders of the Company:

 

(a)        by mutual written consent of Purchaser and the Shareholders’ Representative;

 

(b)        by either Purchaser or the Shareholders’ Representative, if a court of competent jurisdiction or Governmental Authority shall have issued a nonappealable final order, decree or ruling or taken any other action having the effect of permanently restraining, enjoining or otherwise prohibiting the Transaction (provided that the right to terminate this Agreement under this Section 7.1(b) shall not be available to any party who has not complied with its obligations under Section 5.2 and Section 5.6 and such noncompliance materially contributed to the issuance of any such order, decree or ruling or the taking of such action);

 

(c)        by either Purchaser or the Shareholders’ Representative, if the Effective Time shall not have occurred on or before June 30, 2017; provided, however, that the right to terminate this Agreement under this Section 7.1(c) shall not be available to any party whose breach or failure to fulfill any obligation under this Agreement has been the cause of, or resulted in, such failure of the Closing to occur; and

 

(d)        by Purchaser or the Shareholders’ Representative, (i) if any representation or warranty of the other set forth in this Agreement that are qualified by reference to materiality shall not be true and correct or any representation or warranty of the other set forth in this Agreement that is not qualified by reference to materiality shall not be true and correct in all material respects in each case as of the date of this Agreement and as of the Closing Date, as though made on and as of the Closing Date, except to the extent the representation or warranty is expressly limited by its terms to another date, or (ii) upon a breach of or failure to perform in any material respect any covenant or agreement on the part of the other set forth in this Agreement, except in each of (i) and (ii) above, where the failure to perform such covenants or agreements or the failure of such representations and warranties to be so true and correct would not have a Material Adverse Effect (either (i) or (ii) above being a “ Terminating Breach ”).

 

Section 7.2 Effect of Termination . In the event of the termination of this Agreement pursuant to Section 7.1, (a) this Agreement shall forthwith become void and have no further force or effect, and (b) the parties shall have no further liability under this Agreement; provided , that if this Agreement is terminated by (x) a party because of a Terminating Breach of this Agreement by the other party or because one or more of the conditions to the terminating party’s obligations under this Agreement is not satisfied as a result of the other party’s failure to comply with its obligations hereunder, the terminating party’s right to pursue all legal remedies and the other party’s liability in respect thereof shall survive such termination unimpaired, or (y) Purchaser, if the Company or any Shareholder has breached the terms of Section 5.1 or Section 5.4, in which case, the Company shall immediately pay for or reimburse Purchaser for its reasonable out-of-pocket expenses incurred by it or on its behalf in connection with the proposed Transaction, including but not limited to attorney’s fees and accountant’s fees. Notwithstanding the foregoing, the obligations of the parties contained in this Section 7.2, and in the NDA shall survive any such termination.

 

 

 

  46  

 

 

Article VIII
INDEMNIFICATION

 

Section 8.1 Indemnification by Shareholders . Each of the Majority Shareholders shall, jointly and severally, and all other Shareholders, severally and not jointly, shall indemnify, defend and hold harmless in the manner and subject to the limitations and qualifications set forth in this Article VIII, Purchaser and its Affiliates (which shall include the Company following the Effective Time) and their respective officers, directors, agents, employees, subsidiaries, partners, members, controlling persons, agents, accountants, attorneys, successors and assigns (each, an “ Purchaser Indemnitee ”) from and against any and all, actions, suits, proceedings, claims, complaints, disputes, arbitrations or investigations or written threats thereof, including, without limitation, any claim by a third party (collectively, “ Claims ”), and/or Losses resulting from or arising out of:

 

(a)        any breach of any representation or warranty by (i) the Company or any of the Shareholders in this Agreement and/or the Bring-Down Certificate, and (ii) the Company or any of the Shareholders in any Transaction Documents, in each case of clauses (i) and (ii), (which breach shall be determined for purposes of this Article VIII without regard to any qualification based on materiality or Material Adverse Effect contained in such representations and warranties), including any certificate delivered in connection therewith;

 

(b)        (i) any breach by any Shareholder or (ii), prior to the Closing, the Company, in each case of clauses (i) and (ii), of any covenant or obligation of any such Person in this Agreement or any Transaction Document or any certificate delivered therewith;

 

(c)        notwithstanding any matter listed in the Company Disclosure Schedule, (i) any Taxes imposed on the Company or any Shareholder for any period ending on or before the Closing Date (or for the portion of any period up through the Closing Date to the extent a period does not close on such date), including without limitation any Taxes, fees and expenses for which Purchaser is entitled to be reimbursed pursuant to Section 4.2(b); and (ii) Taxes otherwise imposed on the Company or any Shareholder by virtue of the Transaction and any Contemplated Transactions, including without limitation any Taxes, fees and expenses for which Purchaser is entitled to be reimbursed pursuant to Section 4.2(d);

 

 

 

 

  47  

 

(d)        notwithstanding any matter listed in the Company Disclosure Schedule, any claim by a current Company equity holder, former Company equity holder or any other Person following the Effective Time seeking to assert, or based upon the following: (i) ownership or rights to ownership of any stock, options, warrants or other rights to acquire stock of the Company; (ii) any rights of an equity holder of the Company in the capacity of an equity holder, including any option or preemptive rights or rights to notice or to vote (together with the rights described under (i), the “ Ownership Rights ”); (iii) any Ownership Rights under any of the Company charter documents or any other agreement with the Company; (iv) any claim regarding any issuance, reissuance, cash-out, termination or cancellation of any stock, options or other securities by the Company; (v) any Claim that his, her or its securities of the Company were wrongfully repurchased or transferred by the Company; or (vi) the Funds Flow Memorandum and any information contained therein;

 

(e)        any Indebtedness of the Company existing prior to the Closing;

 

(f)        any litigation, arbitration or suit against the Company or any of its directors, officers or employees in their capacity as such that relates to events occurring or circumstances existing prior to the Closing, by any Person other than Purchaser or any of its Affiliates or any of their successors;

 

(g)        any Transaction Expenses;

 

(h)        any amounts payable to the Company’s employees (whether under the Company’s Employee Plans or otherwise) by reason of the Transaction being deemed a termination of the employment of the Company’s employees or contractors, including, without limitation, the following (for clarity, but only to the extent the obligation arises by reason of the Transaction being deemed a termination of employment of the Company’s employees or contractors): severance, salary, commission, bonus, incentives, vacation pay or other benefit accruals or any Termination Liability with respect to such employees or contractors of the Company and their eligible dependents in respect of health insurance under COBRA and any other similar state Laws; and

 

(i)        any Losses with respect to the termination of any Employee Plan in connection with the Contemplated Transactions (but not including any ordinary administrative costs resulting from Purchaser or the Company’s voluntary termination of an Employee Plan following Closing), any unfunded liability under any such Employee Plan, and/or any accrued but unpaid claim under such Employee Plan.

 

The parties acknowledge and agree that, if the Company suffers, incurs or otherwise becomes subject to any Losses as a result of or in connection with any inaccuracy in or breach of any representation, warranty, covenant or obligation, then (without limiting any of the rights of the Company as a Purchaser Indemnitee) Purchaser shall also be deemed, by virtue of its ownership of the stock of the Company, to have incurred Losses as a result of and in connection with such inaccuracy or breach. The parties further acknowledge and agree that the Company’s obligations hereunder shall expire at the Effective Time.

 

 

 

 

  48  

 

Section 8.2 No Contribution; Shareholders’ Representative . The Shareholders shall have no right to seek contribution from the Company with respect to all or any part of any matter, including the indemnification obligations under this Article VIII. In connection with any exercise by Purchaser of its rights hereunder, Purchaser shall be entitled to make all claims through and deal exclusively with the Shareholders’ Representative.

 

Section 8.3 Indemnification by Purchaser . Purchaser agrees to indemnify, defend and hold harmless in the manner and subject to the limitations and qualifications set forth in this Article VIII, the Shareholders, and their respective agents, representatives, Affiliates, successors and assigns (collectively, the “ Company Indemnitees ,” and, together with Purchaser Indemnitees, the “ Indemnitees ”) against, from and in respect of any and all Claims and/or Losses based upon, arising out of, or otherwise in respect of or which may be incurred by virtue of or result from (a) the inaccuracy in or breach of any representation or warranty made by Purchaser in this Agreement, and/or (b) any covenant or agreement made by Purchaser in this Agreement or any Transaction Documents or any certificate delivered therewith, except to the extent that any such Losses arise out of or result from a breach by the Company, or the Shareholders of any representations, warranties or covenants in this Agreement and/or any documents, agreements, instruments or certificates contemplated by this Agreement, or any matters for which a Purchaser Indemnitee has a right of indemnification pursuant to Section 8.1.

 

Section 8.4 Survival . All representations and warranties of the parties contained in this Agreement shall, subject to the limitations set forth in this Section 8.4, survive the Closing. The representations and warranties contained in or made pursuant to this Agreement and/or any documents, agreements, instruments or certificates contemplated by this Agreement, and the indemnity obligations based on a breach of such representations and warranties under Section 8.1(a) and 8.3(a) shall terminate on, and no Claim or action based solely thereon may be initiated after the Holdback Release Date; provided , that (i) the representations and warranties under Section 2.16 (Government Contracts), Section 2.17 (Proprietary Rights), Section 2.22 (Employee Benefit Plans) (the “ Extended Representations ”) and the related indemnity obligations under Section 8.1(a) shall survive until the date that is the third (3 rd ) anniversary of the Closing Date, and (ii) the representations and warranties under Section 2.1 (Organization and Qualification), Section 2.2 (Certificate of Incorporation and Bylaws), Section 2.3 (Capitalization), Section 2.4 (Authority Relative to this Agreement ) , Section 2.18 (Taxes), Section 2.20 (Environmental Matters), Section 2A.1 (Valid Title), Section 2A.2 (Authorization; Binding Effect) (the “ Fundamental Representations ”) and the related indemnity obligations under Section 8.1(a) shall survive until the date that is the tenth (10 th ) anniversary of the Closing Date. Except as otherwise expressly provided herein, the covenants and agreements contained in this Agreement shall survive the execution and delivery hereof and the consummation of the Contemplated Transactions until the expiration of the applicable statute of limitations (including any extensions or waivers thereto). Notwithstanding any other provision of this Agreement, if any Claim for Losses is asserted by any Indemnitee prior to the termination of the representation, warranty or indemnification obligation, the rights of such Indemnitee shall continue with respect to such Claim until the resolution and satisfaction thereof even if not finally resolved until after such termination. It is the express intent of the parties that, if the applicable survival period for an item as contemplated by this Section 8.4 is shorter or longer than the statute of limitations that would otherwise have been applicable to such item, then, by contract, the applicable statute of limitations with respect to such item shall be reduced or extended to the survival period contemplated hereby. The parties further acknowledge that the time periods set forth in this Section 8.4 for the assertion of claims under this Agreement are the result of arms-length negotiation among the parties and that they intend for the time periods to be enforced as agreed by the parties.

 

 

 

 

  49  

 

Section 8.5 Certain Limitations .

 

(a)        No Claim by a Purchaser Indemnitee or Company Indemnitee for indemnification for claims for breaches of representations and warranties pursuant to Section 8.1(a) or Section 8.3(a), respectively, may be made until the amount of all Losses related to such Claims exceeds $75,000 (the “ Basket ”) whereupon the Indemnifying Party shall be obligated to pay in full up to the Cap all amounts for indemnification, including the entire amount of the Basket. The indemnification obligations for claims for breaches of representations and warranties pursuant to Section 8.1(a) or Section 8.3(a), respectively, apply, and the Purchaser Indemnitee or Company Indemnitee shall be entitled to exercise indemnification rights under Section 8.1(a) or Section 8.3(a), respectively, only for any individual claim or series of similar or related claims with respect to which the aggregate Losses resulting therefrom exceed $5,000 (and all Losses, if they so exceed $5,000, arising from any such claim or series of similar or related claims shall be fully indemnified and counted toward the Basket).

 

(b)        The maximum amount of indemnifiable Losses in the aggregate which may be recovered from the Shareholders or Purchaser, respectively, for indemnification for breaches of representations and warranties pursuant to Section 8.1(a) or Section 8.3(a), respectively, and pursuant to Section 7.2(b)(y) with respect to the Shareholders, shall not exceed an amount equal to twenty percent (20%) of the Purchase Price payable to the Shareholders (the “ Cap ”).

 

(c)        Notwithstanding the limitations set forth in Section 8.5(a) and Section 8.5(b), neither the Cap nor the Basket shall apply to (i) Claims based on a breach of the Fundamental Representations or the indemnification obligations under Section 8.1(a) with respect to such matters, and (ii) indemnification obligations under Section 8.1(b) through Section 8.1(i) and Section 8.3(b), for which for both clauses (i) and (ii) the maximum amount of indemnifiable Losses in the aggregate which may be recovered from the Shareholders, or the Purchaser, respectively, shall be the Purchase Price payable to the Shareholders, plus (x) if there is a Shareholder Excess, the Company Adjustment Amount, and minus (y) if there is a Purchaser Deficit, the Purchaser Adjustment Amount; provided, however, that the maximum amount of indemnifiable Losses which may be recovered from each Shareholder (other than the Majority Shareholders) with respect to indemnification claims under Section 8.1 of this Agreement, shall not exceed such Shareholder’s Pro Rata Portion of the Purchase Price, plus (x) if there is a Shareholder Excess, the Company Adjustment Amount, and minus (y) if there is a Purchaser Deficit, the Purchaser Adjustment Amount..

 

(d)        Notwithstanding anything contained in this Agreement to the contrary, (i) no Indemnitee shall be entitled to duplicative recoveries arising out of the same facts or circumstances, or (ii) no Purchaser Indemnitee shall be entitled to indemnification for Losses for which Purchaser has otherwise been compensated pursuant to the adjustments pursuant to Section 1.9.

 

 

 

 

  50  

 

(e)        Losses payable under Article VIII shall be calculated after giving effect to proceeds actually received by an Indemnitee or their Affiliates from insurance policies maintained by the Indemnitee or their Affiliates covering the Losses that are the subject of the claim for indemnification); provided that the amount deemed to be recovered under insurance policies will also be net of the deductible for such policies and any increase in the premium (and retro-premium adjustments) for such policies to the extent arising out of or in connection with such Losses.

 

(f)        The limitations set forth in this Section 8.5 shall not apply to Claims based on fraud or intentional misrepresentation, and any such Claims shall be excluded in calculating the limitations on indemnification obligations of Shareholders set forth in this Section 8.5.

 

(g)        Following the Closing, indemnification pursuant to the provisions of this Article VIII shall be the exclusive remedy of the parties for any misrepresentation or breach of any warranty or covenant contained in this Agreement (without limiting, and without any prejudice to, any right or remedy set forth in any other Transaction Document); provided, however, nothing in this Agreement shall limit any party’s equitable remedies or any remedy any party hereto may have with respect to fraud or intentional breach.

 

Section 8.6 Notice of Indemnification Claims; Notice of Claims .

 

(a)        Promptly after an Indemnitee becomes aware of (i) any facts or events that could give rise to indemnification hereunder, (ii) a Claim made by a third party against such Indemnitee, or (iii) facts or circumstances establishing that an Indemnitee has experienced or incurred Losses subject to indemnification under this Article VIII, then, if the Indemnitee is a Purchaser Indemnitee, such Purchaser Indemnitee shall give to the Shareholders’ Representative, or, if the Indemnitee is a Company Indemnitee, then the Shareholders’ Representative shall give to Purchaser, prompt written notice thereof (in each case, an “ Indemnification Notice ”). The failure to give notice pursuant to Section 8.6(a) or any other similar notice provision of this Agreement shall not affect or limit the Indemnitee’s rights hereunder except, and then only to the extent that, (A) the delay in giving, or failure to give, the notice is determined by final judgment of a court of competent jurisdiction or an arbitrator of competent authority to have actually and materially prejudiced the recipient’s ability to defend against the Claim or (B) notice is given after the expiration of any applicable survival period set forth in Section 8.4. To the extent practicable under the circumstances taking into account the information readily available to the Indemnitee at such time, the Indemnification Notice will describe with reasonable specificity (x) the nature of and the basis for the set-off or indemnification Claim, including any relevant supporting documentation, and (y) if possible, a reasonable estimate of all Losses associated therewith.

 

(b)        Procedure in Event of Indemnification Claim . Subject to the limitations in Section 8.4 and Section 8.5 hereof, if an Indemnitee desires to assert an indemnification Claim pursuant to Section 8.1 or Section 8.3, the Indemnitee promptly shall provide an Indemnification Notice in accordance with the procedures set forth in this Section 8.6(a). Subject to Section 8.4 and Section 8.5, if the recipient of a duly and timely delivered Indemnification Notice does not object within thirty (30) days after receipt of the Indemnification Notice to the propriety of the indemnification Claims described as being subject to indemnification pursuant to Section 8.1 or Section 8.3 or the amount of Losses asserted in the Indemnification Notice, the indemnification Claims described and, if applicable, the amount of Losses asserted in the Indemnification Notice shall be deemed final and binding (hereinafter, collectively with any Claims either agreed to between the parties or finally determined in accordance with Section 9.5, “ Permitted Indemnification Claims ”). If the recipient of a duly and timely delivered Indemnification Notice contests the propriety of an indemnification Claim described in the Indemnification Notice or the amount of Losses associated with such Claim, then such recipient shall deliver to the Indemnitee a written notice detailing with reasonable specificity all specific objections such recipient has with respect to the indemnification Claims contained in the Indemnification Notice (“ Indemnification Objection Notice ”). If the objecting party and the Indemnitee are unable to resolve the disputed matters described in the Indemnification Objection Notice within fifteen (15) Business Days after the date the Indemnitee received the Indemnification Objection Notice, the disputed matters will be subject to the dispute resolution procedures set forth in Section 9.5 hereof. Subject to Section 8.4 and Section 8.5, any undisputed indemnification Claims or Losses contained in the Indemnification Notice shall be deemed to be final and binding and shall constitute a Permitted Indemnification Claim. In addition, subject to Section 8.4 and Section 8.5, if the procedures in Section 9.5 result in all or any portion of an indemnification Claim properly being subject to indemnification pursuant to Section 8.1 or Section 8.3, such Claim or portion thereof shall be final and binding and shall constitute a Permitted Indemnification Claim.

 

 

 

 

  51  

 

(c)        Defense of Third Party Claims . After receipt of an Indemnification Notice in respect of a Claim brought by a third party, Purchaser or Shareholders’ Representative, as applicable, receiving such Notice (the “ Assuming Party ”) shall have the right to assume the defense (at the Assuming Party’s sole cost and expense) of any such Claim through counsel of the Assuming Party’s own choosing by so notifying the Indemnitee in writing within thirty (30) days of receipt of such Indemnification Notice; provided, however, that any such counsel shall be reasonably satisfactory to the Indemnitee. Each Indemnitee shall have the right to employ separate counsel in such Claim and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense of the Indemnitee unless: (i) the Assuming Party has agreed in writing to pay such expenses; (ii) the Assuming Party has failed promptly to assume the defense and employ counsel reasonably satisfactory to such Indemnitee and such expenses would otherwise constitute Losses indemnifiable under Section 8.1 or Section 8.3 (as limited by Section 8.4 and Section 8.5); or (iii) the named parties to any such Claim (including any impleaded parties) include any Indemnitee and the Assuming Party or an Affiliate of the Assuming Party, and such Indemnitee shall have been advised by counsel that either (x) there may be one or more legal defenses available to it which are different from or in addition to those available to the Assuming Party or such Affiliate or (y) a conflict of interest may exist if such counsel represents such Indemnitee and the Assuming Party or its Affiliate; provided , that, if such Indemnitee notifies the Assuming Party in writing that it elects to employ separate counsel in the circumstances described in clause (ii) or (iii) above, the Assuming Party shall not have the right to assume the defense thereof and such counsel shall be at the expense of the Assuming Party to the extent such expenses otherwise constitute Losses indemnifiable under Section 8.1 or Section 8.3 (as limited by Section 8.4 and Section 8.5). Without the consent of the Indemnitees or, in the circumstances described in clause (iii) above, the Assuming Party, such consent not to be unreasonably withheld, the Assuming Party or Indemnitee, as applicable, shall not consent to, and the Indemnitees or Assuming Party, as applicable, shall not be required to agree to, the entry of any judgment or enter into any settlement unless such judgment or settlement (A) includes as an unconditional term thereof the giving of a release from all liability with respect to such Claim by each claimant or plaintiff to each Indemnitee or Assuming Party, as applicable, that is the subject of such third-party Claim, (B) does not include a statement as to or an admission of fault, culpability or a failure to act, by or on behalf of an Indemnitee or Assuming Party, as applicable and (C) in the case of any Claim regarding Taxes, such judgment or settlement does not and will not, in the reasonable determination of Purchaser, give rise or result in any increase in any Tax liability of Purchaser or any of its Affiliates. In case of a judgment or settlement where the elements of clauses (A), (B) and (C) are satisfied, the Assuming Party or Indemnitee, as applicable, may consent, and Indemnitees or Assuming Party, as applicable, will be required to agree to, the entry of such judgment or settlement in respect of such Claim. If an Indemnification Notice is given to an Assuming Party and the Assuming Party does not, within thirty (30) days after the Indemnification Notice is given, give notice to the Indemnitee of its election to assume the defense of such Claim, the Assuming Party will be bound by any determination made in such Claim or any compromise or settlement effected by the Indemnitee. The Indemnitee and the Assuming Party will make available to each other and each other’s attorneys and representatives at all reasonable times, all books and records relating to such Claim and will render to each other such assistance as may reasonably be requested to ensure proper and adequate defense of any such Claim.

 

 

 

 

  52  

 

Section 8.7 Determination of Losses . Losses with respect to any Permitted Indemnification Claim shall be determined without regard to any materiality or Material Adverse Effect qualification set forth in any representation, warranty or covenant. To the maximum extent allowed by Law, all indemnification payments under this Agreement will be treated by the parties as an adjustment to the Purchase Price.

 

Section 8.8 Right of Set-Off .

 

(a)        Set-Off . To the extent that a Purchaser Indemnitee has made a claim for indemnification, it is expressly agreed by the Parties that Purchaser may deduct and set-off the aggregate estimated amount of all such Losses with respect to such claim for indemnification from the Holdback Amount (for claims asserted prior to the Holdback Release Date), any Adjustment Amount, or any Earn-Out Payment and subject to resolution of such claim pursuant to the procedures set forth in this Article VIII. The exercise of such right of set-off by Purchaser in good faith, whether or not ultimately determined to be justified, will not constitute a breach of this Agreement. Neither the exercise of nor the failure to exercise such right of set-off will constitute an election of remedies or limit the Purchaser Indemnitees in any manner in the enforcement of any other remedies that may be available to them.

 

(b)        Distribution of Indemnity Holdback Amount . Pursuant to the terms of this Agreement, the Holdback Amount shall be released to the Shareholders’ Representative (or one or more account(s) designated thereby) on the Holdback Release Date, minus any amounts released from the Holdback Amount to satisfy resolved Claims for indemnification made by a Purchaser Indemnitee; provided, however, if any Purchaser Indemnitee have made claims against the Shareholders prior to any such scheduled release, then the disputed amount of the Holdback Amount (plus accrued interest) will be held by the until resolution in full of such claims.

 

 

 

 

  53  

 

(c)        Distribution of Specific Claim Amounts . Amounts remaining in the Holdback Amount attributable to any claims made prior to the Holdback Release Date shall be distributed upon the resolution of such claims in the manner determined pursuant to such resolution, in each case, subject to reduction as a result of claims made against the Holdback Amount prior to the Holdback Release Date and for any amounts necessary, in the reasonable judgment of Purchaser, to satisfy all unresolved claims as of such applicable distribution date, which amounts shall continue to be held by the Purchaser until final resolutions of such unresolved claims.

 

Article IX
MISCELLANEOUS PROVISIONS

 

Section 9.1 Amendment and Modifications . This Agreement may be amended, modified and supplemented only by written agreement between Purchaser, the Company and the Shareholders which states that it is intended to be a modification of this Agreement; provided that following the Closing, the Agreement may only be amended by the written agreement of Purchaser and the Shareholders.

 

Section 9.2 Waiver of Compliance . Any failure of the Company, or the Shareholders to comply with any obligation, representation, warranty, covenant, agreement or condition herein may be waived in writing by Purchaser, but such waiver or failure to insist upon strict compliance with such obligation, representation, warranty, covenant, agreement or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure. Any failure of Purchaser to comply with any obligation, representation, warranty, covenant, agreement or condition herein may be waived in writing prior to the Closing by the Company and after the Closing by the Shareholders’ Representative, but such waiver or failure to insist upon strict compliance with such obligation, representation, warranty, covenant, agreement or condition shall not operate as a waiver of, or estoppel with respect to, any subsequent or other failure and the waiver of any condition to Closing related to a breach of any party’s representation, warranty, or covenant shall not relieve the party of any liability therefor.

 

Section 9.3 Expenses . Except as set forth in Section 7.2, the parties agree that all fees and expenses incurred by them in connection with this Agreement and the Contemplated Transactions shall be borne by the party incurring such fees and expenses, including, without limitation, all fees of counsel, actuaries, brokers and accountants; provided however that Transaction Expenses, to the extent not deducted from the Purchase Price in accordance with Section 1.2, shall be paid by the Shareholders on or prior to Closing.

 

Section 9.4 Waiver . To the maximum extent permitted by Law, all rights and remedies existing under this Agreement are cumulative to, and not exclusive of, any rights or remedies otherwise available under applicable Law. No failure on the part of any party to exercise or delay in exercising any right hereunder shall be deemed a waiver thereof, nor shall any single or partial exercise preclude any further or other exercise of such or any other right.

 

 

 

 

  54  

 

Section 9.5 Dispute Resolution .

 

(a)        Negotiated Resolution . Except to the extent a different procedure is expressly provided for herein, if any dispute arises (i) out of or relating to, this Agreement, or any alleged breach hereof, or (ii) with respect to any of the Contemplated Transactions (“ Dispute ”), the party desiring to resolve such Dispute shall deliver a written notice describing such Dispute with reasonable specificity to the other parties (“ Dispute Notice ”). If any party delivers a Dispute Notice pursuant to this Section 9.5, or if Purchaser or the Shareholders’ Representative delivers to the other an Indemnification Objection Notice pursuant to Section 8.6, the parties involved in the Dispute shall meet at least twice within the thirty (30) day period commencing with the date of the Dispute Notice or the Indemnification Objection Notice (as the case may be) and in good faith shall attempt to resolve such Dispute (as the case may be).

 

(b)        Arbitration . If the Dispute or indemnification claim is not resolved pursuant to Section 9.5(a) above, the Dispute or indemnification claim shall be settled by arbitration conducted in Los Angeles, California, or such other place as mutually agreed to by the parties, which shall be in accordance with the then effective Comprehensive Arbitration Rules of JAMS. The arbitration of such issues, including the determination of any amount of damages suffered by any party hereto by reason of the acts or omissions of any party, shall be final and binding upon all parties. Judgment on the award rendered by the arbitrator may be entered in any court having jurisdiction. The arbitrator shall have the authority to award any remedy or relief that a court in the State of Delaware could order or grant, including specific performance of any obligation created under this Agreement, the issuance of an injunction or other provisional relief, or the imposition of sanctions for abuse or frustration of the arbitration process. The arbitrator shall apply the Law of the State of Delaware in deciding the merits of any Dispute. The arbitrator shall provide a written and reasoned explanation for any award rendered in the arbitration. By agreeing to arbitration, the parties do not intend to deprive any court of its jurisdiction to issue a pre-arbitral injunction, pre-arbitral attachment, or other order in aid of arbitration proceedings and the enforcement of any award. Except as otherwise set forth in this Agreement, the cost of any arbitration hereunder, including the cost of the record or transcripts thereof, if any, administrative fees, and all other fees involved including reasonable attorneys’ fees incurred by the party determined by the arbitrator to be the prevailing party, shall be paid by the party determined by the arbitrator not to be the prevailing party, or otherwise allocated in an equitable manner as determined by the arbitrator.

 

Section 9.6 Notices . All notices, requests, demands and other communications required or permitted hereunder shall be in writing and shall be delivered by hand, mailed, certified or registered mail with postage prepaid, or sent by reputable overnight courier to the parties at the address set forth below or to such other address as may be furnished in writing to the other parties hereto. All such notices and communications shall be deemed to have been duly given three (3) Business Days after being deposited in the mail, postage prepaid, if mailed; one (1) Business Day after being sent by reputable overnight courier.

 

 

 

  55  

 

 

Purchaser:

Walter S. Woltosz

Chief Executive Officer

Simulations Plus, Inc.

42505 10th St W

Lancaster, CA 93534-7059

 

   

With a copy (which shall not

 

constitute notice) to:

 

Dennis J. Doucette, Esq.

Procopio, Cory, Hargreaves & Savitch, LLP

12544 High Bluff Drive, Suite 300

San Diego, CA 92130

 

or to such other Person or address as Purchaser shall furnish to the Company and the Shareholders in writing.

 

Company (pre-Closing):

Brett A. Howell

6 Davis Drive, PO Box 12317

Research Triangle Park, NC 27709

 

   
Shareholders’ Representative (on behalf of the Shareholders):

Brett A. Howell

6 Davis Drive, PO Box 12317

Research Triangle Park, NC 27709

 

   

With a copy (which shall not

 

constitute notice) to:

 

Amalie L. Tuffin

Hutchison PLLC

3110 Edwards Mill Road, Suite 300

Raleigh, NC 27612

 

or to such other Person or address as the Company or the Shareholders’ Representative shall furnish to Purchaser in writing (with any notice to the Shareholders’ Representative to be deemed adequate notice to all Shareholders).

 

Section 9.7 Assignment . This Agreement and all of the provisions hereof shall be binding upon and inure to the benefit of the parties hereto and their respective successors, but neither this Agreement nor any of the rights, interests or obligations hereunder shall be assigned by any of the parties hereto without the prior written consent of the other party; provided, that, Purchaser may assign this Agreement to an Affiliate of Purchaser provided that such assignment shall not relieve Purchaser of liability hereunder.

 

Section 9.8 Publicity . Neither the Company nor the Shareholders nor Purchaser shall make or issue, or cause to be made or issued, any announcement or written statement concerning this Agreement or the Contemplated Transactions for dissemination to the general public without the prior consent of the other party, and no such announcement or written statement shall disclose the amount or composition of the Purchase Price. This provision shall not apply, however, to any announcement or written statement required (upon the advice of legal counsel) to be made by Law or the regulations of any Governmental Authority, or any exchange upon which the securities of either party may be listed, except that the party required to make such announcement, whenever practicable, shall consult with the other party concerning the timing and content of such announcement before such announcement is made.

 

 

 

 

  56  

 

Section 9.9 Governing Law . This Agreement and the legal relationship among the parties hereto shall be governed and construed under the internal laws of the State of Delaware without regards to its conflict of laws principles.

 

Section 9.10 Counterparts . This Agreement may be executed simultaneously in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Signature by telecopy shall be sufficient to evidence a party’s intention to be bound hereby.

 

Section 9.11 Headings . The headings of the Sections and Articles of this Agreement are inserted for convenience only and shall not constitute a part hereof or affect in any way the meaning or interpretation of this Agreement.

 

Section 9.12 Incorporation of NDA . The terms of the NDA shall continue in full force and effect in all respects. If this Agreement is, for any reason, terminated prior to the Closing, the NDA shall nonetheless continue in full force and effect in all respects without any modification thereto. Notwithstanding the foregoing or any other provision of this Agreement, from and after the Closing, the provisions of the NDA restricting Purchaser shall expire and shall not apply to or restrict in any manner Purchaser’s or Company’s use of any Confidential Information (as defined in the NDA) of the Company.

 

Section 9.13 Entire Agreement . This Agreement, including the exhibits and schedules hereto, the Company Disclosure Schedule and the other documents and certificates delivered pursuant to the terms hereof, and the NDA set forth the final, complete and exclusive agreement and understanding of the parties hereto in respect of the subject matter contained herein, and supersede all prior agreements, promises, covenants, arrangements, communications, representations or warranties, whether oral or written, by any officer, employee or representative of any party hereto, including, without limitation, the Letter of Intent dated October 20, 2016 between the Company, the Shareholders and Purchaser.

 

Section 9.14 Assignments, Successors, and No Third-Party Rights . No party may assign any of its rights under this Agreement without the prior consent of the other parties hereto, except that Purchaser may assign any of its rights under this Agreement to any Subsidiary or Affiliate of Purchaser or as collateral security for any borrowings. Subject to the preceding sentence, this Agreement will apply to, be binding in all respects upon, and inure to the benefit of the successors and permitted assigns of the parties. Except as set forth in Article VIII, nothing expressed or referred to in this Agreement will be construed to give any Person other than the parties to this Agreement any legal or equitable right, remedy, or claim under or with respect to this Agreement or any provision of this Agreement. This Agreement and all of its provisions and conditions are for the sole and exclusive benefit of the parties to this Agreement and their successors and assigns.

 

 

 

 

  57  

 

Section 9.15 Further Assurances . Each of the parties hereto agrees that from time to time, at the request of any of the other parties hereto and without further consideration, it will execute and deliver such other documents and take such other action as such other party may reasonably request in order to consummate more effectively the Contemplated Transactions. The parties shall cooperate with each other in such actions and in securing requisite approvals. Each party shall execute and deliver both before and after the Closing such further certificates, agreements and other documents and take such other actions as the other party reasonably may request to consummate or implement the Contemplated Transactions or to evidence such events or matters.

 

Section 9.16 Representation by Counsel; Interpretation . The Company, on one hand, and Purchaser, on the other hand, each acknowledge that such parties have been represented by counsel in connection with this Agreement and the Contemplated Transactions. Accordingly, any rule of Law or any legal decision that would require interpretation of any claimed ambiguities in this Agreement against the party that drafted it has no application and any such right is expressly waived. The provisions of this Agreement shall be interpreted in a reasonable manner to effect the intent of the parties hereto.

 

Section 9.17 Certain Definitions . For purposes of this Agreement, the term:

 

Acquisition Proposal ” means any proposal or offer made by any Person other than parent or an Affiliate of Purchaser to acquire all or a substantial part of the business or properties of the Company or any capital stock of the Company, whether by Transaction, tender offer, exchange offer, sale of assets, recapitalization or similar transactions involving the Company, division or operating or principal business unit of the Company.

 

Adjusted EBT ” means, with respect to any time period, the earnings before income taxes of the Company for such period, determined in accordance with GAAP, as adjusted by (i) adding back all amortization and depreciation expenses related to the Contemplated Transaction (minus an amount of $16,000), (ii) deducting capitalized software cost and (iii) adding back amortized software cost, all in accordance with GAAP and as set forth and determined in a manner consistent with the methodology set forth on Schedule 1.11. Depreciation for property, plant, equipment and computer equipment is to be included as a deduction in the Adjusted EBT only to the extent it exceeds fifteen thousand Dollars ($15,000) per year for each of the Earn-Out Years.

 

Affiliate ” means a Person that directly or indirectly, through one or more intermediaries, controls, is Controlled by, or is under common Control with, the first mentioned Person.

 

Agreement ” has the meaning set forth in the Preamble.

 

Audited Financial Statements ” means the audited balance sheets of the Company at December 31, 2015, the audited balance sheets of the Company at December 31, 2016, and the related statements of income, stockholders’ equity, and cash flows for the years ended December 31, 2016, together with the notes and supplemental information thereto and the report thereon of Dixon Hughes Goodman, LLP, as delivered to Purchaser prior to the Closing Date and attached to Section 2.8(a) of the Company Disclosure Schedule

 

 

 

 

  58  

 

Business Day ” means any day other than a day on which banks in Los Angeles, California are required or authorized to be closed.

 

COBRA ” means Part 6 of Title I of ERISA and Code Section 4980B and the regulations promulgated under any of them, as amended.

 

Code ” means the Internal Revenue Code of 1986, as amended.

 

Company Common Stock ” means the common stock of Company.

 

Company Data Site ” means the electronic diligence data room website located at Box.com established by the Company to produce diligence materials in connection with the Contemplated Transactions.

 

Contemplated Transactions ” means all of the transactions contemplated by this Agreement and the Transaction Documents.

 

Consortium Agreements ” means the Consortium Agreements entered into by Hamner Institute, the Company (as itself and as an assignee of Hamner Institute’s Consortium Agreements), and the following entities: (i) Astellas Pharma Inc., (ii) AbbVie, Inc., (iii) GlaxoSmithKline Research and Development Ltd, (iv) Bristol-Myers Squibb Company, (v) Daiichi Sankyo, Company, Limited, (vi) Mitsubishi Tanabe Pharma Corporation, (vii) Gilead Sciences, Inc., (viii) Eli Lilly and Company, (ix) Janssen Research and Development, LLC, (x) Merck Sharp & Dohme Corp., (xi) Pfizer Inc., and (xii) Takeda Pharmaceuticals International, Inc.

 

Control ” (including the terms “Controlled by”, and “under common Control with”) means the possession, directly or indirectly or as trustee or executor, of the power to direct or cause the direction of the management or policies of a Person, whether through the ownership of stock, as trustee or executor, by contract or credit arrangement or otherwise.

 

Earn-Out Years ” means (i) the twelve (12) month period commencing June 1, 2017 and ending May 31, 2018, (ii) the twelve (12) month period commencing June 1, 2018 and ending May 31, 2019, and (iii) the twelve (12) month period commencing June 1, 2019 and ending May 31, 2020.

 

Effective Time ” means 11:59 p.m. San Diego City time on the day immediately preceding the Closing Date.

 

FIRPTA Certificates ” means the non-foreign affidavits executed by each of the Shareholders as of the Closing Date, sworn under penalty of perjury and in form and substance required under the Treasury Regulations issued pursuant to Section 1445 of the Code stating that Company is not a “Foreign Person” as defined in Section 1445 of the Code.

 

GAAP ” means accounting principles generally accepted in the United States.

 

 

 

 

  59  

 

Government Agency ” means (a) the United States Government, including all departments and agencies of any branch of the United States Government, all independent agencies or instrumentalities and all non-appropriated fund activities within the United States Government and United States Government corporations, and (b) any state, local or foreign government, including all departments, agents, agencies, branches, independent agencies or instrumentalities, activities, and non-appropriated fund activities of or within a state, local or foreign government and all state, local or foreign government corporations.

 

Government Contract ” means any prime contract, grant, research or collaboration agreement, subcontract, purchase order, task order, delivery order, teaming agreement, joint venture agreement, strategic alliance agreement, basic ordering agreement, pricing agreement, letter contract or other similar arrangement of any kind that is currently active in performance, has been active in performance at any time in the five (5) year period prior to the Effective Time, or has not been closed-out under the procedures of the Governmental Agency responsible for administering the Government Contract as of the Effective Time, with (i) any Governmental Agency, (ii) any prime contractor of a Governmental Agency in its capacity as a prime contractor, or (iii) any subcontractor at any tier with respect to any contract of a type described in clauses (i) or (ii) above. A task, purchase or delivery order under a Government Contract shall not constitute a separate Government Contract, for purposes of this definition, but shall be part of the Government Contract to which it relates.

 

Government Contract Proposal ” shall mean any proposal, bid or quotation for awards of new Government Contracts made by the Company or any of its Subsidiaries for which no award has been made and any proposal, bid, request for equitable adjustment, contract change proposal, proposal for modification or indirect cost submission on any existing Government Contract.

 

Governmental Authority ” means any court, administrative or regulatory agency or commission, Government Agency or other governmental authority of competent jurisdiction.

 

Governmental Authorization ” means any approval, consent, license, permit, registration, certificate, waiver or other authorization issued, granted, given, or otherwise made available by or under the authority of any Governmental Authority or pursuant to any Law.

 

Hamner Institute ” means The Hamner Institutes of Health Sciences.

 

Holdback Release Date ” means the date that is eighteen (18) months following the Closing Date.

 

Indebtedness ” means with respect to any Person at any date, without duplication: (a) all obligations of such Person for borrowed money or in respect of loans or advances (other than customer prepayments or deposits characterized as short term liabilities under GAAP); (b) all obligations of such Person evidenced by bonds, debentures, notes or other similar instruments; (c) all obligations of such Person that are not characterized as short term liabilities under GAAP; (d) all obligations in respect of letters of credit, whether or not drawn, and bankers’ acceptances issued for the account of such Person; (e) all capitalized lease liabilities of such Person; (f) all interest rate protection agreements of such Person (valued on a market quotation basis); (g) all obligations of such Person secured by a contractual lien; (h) all guarantees of such Person in connection with any of the foregoing; (i) any debt-like obligation or financing-type arrangement in respect of the deferred purchase price of property or property received as of the Closing with respect to which such Person is liable, contingently or otherwise, as obligor or otherwise; (j) all earn-out obligations of such Person; and (k) any accrued interest, prepayment premiums or penalties or other costs or expenses related to any of the foregoing.

 

 

 

 

  60  

 

Independent Firm ” means Grant Thornton LLP or, if it is unable or unwilling to serve, another nationally recognized accounting firm mutually acceptable to Purchaser and the Shareholders’ Representative.

 

Intellectual Property Rights ” means any and all United States and foreign (a) patents and patent applications (including without limitation docketed patent disclosures awaiting filing, reissues, divisions, continuations, continuations-in-part and extensions), patent disclosures awaiting filing determination, inventions and improvements thereto, (b) trademarks, service marks, certification marks, trade name rights, trade dress, logos, business and product names, slogans, and registrations and applications for registration thereof, (c) copyrights (statutory or otherwise) and registrations thereof, (d) inventions, processes, designs, formulae, trade secret rights, know-how, industrial models, confidential, technical and business information, manufacturing, engineering and technical drawings, and product specifications, (e) intellectual property rights similar to any of the foregoing, (f) computer software, and (g) copies and tangible embodiments thereof (in whatever form or medium, including without limitation electronic media).

 

Interim Balance Sheet ” means the unaudited balance sheet of the Company dated as of the Interim Balance Sheet Date.

 

Interim Balance Sheet Date ” means December 31, 2016.

 

JAMS ” JAMS Arbitration, Mediation and ADR Services.

 

Knowledge ” or “ Company’s Knowledge ” means the knowledge of any of the officers, directors or shareholders of the Company, including the Shareholders, after making due inquiry of all officers and other employees charged with administrative or operational responsibility of such matters, or that an ordinary and prudent business Person employed in the same capacity in the same type and size of business as such individual would reasonably be expected to have knowledge of such fact or other matter.

 

Law ” or “ Laws ” means any law, statute, code, ordinance, regulation, rule or other binding obligation or requirement of any Governmental Agency or Governmental Authority.

 

Licensed Intellectual Property ” means Intellectual Property Rights licensed to the Company or which the Company has the right to use, including Off-the-Shelf Software.

 

“Liens ” means any charge, Claim, community property interest, condition, equitable interest, lien, option, pledge, security interest, right of first refusal, easement, deed of trust, mortgage, right-of-way, encroachment, conditional sales agreement, or any other right or adverse claim of any third party of any nature whatsoever, whether voluntarily incurred or arising by operation of Law, or restriction of any kind, including any restriction on use, voting, transfer, receipt of income, or exercise of any other attribute of ownership, and including, without limitation, any Contract to give any of the foregoing in the future; the term “Lien” does not include statutory liens for Taxes not yet due and payable.

 

 

 

 

  61  

 

Losses ” means (whether or not involving a third-party claim) any cost, loss, liability, obligation, damage (including incidental, special, punitive and consequential damages), expense, loss of profit or diminution in value, interest, penalties, compliance costs, costs of mitigation, reasonable attorney’s fees and amounts paid in investigation, defense or settlement of any of the foregoing.

 

Material Adverse Effect . ” When used in connection with the Company, or Purchaser or any of its subsidiaries, as the case may be, the term “Material Adverse Effect” means any change, effect or circumstance that is materially adverse to the business, assets, condition (financial or otherwise) or results of operations of the Company, or Purchaser and its subsidiaries, as the case may be, in each case taken as a whole .

 

Majority Shareholders ” means the following Shareholders: (i) Brett Howell; (ii) Lisl Shoda; (iii) Scottington Siler; (iv) Paul Watkins; and (v) Jeffrey Woodhead.

 

NDA ” means that certain Confidentiality and Nondisclosure Agreement dated September 12, 2016 between Purchaser and the Company.

 

Net Working Capital ” means the difference between: (a) the sum of the Company’s tangible current assets determined under GAAP (including, for purposes of clarity, cash, accounts receivable and prepaid items determined under GAAP); and (b) the sum of the Company’s current liabilities determined under GAAP, including but not limited to, accounts payable, deferred revenue (current), accrued expenses, bonus accruals, balance sheet adjustments, lease obligation (current) and accrual for tax liability, provided that “Net Working Capital” shall (x) include at least Five Hundred Thousand Dollars ($500,000) of cash, and (y) exclude deferred tax assets and liabilities.

 

Off-the-Shelf Software ” means unmodified, generally available, commercial, off-the-shelf software or other non-material shrink wrap or downloadable software or software as a service software available to Purchaser on nondiscriminatory terms and conditions used in the operation of the business of the Company.

 

Order ” means any order, judgment, ruling, injunction, assessment, award, decree, writ or other binding decision of any Governmental Authority or Government Agency.

 

Person ” means an individual, corporation, partnership, limited liability company, association, joint venture, trust, unincorporated organization, other entity or group (as defined in Section 13(d)(3) of the Exchange Act);

 

 

 

 

  62  

 

Pro Rata Portion ” means with respect to each Shareholder, the percentage obtained by dividing (a) the number of shares of Company Common Stock owned by such Shareholder immediately prior to the Effective Time, by (b) the number of Purchased Shares.

 

Securities Act ” means the Securities Act of 1933, as amended.

 

Subsidiary ” means, with respect to any Person, any corporation of which a majority of the total voting power of shares of stock entitled (without regard to the occurrence of any contingency) to vote in the election of directors, managers or trustees thereof is at the time owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of such Person or a combination thereof, or any partnership, association or other business entity of which a majority of the partnership or other similar ownership interest is at the time owned or controlled, directly or indirectly, by such Person or one or more Subsidiaries of such Person or a combination thereof. For purposes of this definition, a Person is deemed to have a majority ownership interest in a partnership, association or other business entity if such Person is allocated a majority of the gains or losses of such partnership, association or other business entity or is or controls the managing director or general partner of such partnership, association or other business entity.

 

Target Net Working Capital ” means Two Hundred Fifty Thousand Dollars ($250,000).

 

Tax ” or “ Taxes ” means (a) any federal, state, local, or foreign income, gross receipts, gross margin, license, payroll, employment, excise, severance, stamp, occupation, premium, windfall profits, environmental (including taxes under Code Section 59A), customs duties, capital stock, franchise, profits, withholding, social security (or similar excises), unemployment, disability, ad valorem, real property, personal property, sales, use, transfer, registration, value added, alternative or add-on minimum, estimated, or other tax of any kind whatsoever, including any interest, penalty, or addition thereto, whether disputed or not, by any Governmental Authority responsible for imposition of any such tax (domestic or foreign), (b) in the case of the Company, liability for the payment of any amount of the type described in clause (a) as a result of being or having been on or before the Closing Date a member of an affiliated, consolidated, combined or unitary group, or a party to any agreement or arrangement, as a result of which liability of the Company to a Governmental Authority is determined or taken into account with reference to the liability of any other Person, and (c) liability of the Company for the payment of any amount as a result of being party to any Tax Sharing Agreement or with respect to the payment of any amount of the type described in (a) or (b) as a result of any existing express or implied obligation (including an indemnification obligation).

 

Tax Return ” means any return, declaration, disclosure, election, schedule, estimate, report, claim for refund, estimates or information return or statement relating to Taxes, including any schedule or attachment thereto, and including any amendment thereof.

 

Tax Sharing Agreement ” means all existing agreements or arrangements (whether or not written) binding the Company that provide for the allocation, apportionment, sharing or assignment of any Tax liability or benefit, or the transfer or assignment of income, revenues, receipts or gains for the principal purpose of determining any Person’s Tax liability.

 

 

 

 

  63  

 

Termination Liability ” means all Losses incurred by Purchaser or the Company as a result of the assignment or termination of employees or consultants of the Company at Closing with respect to periods on or prior to the Closing Date, including severance, outplacement, vacation pay, salary, commissions and benefits for periods prior to the Closing Date, claims of wrongful termination, age, race or sex discrimination or the like, liability under WARN, COBRA and state benefits continuation Laws, and any Taxes or penalties payable with respect to any of the foregoing payments or liabilities.

 

Transaction Documents ” means this Agreement, the Shareholder Release, the Non-Competition Agreement and other each agreement, document, instrument or certificate contemplated by this Agreement or to be executed by Purchaser, the Company or the Shareholders in connection with the consummation of the Contemplated Transactions, in each case only as applicable to the relevant party or parties to such Transaction Documents, as indicated by the context in which such term is used.

 

Transaction Expenses ” means, solely to the extent not paid prior to Closing, (a) the aggregate amount of all fees and expenses incurred by the Shareholders at any time, or the Company prior to the Closing, regardless of when payable (including the fees and expenses of any legal counsel, accountant, auditor, broker, financial advisor or consultant retained by or on behalf of the Shareholder or the Company), arising from, relating to or in connection with this Agreement, the Transaction Documents and/or the Contemplated Transactions, it being understood and agreed that all fees and expenses of Dixon Hughes Goodman, LLP related to the Company’s 2016 audit shall be deemed Transaction Expenses for purposes of this Agreement, and (b) any other fees and expenses of the Company and/or the Shareholders to be paid at Closing as set forth in the Transaction Expense Schedule.

 

WARN ” means the Worker Adjustment and Retraining Notification Act of 1988, as amended, and each similar state, local or foreign Law or regulation.

 

Section 9.18 Rules of Construction . This Agreement shall be construed in accordance with the following rules of construction:

 

(a)        the terms defined in this Agreement include the plural as well as the singular;

 

(b)        all references in the Agreement to designated “ Articles ,” “ Sections ” and other subdivisions are to the designated articles, sections and other subdivisions of the body of this Agreement;

 

(c)        pronouns of either gender or neuter shall include, as appropriate, the other pronoun forms;

 

(d)        the words “herein,” “hereof” and “hereunder” and other words of similar import refer to this Agreement as a whole and not to any particular Article, Section or other subdivision;

 

(e)        the words “includes” and “including” are not limiting;

 

 

 

 

  64  

 

(f)        all references to days shall be deemed to refer to calendar days unless this Agreement specifically refers to Business Days;

 

(g)        the terms “made available,” “delivered” and “provided to” when used in reference to the Company and/or the Shareholders’ Representative having made or making items or information available to, or to having provided information to, Purchaser or Transaction Sub, shall mean that such items or information were (i) posted prior to the date hereof to the Company Data Site including the secured folders located therein; and

 

(h)        reference to any Law means as amended, modified, codified, replaced or re-enacted, in whole or in part, and in effect on the date hereof, including rules, regulations, enforcement procedures and any interpretations promulgated thereunder.

 

[SIGNATURES BEGIN ON FOLLOWING PAGE]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  65  

 

 

IN WITNESS WHEREOF , the parties hereto have caused this Stock Purchase Agreement to be duly executed as of the day and year first above written.

 

SIMULATIONS PLUS, INC.

 

 

By: /s/ Walter S. Woltosz

Walter S. Woltosz, Chairman & CEO

 

 

DILISYM SERVICES, INC.

 

 

By: /s/ Brett A. Howell

Brett A. Howell, CEO

 

 

SHAREHOLDERS:  
   

/s/ Brett A. Howell

Brett A. Howell

/s/ Bud M. Nelson

Bud M. Nelson

   

/s/ Grant Generaux

Grant Generaux

/s/ Lisl Shoda

Lisl Shoda

   

/s/ Diane Longo

Diane Longo

/s/ Scottington Siler

Scottington Siler

   

Paul Watkins

Paul Watkins

/s/ Jeffrey Woodhead

Jeffrey Woodhead

   
   
   

SHAREHOLDERS REPRESENTATIVE:

 

/s/ Brett A. Howell

Brett A. Howell

 

 

 

  66  

 

 

COMPANY DISCLOSURE SCHEDULE

[TO FOLLOW]

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

     

 

 

EXHIBIT A

 

FORM OF NON-COMPETITION AGREEMENT

 

[ATTACHED]

 

 

 

 

 

 

 

 

 

 

     

 

 

NON-COMPETITION AGREEMENT

 

This Non-Competition Agreement (this “ Agreement ”) is dated June 1, 2017 (the “ Closing Date ”), by and among (i) Simulations Plus, Inc., a California corporation (“ Purchaser ”), and (ii) the shareholders of DILIsym Services, Inc., a North Carolina corporation (the “ Company ”) listed on the signature pages hereto (together the “ Shareholders ”, and each a “ Shareholder ”). Each of the foregoing parties shall be referred to separately herein as a “ Party ” and together as the “ Parties ”.

 

RECITALS

 

WHEREAS, pursuant to the terms and subject to the conditions set forth in that certain Stock Purchase Agreement dated May 1, 2017 (the “ Purchase Agreement ”) among the Company, Purchaser, the Shareholders, and Brett A. Howell as the Shareholders’ Representative, Purchaser shall acquire all of the Company’s outstanding capital stock from the Shareholders (the “ Transaction ”);

 

WHEREAS, the Shareholders are shareholders of the Company and are selling all of their equity interests in the Company;

 

WHEREAS, in order to induce Purchaser to enter into the Purchase Agreement and to protect adequately its interests, it is essential that the Shareholders have agreed to enter into this Agreement in consideration of the transactions contemplated by, and pursuant to Section 6.2(f) of the Purchase Agreement;

 

WHEREAS, this Agreement is integral to the transactions contemplated by the Purchase Agreement, and it is acknowledged and agreed that the Purchaser would not consummate such transactions (or pay the consideration specified in the Purchase Agreement) absent the Shareholders’ execution and delivery of this Agreement, and this Agreement being in full force and effect and valid, binding and enforceable against the Shareholders as of the Closing Date and thereafter, as set forth below;

 

WHEREAS, for the avoidance of doubt, (i) the Shareholders are not entering into this Agreement in his or her capacity as an employee of the Company, and (ii) each of the Shareholders enter into this Agreement in connection with, and ancillary to, the sale of the Company; and

 

WHEREAS, the Parties acknowledge and agree that the restrictive covenants below shall be construed in the sale of business context, including, but not limited to, the Prohibited Activities covenant set forth in Section 4 below.

 

NOW, THEREFORE, in consideration of the premises set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:

 

 

  A- 1  

 

 

AGREEMENT

 

1.       Definitions . Capitalized terms not expressly defined in this Agreement shall have the meanings ascribed to them in the Purchase Agreement.

 

(a)        The term “ Confidential Information ” means all of the confidential and proprietary information of the Company and its Affiliates existing as of the date hereof and/or hereafter acquired by the Purchaser pursuant to the Transaction, including all information and compilations of information of any kind, type or nature (tangible and intangible, written or oral, and including information contained, stored or transmitted through any electronic medium) relating to the financial conditions, results of operations, business, properties, assets, liabilities or future prospects of the Company, special arrangements regarding the pricing and purchase of products or services including proprietary methods, cost information, customer and potential customer lists and contact information, pricing and volume by customer, customer preferences, supplier information, agency and contractor relationships and contact information, sales and profit information, goodwill, any other Trade Secrets, including information concerning services and products, developments, techniques, processes, formulae, know-how, systems, new service, product and marketing plans, inventions, discoveries, patent applications, ideas, designs, drawings, test data, computer programs, software (including object code and source code), databases, technologies, systems, structures and architectures, methods, research, procurement and sales activities and procedures, promotion and pricing techniques and credit and financial data concerning customers and potential customers of the Company as well as information relating to the management operation or planning of the business of the Company, and technical proprietary information and any other intangible assets whether communicated orally, electronically, in writing or in any other tangible media. Notwithstanding the foregoing, Confidential Information shall not include, and nondisclosure and nonuse obligations under this Agreement shall not apply to, information that is generally available to the public in the ordinary course of business of the Company.

 

(b)        The term “ Trade Secrets ” means all of the information of the Company existing as of the date hereof and/or hereafter acquired by the Company or the Purchaser pursuant to the Transaction, and information of the licensors, suppliers, clients, vendors, and customers of Company, without regard to form, including, but not limited to, technical or nontechnical data, a formula, a pattern, a compilation, a program, a device, a method, a technique, a drawing, a process, financial data, financial plans, product plans, a list of actual customers, clients, licensors, or suppliers, or a list of potential customers, clients, licensors, or suppliers, and which such information (i) derives independent economic value, actual or potential, from not being generally known to the public or to other persons who can obtain economic value from its disclosure or use; and (ii) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy.

 

 

 

  A- 2  

 

 

2.       Acknowledgments and Representations by Shareholders .

 

(a)       Acknowledgments. Shareholders acknowledge that:

 

(i)        the Purchaser has required that Shareholders make the covenants set forth in Sections 3 and 4 of this Agreement as a condition to the consummation of the transactions contemplated by the Purchase Agreement;

 

(ii)        but for the provision of the covenants set forth herein, Purchaser would not acquire all of the capital stock of the Company;

 

(iii)        the covenants contained herein are an integral, and not severable, material component of the basis of the consideration being paid by Purchaser which consideration would not have been agreed to by Purchaser but for the existence and enforceability of this Agreement;

 

(iv)        each Shareholder had the opportunity to be represented by counsel of his or her choice and based upon the advice of such counsel, if any, and other advisers, Shareholders have knowingly and willingly agreed to enter into and agree to the enforcement of this Agreement and the covenants herein contained;

 

(v)        the transactions contemplated by the Purchase Agreement and payment of the Purchase Price directly benefit the Shareholders and constitute sufficient consideration for the Shareholders to enter into this Agreement;

 

(vi)        the provisions of this Agreement are necessary to protect the goodwill and the business of the Company (all of which are being acquired by Purchaser) and that this Agreement and the covenants herein are necessary and reasonable in duration, scope and geographic territory to protect such business following the Transaction;

 

(vii)        prior to the Transaction, the Shareholders occupied a position of trust and confidence with the Company and have had access to and have become familiar with the Confidential Information and the Trade Secrets, all of which are being acquired by Purchaser; and

 

(viii)        Purchaser and the Company would be irreparably damaged if any Shareholder were to breach the covenants set forth in Sections 3 or 4 of this Agreement.

 

(b)       Representations . Shareholders represent and warrant (on which representation and warranty each Shareholder expressly acknowledges Purchaser is relying in determining the appropriate geographic area for purposes of the restrictive covenants herein set forth) that the Company currently carries on its business, and sells and offers for sale its products and/or services, in (i) the State of North Carolina, (ii) states bordering North Carolina, (iii) states east of the Mississippi River, and (iv) the United States of America, (the “ Restricted Territory ”):

 

 

 

 

  A- 3  

 

3.       Nondisclosure and Nonuse of Confidential Information and Trade Secrets .

 

(a)        Each of the Shareholders acknowledges and agrees that the Confidential Information and the Trade Secrets were the property of the Company prior to the Closing, and shall remain the property of the Company immediately following the Closing. None of the Shareholders shall do anything inconsistent with the ownership of the Confidential Information and the Trade Secrets by the Company and Purchaser. From and after the date of this Agreement, each of the Shareholders agrees that he or she will not, and will not permit any party acting on behalf of, in conjunction or association with, or at the direction of such Shareholder, at any time, disclose to any unauthorized Persons or use for his or her own account or for the benefit of any third Person, any Confidential Information or the Trade Secrets, whether such Shareholder has such information in his or her memory or embodied in writing or other physical or tangible form or media, without Purchaser’s and the Company’s express written consent, which may be withheld in the Purchaser’s and the Company’s sole discretion, unless (a) such Confidential Information and the Trade Secrets enters the public domain subsequent to the date hereof through no fault of a Shareholder and through no breach of confidentiality to Purchaser or the Company; or (b) the communication of such Confidential Information and the Trade Secrets is in response to a valid order by a Governmental Authority or is otherwise required by any applicable Law; provided , however , in the event that any Shareholder is legally compelled to disclose any of the Confidential Information and the Trade Secrets, Shareholder shall provide the Purchaser and the Company with immediate written notice of such requirement so that the Purchaser and the Company may seek a protective order or other appropriate remedy or waive compliance with this Section 3. If, failing the entry of a protective order, such Shareholder is, in the opinion of his or her counsel, compelled to disclose any Confidential Information and the Trade Secrets, he or she may disclose only that portion of the Confidential Information and the Trade Secrets that his or her counsel advises is compelled to be disclosed by Law and such Shareholders will exercise reasonable efforts to obtain assurance that confidential treatment will be accorded to that portion of the Confidential Information and the Trade Secrets that is being disclosed. In any event, no Shareholder will oppose action by the Purchaser or the Company to obtain an appropriate protective order or other reliable assurance that confidential treatment will be accorded the Confidential Information and the Trade Secrets. Each Shareholder agrees to use commercially reasonable efforts, upon request from time to time, to locate and provide to the Purchaser and the Company such specific items of Confidential Information and the Trade Secrets that may be reasonably requested by the Purchaser or the Company from time to time, whether embodied in electronic, hard copy or any other form, that Shareholders may then possess or have under a Shareholder’s control.

 

(b)        The obligations under this Agreement shall: (i) with regard to the Trade Secrets, remain in effect as long as the information constitutes a trade secret under applicable Law; and (ii) with regard to the Confidential Information, remain in effect for so long as such information constitutes Confidential Information as defined in this Agreement.

 

(c)        The confidentiality, property, and proprietary rights protections available in this Agreement are in addition to, and not exclusive of, any and all other rights to which the Purchaser is entitled under applicable federal and state law, including, but not limited to, rights provided under copyright laws, trade secret and confidential information laws, and laws concerning fiduciary duties.

 

 

 

 

  A- 4  

 

4.       Prohibited Activities . As an inducement for Purchaser to consummate the transactions contemplated in the Purchase Agreement, each of the Shareholders, to the extent provided in this Agreement, agrees with respect to his or herself that:

 

(a)        For a period of four (4) years after the Closing Date (the “ Restricted Term ”):

 

(i)        Each of the Shareholders will not, and will not permit any party acting on behalf of, in conjunction or association with, or at the direction of such Shareholder to, directly or indirectly, in any market area in the Restricted Territory, engage or invest in, own, manage, operate, develop, consult, finance, control or participate in any manner in the ownership, management, operation, financing or control of, or lend money or credit to any business whose products, services or activities compete, directly or indirectly, with the Company as of the Closing Date, including, but not limited to, the business of Purchaser and its Subsidiaries (collectively, the “ Business ”); provided, however, that any Shareholder may purchase or otherwise acquire up to (but not more than) one percent (1%) of any class of securities of any enterprise (but without otherwise participating in the activities of such enterprise) if such securities are listed on any national or regional securities exchange or have been registered under Section 12(g) of the Securities Exchange Act of 1934, as amended, provided , further , that no Shareholder, in any way, participates, either directly or indirectly, in the management, operation or other activities of such enterprise, whether as a consultant, employee, officer, director, advisor, board member or otherwise. Notwithstanding, this subsection 4(a)(i) shall not prevent any Shareholder from having such a position with, or providing services to, a business described above if such position and services are in no way similar to the position Shareholder previously held with, or the services previously provided to, the Company, and further that such position and such services do not assist the business in competing with the Company.

 

(ii)        Each of the Shareholders will not, and will not permit any party acting on behalf of, in conjunction or association with, or at the direction of such Shareholder to, directly or indirectly, either for themselves or any other Person, (a) induce or attempt to induce any employee, independent contractor, or other Persons providing services to the Company prior to the Closing to leave the employ of the Company or its Affiliates or to cease providing services to the Company or its Affiliates (including Purchaser), (b) in any way interfere with the relationship between the Company or its Affiliates (including Purchaser) and any employee or independent contractor of the Company or its Affiliates prior to the Closing or any other Person providing services to the Company or its Affiliates prior to the Closing, (c) employ or otherwise engage or hire (including participating in the interviewing, selecting, recruiting, screening, hiring, training or on-boarding) as an employee, independent contractor or otherwise, any employee or independent contractor of the Company or its Affiliates or any Person who has been such an employee or independent contractor of the Company or its Affiliates within the six (6) months preceding the Closing Date, or (d) induce or attempt to induce any customer, supplier, licensee or business relation of the Company or its Affiliates prior to the Closing to cease doing business with the Company or its Affiliates (including the Purchaser) or in any way interfere with the relationship between any customer, supplier, licensee or business relation of the Company or its Affiliates prior to the Closing and the Purchaser or its Affiliates.

 

(iii)        Each of the Shareholders will not, and will not permit any party acting on behalf of, in conjunction or association with, or at the direction of such Shareholder to, directly or indirectly, either for themselves or any other Person, solicit the business of, or contact or engage in business with, any Person known to such Shareholder to be a customer of the Company within the one year period prior to the Closing or included on any customer list of the Company or its Affiliates as of the Closing with respect to services or products that compete in any respect with the Business of the Company or any of its Affiliates prior to the Closing.

 

 

 

 

  A- 5  

 

(iv)        Each Shareholder agrees that the restrictions set forth above are ancillary to or part of otherwise enforceable agreements, are supported by independent valuable consideration, and that the limitations as to time, geographical area, and scope of activity to be restrained by this Section 4 are reasonable and acceptable in all respects, do not impose any greater restraint than is reasonably necessary to protect the goodwill and other business interests of the Company acquired by the Purchaser in the Transaction, and are more than adequately paid for in the significant consideration derived by the Shareholders under the Purchase Agreement. Each Shareholder ratifies the restrictions set forth in this Section 4, agrees not to challenge, and covenants not to sue the Company or Purchaser regarding, the enforceability of the covenants stated herein.

 

(b)        The Parties agree that, if for any reason a court disagrees with the agreements and the acknowledgements of the Parties in this Agreement, the court will have jurisdiction to modify any of the covenants of this Section 4 in accordance with the respective court’s ruling as to reasonableness or scope of application and that, consistent with Section 7 of this Agreement, this Agreement shall remain enforceable and in force as modified or amended, including the power to reduce or delete specific words and phrases by “blue penciling” or otherwise and the reduced or blue penciled form of such provision shall then be enforceable by law. In the event of a breach by any Shareholder of any covenant set forth in Section 4(a) of this Agreement, the term of such covenant will be extended by the period of the duration of such breach. Each of the Shareholder’s obligations under this Section 4 shall survive the closing of the transactions contemplated by the Purchase Agreement for the Restricted Term.

 

(c)        The covenants of the Shareholders contained in this Section 4 will be construed as independent of any other provision in this Agreement, the Purchase Agreement, or any Transaction Documents, and the existence of any claim or cause of action by a Shareholder against the Purchaser or the Company will not constitute a defense to the enforcement by the Company or Purchaser of such covenants. Each Shareholder further agrees that notwithstanding any other alleged breach of this Agreement, the provisions of this Section 4 will be valid and binding upon each Shareholder.

 

5.       Nondisparagement . During the Restricted Term, each of the Shareholders agrees that such Shareholder will not disparage or make negative statements (or induce or encourage others to disparage or make negative statements) about the Company, the Company’s products and/or services, Purchaser or any of their past or present officers, directors, agents, employees, attorneys, successors and assigns (as applicable), including, without limitation, criticizing such Person’s business strategy. For the purposes of this Agreement, the term “disparage” means any comments or statements, written or verbal, that are derogatory or which would adversely affect in any manner: (i) the conduct of the Purchaser’s or Company’s business; (ii) the business reputation or relationships of the Purchaser or Company and/or any of either of their past or present officers, directors, agents, employees, attorneys, successors and assigns (as applicable); or (iii) the reputation or merchantability of any of the Purchaser’s or Company’s products and/or services.

 

 

 

  A- 6  

 

 

6.       Remedies . If any Shareholder breaches the covenants set forth in Sections 3 or 4 of this Agreement, Purchaser and the Company will be entitled to seek all of the following remedies:

 

(a)        Damages from such Shareholder;

 

(b)        Injunctive or other equitable relief with respect to such Shareholder without posting bond to restrain any breach or threatened breach or otherwise to specifically enforce the provisions of Sections 3 or 4 of this Agreement, it being agreed that money damages alone would be inadequate to compensate Purchaser and/or the Company and would be an inadequate remedy for such breach; and/or

 

(c)        Any other rights Purchaser and/or the Company may have at law, in equity or under contract with respect to such Shareholder.

 

The rights and remedies of the Parties to this Agreement are cumulative and not alternative.

 

7.       Independent Enforcement. Each of the covenants set forth in Sections 3, 4 and 5 of this Agreement shall be construed as agreements independent of (a) any other agreements, or (b) any other provision in this Agreement, and the existence of any claim or cause of action by the Shareholders against the Purchaser, whether predicated on this Agreement or otherwise, regardless of who was at fault and regardless of any claims that either the Shareholders or the Purchaser may have against the other, shall not constitute a defense to the enforcement by the Purchaser of any of the covenants set forth in Sections 3, 4 and 5 of this Agreement. The Purchaser shall not be barred from enforcing any of the restrictive covenants set forth in Sections 3, 4 and 5 of this Agreement by reason of any breach of (i) any other part of this Agreement, or (ii) any other agreement with the Shareholders.

 

8.       Severability . Whenever possible each provision and term of this Agreement will be interpreted in a manner to be effective and valid, but if any provision or term of this Agreement is held to be prohibited or invalid, then such provision or term will be ineffective only to the extent of such prohibition or invalidity, without invalidating or affecting in any manner whatsoever the remainder of such provision or term or the remaining provisions or terms of this Agreement. If any of the covenants set forth in Section 4 of this Agreement are held to be unreasonable, arbitrary, against public policy or otherwise unenforceable as written, such covenants will be considered divisible with respect to time, geographic area, and scope of activity to be restrained and in such lesser time, geographic area, and scope of activity to be restrained will be effective, binding, enforceable and in force against Shareholders.

 

9.       Successors and Assigns . This Agreement will be binding upon Purchaser and the Shareholders and will inure to the benefit of Purchaser, the Company and the Shareholders and their respective successors and assigns. This Agreement may be assigned by the Purchaser to (i) its Affiliates, and (ii) its successors by merger, consolidation, business combination, conversion or sale of all or substantially all of the Purchaser’s assets, but may not be assigned by any of the Shareholders.

 

 

 

 

  A- 7  

 

10.       Waiver . Neither the failure nor any delay by any party in exercising any right, power or privilege under this Agreement will operate as a waiver of such right, power or privilege, and no single or partial exercise of any such right, power or privilege will preclude any other or further exercise of such right, power or privilege or the exercise of any other right, power or privilege. To the maximum extent permitted by applicable Laws, (a) no claim or right arising out of this Agreement can be discharged by one party, in whole or in part, by a waiver or renunciation of the claim or right unless in writing signed by the other party; (b) no waiver that may be given by a party will be applicable, except in the specific instance for which it is given; and (c) no notice to or demand on one party will be deemed to be a waiver of any obligation of such party or of the right of the party giving such notice or demand to take further action without notice or demand as provided in this Agreement.

 

11.       Governing Law; Jurisdiction . This Agreement shall be construed and enforced in accordance with the internal laws of the State of North Carolina without regard to any conflicts or choice of law principles that would require the application of the laws other than the internal laws of the State of North Carolina. The parties (a) hereby irrevocably submit to the jurisdiction of the state courts of North Carolina, and to the jurisdiction of the United States District Court for the Eastern District of North Carolina, for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement or any document collateral hereto or the subject matter hereof or thereof brought by any party or their respective successors or assigns and (b) hereby waive, and agree not to assert, by way of motion, as a defense or otherwise, in any such suit, action or proceeding, any claim that it is not subject personally to the jurisdiction of the above-named courts, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper, or that this Agreement or any document collateral thereto or the subject matter hereof or thereof may not be enforced in or by such court, and (c) hereby waive and agree not to seek any review of the decision of a North Carolina state or federal court by any court of any other jurisdiction that may be called upon to grant enforcement of the judgment of any such North Carolina state or federal court. Notwithstanding, Purchaser and the Company may seek injunctive relief (as described in Subsection 6(b)) in any other appropriate venue.

 

12.       Entire Agreement . This Agreement, the Purchase Agreement and any ancillary agreements or related agreements thereto constitute the entire agreement between the parties with respect to the subject matter of this Agreement and supersede all prior written and oral agreements and understandings between Purchaser, the Company and Shareholders with respect to the subject matter of this Agreement. This Agreement may not be amended, except by a written agreement executed by the party to be charged with the amendment.

 

13.       Counterparts . This Agreement may be executed in counterparts (including by facsimile or e-mailed Adobe® portable document format file), all of which shall constitute one document, and that by the signature(s) hereto, the undersigned further agree that facsimile or e-mailed Adobe® portable document format file signatures shall be effective for all purposes.

 

14.       Section Headings; Construction . The headings of Sections in this Agreement are provided for convenience only and will not affect its construction or interpretation. All references to “Section” or “Sections” refer to the corresponding Section or Sections of this Agreement unless otherwise specified. All words used in this Agreement will be construed to be of such gender or number as the circumstances require. Unless otherwise expressly provided, the words “including” and “includes” do not limit the preceding words or terms.

 

 

 

  A- 8  

 

 

15.       Notices . All notices, consents, waivers and other communications under this Agreement must be in writing and will be deemed to have been duly given when (a) delivered by hand (with written confirmation of receipt), (b) sent by facsimile (with written confirmation of receipt), provided that a copy is mailed by registered mail, return receipt requested, or (c) when received by the addressee, if sent by a nationally recognized overnight delivery service (receipt requested), in each case to the appropriate addresses and facsimile numbers set forth below (or to such other addresses and facsimile numbers as a party may designate by notice to the other parties):

 

 

 

If to Purchaser (and the Company following the Closing):

 

 

 

 

 

Walter S. Woltosz

Chief Executive Officer

Simulations Plus, Inc.

42505 10 th St W

Lancaster, CA 93534-7059

Facsimile No.:

 

 

with a copy (which shall not constitute notice) to:

 

 

 

Procopio, Cory, Hargreaves & Savitch LLP

12544 High Bluff Drive, Suite 300

San Diego, CA 92130

Attn: Dennis J. Doucette

Facsimile No.: (858) 523-4305

 

   

If to a Shareholder:

 

 

 

 

 

To his or her respective address listed on the signature page hereto

 

 

with a copy (which shall not constitute notice) to:

 

 

 

Amalie L. Tuffin

Hutchison PLLC

3110 Edwards Mill Road, Suite 300

Raleigh, NC 27612

Facsimile No.: (855) 373-3417

 

 

16.       No Third Party Beneficiaries . No person, firm or corporation other than the Purchaser and Shareholders shall have any rights under this Agreement or the provisions contained herein.

 

17.       Attorneys’ Fees . In the event of litigation relating to this Agreement, the prevailing party, shall be entitled to recover reasonable attorneys’ fees and costs of litigation in addition to all other remedies available at law or in equity, as determined by the court or arbitrator in accordance with N.C. Gen. Stat. § 6-21.6. The parties to this Agreement hereby acknowledge this Agreement is a contract entered into primarily for business or commercial purposes.

 

 

 

  A- 9  

 

 

18.       Individual Liability . The liability for breach of this Agreement by any Shareholder shall be attributable to that individual Shareholder only and no other Shareholder shall have any responsibility therefore unless such Shareholder is independently in breach of this Agreement.

 

19.       Shareholders’ Representative . Nothing in this Agreement shall be construed to prevent or impair a Shareholder, if serving as the Shareholders’ Representative under the Purchase Agreement, from satisfying all of such Shareholder’s duties as such Shareholder Representative (which may require disclosing Confidential Information to counsel in such capacity).

 

( The remainder of this page intentionally left blank/Signature page follows )

 

 

 

 

 

 

 

  A- 10  

 

 

IN WITNESS WHEREOF, the parties have executed and delivered this Agreement as of the date first above written.

 

SHAREHOLDERS:

 

____________________________________

Grant Generaux

Address:

 

____________________________________

Brett Howell

Address:

 

___________________________________

Diane Longo

Address:

 

____________________________________

M. Bud Nelson

Address:

 

____________________________________

Lisl Shoda

Address:

 

____________________________________

Scottington Siler

Address:

 

___________________________________

Paul Watkins

Address:

 

____________________________________

Daniel Weiner

Address:

 

___________________________________

Jeffrey Woodhead

Address:

 

____________________________________

Kyunghee Yang

Address:

 

 

PURCHASER:

 

SIMULATIONS PLUS, INC.

 

 

By: ______________________________________________

Walter S. Woltosz, CEO

 

 

 

 

[Signature page to Non-Competition Agreement]

  A- 11  

 

 

 

EXHIBIT B

 

FORM OF GENERAL RELEASE OF CLAIMS

 

[ATTACHED]

 

 

 

 

     

 

 

 

GENERAL RELEASE

 

This General Release is made and entered into as of June 1, 2017 (this “ Release ”), by and among (i) DILIsym Services, Inc., a North Carolina corporation (the “ Company ”), and (ii) each of the shareholders of the Company (each, a “ Shareholder ” and collectively, the “ Shareholders ”). Each of the foregoing parties shall be referred to separately herein as a “ Party ” and together as the “ Parties ”.

 

RECITALS

 

WHEREAS, pursuant to the terms and subject to the conditions set forth in that certain Stock Purchase Agreement dated May 1, 2017 (the “ Purchase Agreement ”) among the Company, Simulations Plus, Inc., a California corporation (“ Purchaser ”), the Shareholders and Brett A. Howell in the capacity as Shareholders’ Representative, Purchaser shall acquire all of the Company’s outstanding ownership interests from the Shareholders (the “ Transaction ”);

 

WHEREAS, the Shareholders are the sole shareholders of the Company and are selling all of the outstanding equity interests of the Company;

 

WHEREAS, in order to induce Purchaser to enter into the Purchase Agreement and to protect adequately the interests of the Purchaser, it is essential that the Shareholders have agreed to enter into this Agreement in consideration of the transactions contemplated by, and pursuant to Section 6.2(s)(v) of the Purchase Agreement; and

 

WHEREAS, this Agreement is integral to the transactions contemplated by the Purchase Agreement, and it is acknowledged and agreed that the Purchaser would not consummate such transactions (or pay the consideration specified in the Purchase Agreement) absent the Shareholders’ execution and delivery of this Agreement, and this Agreement being in full force and effect and valid, binding and enforceable against the Shareholders as of the Closing Date and thereafter, as set forth below.

 

NOW, THEREFORE, for good and valuable consideration, including the covenants contained herein and for the Parties’ participation in the Transaction and the resulting payment of the purchase price thereunder to the Shareholders, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:

 

AGREEMENT

 

1.       Definitions. Capitalized terms used but otherwise not defined herein shall have the meanings ascribed to them in the Purchase Agreement.

 

2.       Release . The Shareholders on behalf of themselves (and for their successors, assigns, agents, spouse (if any), predecessors, heirs, relatives, executors, administrators and representatives), hereby irrevocably and unconditionally release and forever discharge the Company and the Company’s Affiliates (including Purchaser) and each of their respective past, present or future officers, directors, employees, members, managers, stockholders, representatives, predecessors, successors, assigns (individually, each a “ Released Party ” and collectively, the “ Released Parties ”), of and from any and all proceedings, demands, rights, causes, causes or manners of action, suits, obligations, liabilities, debts, sums of money, accounts, bills, dues, covenants, undertakings, promises, contracts, agreements, charges, complaints, controversies, grievances, damages, judgments, actions, claims, losses, costs or expenses of any kind whatsoever (including related attorneys’ fees and costs), known or unknown, suspected or unsuspected, matured, unmatured or contingent, potential or direct, at law or in equity, whether based in statute, common law or otherwise, that Shareholders may now have or have ever had against the Released Parties or any of them by reason of any act, omission, transaction, or event occurring up to and including the consummation of the Transaction on the date of this Release (the “ Claims ”); but excluding any rights of any Shareholders (including their successors, assigns, and representatives) under the Purchase Agreement and the Transaction Documents.

 

 

  B- 1  

 

 

3.       Section 1542 Release . The Shareholders acknowledge that there is a possibility that subsequent to the execution of this Release, the Shareholders will discover facts or incur or suffer Claims that were unknown or unsuspected at the time this Release was executed, and which if known by the Shareholders at that time may have materially affected the Shareholders’ decision to execute this Release. The Shareholders acknowledge and agree that by reason of this Release, and the releases contained herein, the Shareholders are assuming any risk of such unknown facts and such unknown and unsuspected Claims. The Shareholders have been advised of the existence of Section 1542 of the California Civil Code (“ Section 1542 ”) which provides:

 

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.

 

Notwithstanding such provisions, this Release shall constitute a full release in accordance with its terms. The Shareholders hereby knowingly and voluntarily waive the provisions of Section 1542, as well as any other statute, law or rule of similar effect.

 

4.       No Assignment of Claims . The Shareholders represent to the Released Parties that the Shareholders have made no assignment or transfer of any of the Claims herein above mentioned or implied.

 

5.       Bar To Claims . In signing this Release, the Shareholders acknowledge and intend that this Release shall be effective as a bar to each and every one of the Claims herein above mentioned or implied. The Shareholders expressly consent that this Release shall be given full force and effect according to each and all of its express terms and provisions, including those relating to unknown and unsuspected Claims (notwithstanding any state statute that expressly limits the effectiveness of a general release of unknown, unsuspected or unanticipated Claims), if any, as well as those relating to any other Claims herein above mentioned or implied. The Shareholders acknowledge and agree that this waiver is an essential and material term of this Release and that without such waiver the Purchaser would not have agreed to consummate the transactions contemplated by the Purchase Agreement. The Shareholders further agree that in the event any of them should assert any Claim seeking damages against any of the Released Parties, this Release shall serve as a complete defense to any such Claim. The Shareholders further agree that there does not exist any Claim of the type described in or implied by the first paragraph hereof and they are not aware of any pending or threatened Claims of the type described in or implied by the first paragraph hereof.

 

 

 

  B- 2  

 

 

6.        Covenant Not to Sue . The Shareholders further agree not to bring, continue or maintain any claim or legal proceeding against any Released Party before any court, administrative agency or other forum by reason of any Claim hereby released. If any agency or court assumes jurisdiction of any Claim released hereby against any Released Party, the Shareholders will direct that agency or court to withdraw from or dismiss the matter with prejudice. The Shareholders also agree that if any Shareholder violates this Release by suing a Released Party with respect to any Claim hereby released, the Shareholders will pay all costs and expenses of defending against the suit incurred by any Released Party, including reasonable attorney’s fees.

 

7.        No Admission . The Shareholders agree that neither this Release, nor the furnishing of the consideration for this Release, shall be deemed or construed at any time to be an admission by any Released Party or the Shareholders of any improper or unlawful conduct.

 

8.        Certain Acknowledgements . In connection with execution of this Release, each of the Shareholders acknowledges, understands and agrees that such Shareholder:

 

(a) Has carefully read and fully understands all of the provisions of this Release and the Purchase Agreement, and has had the opportunity to discuss the same and its consequences with his or her attorneys;

 

(b) Is, through this Release, releasing the Released Parties from any and all Claims the Shareholder may have against the Released Parties;

 

(c) Knowingly and voluntarily agrees to all the terms set forth in this Release;

 

(d) Knowingly and voluntarily intends to be legally bound by this Release;

 

(e) Was advised and is hereby advised in writing to consult with an attorney of his or her choice prior to executing this Release concerning its meaning and application; and

 

(f) Agrees that the provisions of this Release may not be amended, waived, changed or modified except by an instrument in writing signed by the Parties.

 

9.        Governing Law . This Release shall be governed and controlled as to validity, enforcement, interpretation, construction, effect and in all other respects by the internal laws of the State of California applicable to contracts made in that state, without giving effect to any choice of law or conflict of law provision or rule that would cause the application of the laws of any jurisdiction other than the State of California.

 

10.        Severability . Whenever possible, each provision of this Release shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision

 

 

 

  B- 3  

 

of this Release is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other provision or any other jurisdiction, but this Release shall be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision had never been contained herein. The remedies provided herein are cumulative and not exclusive of any remedies provided by applicable law.

 

11.       Entire Agreement . This Release, the Purchase Agreement and the Transaction Documents supersede any previous agreement, negotiation or understanding regarding the subject matter hereof, whether in writing or otherwise. No promises or agreements not contained herein or therein have been made by the Released Parties to induce the Parties to enter into this Release.

 

12.       Additional Documentation and Cooperation . The Parties agree to execute such additional documentation and cooperate in further proceedings necessary to effectuate the terms of this Release without charge or other consideration.

 

13.       Headings . Section and paragraph headings contained in this Release are for convenience and shall not be considered for any purpose in construing this Release.

 

14.       Successors and Third-Party Beneficiaries . This Release shall bind and inure to the benefit of the Parties and their respective successors.

 

15.       Attorneys' Fees . Should any action or other proceeding be necessary to enforce any of the provisions of this Release the prevailing Party will be entitled to recover its, his or her actual attorneys' fees incurred in each and every action or proceeding, including any and all appeals or petitions therefrom.

 

16.       Waiver of Terms . A waiver of any term or condition of this Release will not be deemed to be, and may not be construed as, a waiver of any other term or condition hereof.

 

17.       Representation . Each of the Parties hereto warrants and represents that in executing this Release, it has relied on legal advice from the attorney of its, his or her choice, that the terms of this Release and its consequences have been completely read and explained to each of the Parties by said attorney, and that each of the Parties fully understands the terms of this Release.

 

[Remainder of page intentionally left blank; Signature page follows]

 

 

  B- 4  

 

 

 

IN WITNESS WHEREOF, the Parties have executed this General Release as of the date first written above.

 

 

SHAREHOLDERS:

 

____________________________________

Grant Generaux

Address:

 

____________________________________

Brett Howell

Address:

 

___________________________________

Diane Longo

Address:

 

____________________________________

M. Bud Nelson

Address:

 

____________________________________

Lisl Shoda

Address:

 

____________________________________

Scottington Siler

Address:

 

___________________________________

Paul Watkins

Address:

 

____________________________________

Daniel Weiner

Address:

 

___________________________________

Jeffrey Woodhead

Address:

 

____________________________________

Kyunghee Yang

Address:

 

 

COMPANY:

 

DILIsym Services, Inc.

 

 

By: ___________________________

Name:

Title:

 

 

 

[Signature Page to General Release]

 

 

  B- 5  

 

 

SCHEDULE 1.11

EARN-OUT SCHEDULE

 

 

 

 

 

     

 

Exhibit 31.1

 

RULE 13A-14(A) CERTIFICATION

 

SIMULATIONS PLUS, INC.

a California corporation

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

 

I, Walter S. Woltosz, certify that:

 

  1. I have reviewed this Quarterly Report on Form 10Q of Simulations Plus, Inc., a California corporation;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its condensed subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

  5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and

 

  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Dated: July 10, 2017 By: /s/ Walter S. Woltosz
   

 

Walter S. Woltosz
Chief Executive Officer

(Principal Executive Officer)

 

 

Exhibit 31.2

 

RULE 13A-14(A) CERTIFICATION

 

SIMULATIONS PLUS, INC.

a California corporation

 

CERTIFICATION OF CHIEF EXECUTIVE OFFICER

 

I, John R. Kneisel, certify that:

 

  1. I have reviewed this Quarterly Report on Form 10Q of Simulations Plus, Inc., a California corporation;

 

  2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

  3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

  4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

  (a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its condensed subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

  (b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

  (c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

  (d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

  

  5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

 

  (a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company's ability to record, process, summarize and report financial information; and

 

  (b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 

Dated: July 10, 2017 By: /s/ John R. Kneisel
   

John R. Kneisel
Chief Financial Officer

(Principal Financial Officer)

 

 

 

Exhibit 32

 

CERTIFICATIONS PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)

 

In connection with the Quarterly Report of Simulations Plus, Inc., a California corporation (the “Company”), on Form 10-Q for the quarter ended May 31, 2017 as filed with the Securities and Exchange Commission, Walter S. Woltosz, Chief Executive Officer of the Company and John R. Kneisel, Chief Financial Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. § 1350, that to his/her knowledge:

 

  (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

  (2) The information contained in the report fairly presents, in all material respects, the financial condition and result of operations of the Company.

 

/s/     Walter S. Woltosz     

Walter S. Woltosz

Chief Executive Officer

(Principal Executive Officer)

July 10, 2017

 

 

/s/     John R. Kneisel     

John R. Kneisel

Chief Financial Officer

(Principal Financial Officer)

July 10, 2017

 

(A signed original of this written statement required by Section 906 has been provided to Simulations Plus, Inc. and will be retained by Simulations Plus, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.)